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ABSTRACT 
HIV associated lipodystrophy (HIVLD), an adverse effect of combination 
antiretroviral therapy (cART), further introduces complexity in the management of HIV 
infection. There is also increased of cardiovascular disease in HIV patients, even in the 
absence of HIVLD.  cART impairs adipogenesis and dysregulates the secretion of adipokines, 
fat and glucose metabolism in the adipose tissue. This is seen with both protease inhibitors 
(PIs) and nucleoside reverse transcriptase inhibitors. The aim of this thesis was to examine 
the pathogenesis of cART-induced metabolic disturbances using in vitro models (adipocytes) 
and in vivo (gene association) studies.  
Plasma levels of IL18, an adipokine associated with insulin resistance, are elevated 
in HIVLD patients. The murine 3T3-F442A cell line was used as an in vitro model to assess the 
effects of PIs (lopinavir [LPV], ritonavir [RTV], atazanavir [ATV]) and NNRTIs (efavirenz [EFV]) 
in the presence or absence of telmisartan (TEL; 1-5µM). All antiretrovirals (ARV) resulted in 
a dose dependent increase in IL18 protein levels by ELISA (LPV, 330pg/ml+2.1 [p=0.008]; ATV, 
267.3+5.1 [p=0.0001]; RTV, 265.7+2.2 [p=0.0005] and EFV, 98.6+2.4 [p=0.0004]) as 
compared to the vehicle control; this also correlated with IL18 gene expression determined 
by RT-PCR. Sequenom MALDI-TOF was used to genotype 14 single nucleotide polymorphisms 
(SNPs) in the IL18 gene in ARV-treated patients with (HIVLD+; n=115) and without LD (HIVLD-
; n=51), but no association was identified.  ARV treatment also resulted in the upregulation 
of NFATC4 gene expression (LPV, 1.9+0.05 [p=0.0015]; ATV, 2.1+0.1 [p=0.0007]; RTV, 
1.4+0.05[ p=0.0002] and EFV, 1.8+0.85 [p=0.0001]) as compared to the vehicle. Co-
incubation with TEL partially attenuated ARV-mediated upregulation of IL18 (1.6+0.2 
[p=0.01) and NFATc4 (1.2+0.1 [p=0.0001]). siRNA knockdown of NFATc4 in adipocytes 
resulted in significant upregulation in the levels of adiponectin and PPARgamma and down-
regulation in IL6 secretion levels following treatment with ARVs. The data suggest that ARV-
induced upregulation of NFATc4 could be a mediator of ARV-induced adipocyte toxicity and 
potentially insulin sensitivity.   
This study also observed changes in the regulation of various miRNAs following ARV 
treatment. Validation experiments confirmed LPV to result insignificant downregulation of 
miR-103 (0.5+ 0.01[p=0.002]) and miR-107 (0.4+ 0.03[p=0.001]) along with their target gene, 
Cav-1 (0.6+ 0.01[p=0.01]) during adipogenesis; this was reversed by co-incubation with Tel.     
A systematic review of the genetic associations with HIVLD was also undertaken – 
this identified that polymorphisms in mitochondrial DNA and cytokines had been the primary 
ones studied using a candidate gene approach.  The results showed that several SNP 
associations have been identified which are biologically plausible, but in almost all cases, 
replication of the findings in different cohorts has either been contradictory or limited.  This 
may be due to several reasons including small sample sizes, different diagnostic criteria used 
for HIVLD, differences in genetic strategy, ethnic variation in genetic architecture and 
differences in drugs used across different cohorts.  Although further studies in larger patient 
groups with HIVLD should be undertaken, this may not be possible given its rarity now in 
clinical practice, and perhaps the emphasis should switch to insulin resistance per se.    
              In summary, PIs and NNRTIs upregulate proinflammatory cytokines with NFATc4 
potentially playing a major role in their transcriptional upregulation. Differential regulation 
of specific miRNAs were also found to be important in ARV-mediated dysregulation 
ofadipogenesis; further validation work which evaluates their role in adipocyte toxicity in 
vitro and in vivo is now warranted. Whilst this study did not find any genetic association with 
HIVLD, future studies using larger sample sizes and better defined phenotypes are now 
required. 
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1.1 AIDS and HIV: the current scenario  
Acquired immunodeficiency syndrome (AIDS) is caused by human immunodeficiency 
virus (HIV) (Emery, Neuhaus et al. 2008, Wilen, Tilton et al. 2012). It is a serious threat 
to worldwide public health and has spread from its site of origin in Africa to the rest 
of the world. HIV transmits from humans to humans through sexual intercourse, 
blood transfusion, needle sharing and general blood to blood contact. There were 35 
million [33.2 million–37.2 million] people living with HIV at the end of 2013 and more 
people are living longer because of antiretroviral therapy (ART) (www.unaids.org).  
 
Figure 1.1.  People living with HIV by country, 2013 (Adapted from www.unaids.org) 
The profound effect of the HIV pandemic has led to tremendous research efforts to 
elucidate the mechanisms of the HIV life cycle and identify susceptible targets for 
therapeutic intervention. The number of HIV cases remains high but AIDS related 
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deaths have reduced in comparison to previous years which is the result of multiple 
factors including improved education and higher availability of antiretroviral 
treatments to HIV patients in developing countries. The role of antiretroviral drugs 
has been significant in the improvement of the living standards of HIV patients.  
However their use has also resulted in some adverse effects such as hypersensitivity 
and lipodystrophy (Johnson and Neilands 2007). 
1.2 Pathogenesis of AIDS 
1.2.1 The Structure of HIV virus  
HIV-1 virus was first studied in 1983 (Gallo, Sarin et al. 1983) and HIV-2  virus was 
identified in 1986 in West African patients with AIDS (Clavel, Guetard et al. 1986). 
The size of mature HIV-1 virus is between 110 to 128 nm (Gentile, Adrian et al. 1994). 
There are two single RNA strands in the core of the virus molecule enveloped by a 
p24 core antigen and p17 matric antigen. Together p24 and p17 maintain the shape 
of the virion. The viral core contains various proteins including reverse transcriptase, 
integrase, protease, vpr, vif, nef, nucleocapsid proteins, p6 and p7.  The outer most 
layer consists of a lipid bilayer taken from the host cell membrane and this contains 
both host cell proteins and viral proteins gp41 and gp120 (Figure 1.2). The viral 
genome consists of approximately 9749 nucleotides and contains 9 genes (pol, gag, 
env, nef, tat, rev, vpu, vpr, and vif) encoding 18 proteins (Wong-Staal 1991). There 
are three structural genes (gag, pol and env) and six accessory genes (nef, tat, rev, 
vpu, vpr and vif) which are essential for viral replication. Viral proteins and their 
function, with location, are described in the table 1.1 (Ratner, Haseltine et al. 1985). 
18 
 
 
Fig. 1.2.  The structure of HIV-1 virion. 
 
Figure 1.3.  Genomic  map of HIV-1 virus. Detailed functions of the all the genes are 
described in Table 1.1 (Gentile, Adrian et al. 1994). 
 
Table 1.1. Proteins produced by HIV-1 viral genome and related functions 
(Engelman and Cherepanov 2012). 
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Gene 
name  
Size Function Localisation  
Gag 
MA 
CA 
NC 
p17 
p24 
p7 
p6 
Membrane anchoring, envelope 
interaction, nuclear transport of viral 
core 
Core capsid 
Nucleocapsid, binds and protects 
RNA  
Binds Vpr 
 
Virion core 
Pol 
PR 
RT 
RNAse H 
IN 
p15 
p66, 
 p51 
p15 
p31 
Gag/Pol cleavage and maturation 
Reverse transcription 
Degradation of RNA after DNA 
synthesis 
Integration of newly formed DNA 
into host cell genome 
Virion core 
Env gp120,  
gp41 
External viral glycoprotein which 
binds to CD4 and secondary 
receptors  
Lipid bilayer of 
virion 
Tat p16, p14  Viral transcription activation Virion core 
Rev p19 Transport of RNA and stability  Travels 
between 
nucleus and 
membrane  
 
Vif p23 Promotes virion maturation Cytoplasm and 
Virion 
Vpr p10-p15 Inhibition of cell division & arresting 
of cells at G2/M phases  
Virion, Nucleus 
Vpu p16 Release of viral particles outside the 
cell, degradation of CD4 cells in the 
ER 
Integral 
membrane 
protein 
Nef p25-p27 CD4 and class 1 MHC down 
regulation  
Nucleus of host 
cells and 
nucleolus  
 
 
 
 
 
1.2.2 HIV-1 replication cycle  
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HIV-1 targets mainly CD4 T-lymphocytes and its process of entry and replication is 
very well described (Figure 1.4) (Engelman and Cherepanov 2012). HIV is a retrovirus 
containing two single strands of RNA. The viral envelope glycoproteins bind CD4 
receptors and the membrane spanning co-receptor, resulting in the fusion of viral 
membrane into the target cell membrane, subsequently un-coating the viral core 
shell and releasing the viral particles inside the host cell (Chen, Vogan et al. 2005). 
This is followed by reverse transcription of viral RNA to linear double stranded DNA 
which integrates into the host cell genome irreversibly to perpetuate infection 
(Gelmann, Popovic et al. 1983).  
Integration marks the late stage of HIV-1 replication and the focus then shifts towards 
the expression, or transcription of the viral gene by a viral protein called Tat. This 
recruits host cell proteins to perform its role efficiently, resulting in the biogenesis of 
the new viral mRNA molecules (Daugherty, Liu et al. 2010). Rev protein complex 
binds to viral RNA and transports it out of the nucleus of the host cell into the 
cytoplasm (Jain and Belasco 2001, Daugherty, Booth et al. 2010). The large structural 
viral polypeptide molecules produced after translation of viral mRNA are cut into 
smaller functional molecules such as Gag and Gag-pol by viral protease enzyme 
(Venaud, Yahi et al. 1992). The mature viral proteins combine to assemble a viral core 
encapsulating the viral RNA and are then released by budding off from the host cell 
membrane (Richman 2001). 
21 
 
 
 
Figure 1.4. HIV-1 replication cycle Initially, the Env (glycoprotein) binds with the CD4 receptor and CC- chemokine receptor 5 (CCR5) resulting the fusion of viral 
membrane into the CD4 cell membrane consequently viral particle enters the cell. Then viral enzymes reverse transcribe viral RNA into DNA which is transferred 
to host cell nucleus and eventually ends up being the part of cellular DNA. POL-II (polymerase –II) conducts viral DNA transcription to generate viral mRNA 
resulting in the assembly of viral proteins. Upon maturation, viral proteins, encapsulate newly transcribed viral RNA strand and eventually bud off the cells to 
leave the cell and infect other cells in the surrounding environment. INSTI, integrase strand transfer inhibitor; LTR, long terminal repeat; NNRTI, non-nucleoside 
reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor (Engelman and Cherepanov 2012)
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1.3 Anti-HIV Chemotherapeutic intervention  
1.3.1 The basic principle of anti-HIV chemotherapy and HIV drug classification 
The basic principle behind all the strategies employed in anti HIV-chemotherapy is to 
use drugs to target and inhibit HIV-1 viral infection at critical stages of its replication. 
There are 25 anti-HIV drugs  approved by the FDA and several more in various stages 
of clinical trials (De Clercq 2009). These drugs are described below. 
1.3.2 Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs and 
NtRTIs) 
Currently there are seven FDA approved NRTIs and NtRTIs which target the catalytic 
site of the HIV reverse transcriptase and bind to it. The cellular entry of this class of 
drugs is normally by passive diffusion, or requires carrier mediated transport. Due to 
low membrane permeability and their hydrophilic nature, equilibrative and 
concentrative families of nucleoside transporters mediate their cellular diffusion 
(Cass, Young et al. 1999). In order to be activated NRTIs/NtRTIs are phosphorylated 
to form triphosphate anabolites after entry into the cells (De Clercq 2009).  Their 
phosphorylation requires the kinase of the host cells  (Bazzoli, Jullien et al. 2010). 
Renal excretion of emtricitabine (FTC), lamivudine (3TC) and tenofovir disoproxil 
fumarate (TDF) is unchanged but abacavir (ABC), didanosine (ddI), stavudine (d4T) 
and zidovudine (AZT) require depurination and depyrimidation. Adverse effects 
related to NRTIs/NtRTIs are mainly because of mitochondrial toxicity resulting in 
lipoatrophy, fat wasting or myopathy and cardiopathy (Cote, Brumme et al. 2002). 
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1.3.3 Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
Unlike NRTIs, the NNRTIs interact in a non-competitive manner with an allosteric site 
located a short distance from the active site of HIV reverse transcriptase, blocking its 
activity. This class of drugs also blocks the hydrophobic pocket within the RNA 
dependant DNA polymerase domain of the p66 RT sub-unit (De Clercq 2004). As 
potent antiretrovirals, efavirenz and nevirapine are commonly recommended as 
first-line antiretrovirals for naïve patients, while etravirine is used in experienced 
patients (Nelson, Hill et al. 2014). To date there are five NNRTIs approved by the FDA, 
but only four of them are in common use:  efavirenz; nevirapine; etravirine; and 
rilpivirine. Delavirdine is not commonly used due to the pill burden, dosing 
frequency, and adverse effects when compared with other NNRTIs according to 
treatment guidelines (http://aidsinfo.nih.gov/guidelines). 
Rilpivirine is a next-generation NNRTI and shows much better results when compared 
to all previously used NNRTIs in terms of adverse events, central nervous system 
effects, rash and lipid abnormalities when only one 25mg pill/day is taken 
(Ripamonti, Bombana et al. 2014).In general, all NNRTIs show favourable 
pharmacokinetics and rare major side effects. Efavirenz causes neuropsychiatric 
adverse effects in more than half of the HIV patients receiving it as a first-line  
treatment, suggesting its role in first-line treatment should be reconsidered 
(Leutscher, Stecher et al. 2013). Nevirapine is an extensively prescribed 
antiretroviral, which has an increased risk of severe toxicity when antiretroviral-naive 
individuals with higher CD4 T-cell counts initiate nevirapine containing regimens 
(Haas, Mootsikapun et al. 2012). Pregnant HIV positive females with high CD4 cell 
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counts have been shown to experience higher rates of symptomatic hepatotoxicity 
and rash (Phanuphak, Apornpong et al. 2007).  
Low-frequency HIV variants are resistant due to mutations against old NNRTIs, e.g. 
efavirenz, especially at HIV reverse transcriptase (RT) amino acid (aa) positions, K103 
and Y181.  This suggests a need for new NNRTIs and further investigation (Gupta, 
Lataillade et al. 2014). Rilpivirine was considered an ideal anti-HIV agent because of 
the ease of synthesis and formulation and its high potency (De Clercq 2009). 
However, it has recently been reported that the E138A mutant strain of HIV-1 
showed significant resistance to Rilpivirine in a cohort of patients in northern France 
and needs to be further investigated in other cohorts (Jeulin, Foissac et al. 2014).  
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Figure 1.5. Chemical structure  of nucleotide reverse transcriptase inhibitors (NRTIs) 
(De Clercq 2009).  
 
26 
 
1.3.4 Protease inhibitors (PIs) 
The cleavage of the gag and gag-pol precursor proteins, structural proteins, reverse 
transcriptase and integrase is performed by HIV protease (PR) in a process called viral 
maturation.  That is to say, HIV protease is responsible for the maturation and 
infectivity of progeny virions (Kohl, Emini et al. 1988). Upon inhibition of HIV-PR, 
nascent HIV virions cannot infect their target cells. Therefore, protease inhibitors are 
an effective tool in the blocking and prevention of the formation of mature and 
infectious virus particles. Currently, all nine protease inhibitors (PIs) licenced by the 
FDA have the same structural scaffold, a hydroxyethlene bond, making these 
compounds peptidomimetic, but non-scissile substrate analogues for the HIV-PR (De 
Clercq 2004). The first problem faced by all HIV drugs, including HIV-PR, is drug 
resistance due to mutations in the HIV viral genome. The selection of the mutation is 
not only done in the protease substrate binding cleft but also in the proximity of the 
active site of the enzyme (Winters and Merigan 2005, Kozisek, Saskova et al. 2008).  
HIV virus also rescues itself under pressure of PIs by changing the protease substrate 
cleavage site, resulting in a structurally different gag and gag-pol protein, leading to 
resistance to PIs (Doyon, Croteau et al. 1996, Mammano, Petit et al. 1998, Nijhuis, 
van Maarseveen et al. 2007). The second major issue with PIs is their tolerability, 
toxicity and problems with adherence. Initially it was thought that PIs only interfere 
with HIV proteases because of the absence of similar enzymes in the body but this 
proved to be wrong. It was found that protease inhibitors interact with lipid 
metabolism and lipid trafficking pathways thereby contributing to dyslipidemia and 
cardiovascular disease in the long term. Consequently, PI induced drug toxicity has 
27 
 
been recognised to be a serious complication that can sometimes be a more serious 
danger to the patient’s life than HIV itself (Nolan, Reiss et al. 2005, Shibuyama, 
Gevorkyan et al. 2006, Wohl, McComsey et al. 2006).  
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Figure. 1.6. Chemical Structure  of protease inhibitors. (De Clercq 2009) 
 
There are nine protease inhibitors currently approved by the FDA, as shown in Table 
1.2. All the PIs are competitive inhibitors of HIV-PR. Except for tipranavir (TPV), all PIs 
are peptidomimetics. All the PIs are active against HIV-2 with the exception of 
lopinavir (LPV), which is less effective in cases of HIV-2 (Witvrouw, Pannecouque et 
al. 2004). All protease inhibitors are approved for oral administration only. However, 
their gastrointestinal absorption is poor (Polli, Jarrett et al. 1999) resulting in a low 
effective concentration in the circulation and particularly in viral sanctuary sites such 
as CNS and the genital tract (Lowe, Wensing et al. 2006, Kwara, Delong et al. 2008). 
The drug level must be maintained above the suitable inhibitory concentration to 
suppress viral growth, especially in the CNS and the genital tract since low 
concentrations of the drug could lead to development of viral resistance.   
To overcome this limitation of PIs, potent inhibitors of cytochrome P450 (CYP) 
isoform 3A4, such as ritonavir are used along with another PI e.g. lopinavir, to achieve 
higher concentrations in the blood stream.  Saquinavir (SQV) was the first protease 
inhibitor licenced for HIV treatment by the FDA. It was designed to target Phe-Pro 
and Tyr-Pro bonds in HIV-PR and replace it with hydroxyethylamine isostere (Roberts, 
Martin et al. 1990). Insufficient bioavailability of SQV (less than 4%) was the major 
setback (Kilby, Sfakianos et al. 2000).  Consequently, its use as an independent drug 
named Fortovase® was replaced with a new brand called Invirase® containing both 
saquinavir and ritonavir. The common adverse effects of SQV were reported as 
abdominal discomfort, diarrhoea and nausea (Figgitt and Plosker 2000). 
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Ritonavir was approved as an antiretroviral initially, but showed significant cross 
resistance with other PIs and also resulted in frequent adverse effects e.g. nausea, 
abdominalgia and diarrhoea. Consequently its use as an antiretroviral drug was 
restricted and limited to a newly appointed role as a booster drug because it proved 
to be potent inhibitor of CYP3A4 (Figgitt and Plosker 2000). Another first generation 
PI, indinavir was widely used clinically but has been abandoned completely because 
of side effects such as nephrolithiasis and lipodystrophy (Gentle, Stoller et al. 1997, 
Nadler, Rubenstein et al. 2003). Nelfinavir was the first protease inhibitor used to 
treat both adults and children suffering from HIV but is not widely used because of 
severe gastrointestinal toxicity, resulting in diarrhoea (Bardsley-Elliot and Plosker 
2000).  
The first of the second generation PIs, lopinavir, is widely available and used under 
the trade name, Kaletra®.  It was designed to inhibit the mutant protease of HIV 
containing a mutation called V82A (Sham, Kempf et al. 1998). There are still some 
mutations of HIV, such as 147A, which are not susceptible to LPV (Kempf, Isaacson et 
al. 2001, Kagan, Shenderovich et al. 2005). There are similar adverse effects to LPV 
as there were with older PIs, such as gastrointestinal events including abdominal 
pain, gaseous symptoms, diarrhoea and lipodystrophy (Croxtall and Perry 2010). 
Lopinavir is also associated with insulin resistance (Dejkhamron, Unachak et al. 
2014). Atazanavir is a relatively new second generation PI and much more beneficial 
than previously used PIs. It is recommended that atazanavir should be used with 
other ARVs. It is much more readily absorbed when taken with food and its 
concentration in blood increases 10 fold when used with ritonavir which acts as a 
booster. Low pill burden, ease of administration and reduced interaction with the 
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lipids make it desirable for treatment (Le Tiec, Barrail et al. 2005). Atazanavir can 
cause hyperbilirubinaemia leading to apparent jaundice (Pokorná, Machala et al. 
2009).  
Fosamprenavir is a pro-drug of amprenavir and almost completely converted into 
amprenavir by alkaline phosphatase in the gut epithelium. Its structure is based on 
amprenavir and was mainly designed to improve the pharmacokinetics and 
therapeutic potency of amprenavir which was discontinued in 2004 (Barbour, 
Gibiansky et al. 2014). Less than 1% of fosamprenavir is eliminated via urine and the 
rest is eliminated from the circulation by the liver. In the liver CYP3A4 is inhibited and 
induced by fosamprenavir. Normally it is given along with a tiny dose of ritonavir, 
which acts as a booster to increase its levels in the blood (Wire, Shelton et al. 2006).  
Tipranavir is a non-peptidic inhibitor (Poppe, Slade et al. 1997) and broadly inhibits a 
wide range of PI resistant strains of HIV-PR (Larder, Hertogs et al. 2000). 
Gastrointestinal disturbance is reported for all PIs, but in the case of tipranavir, 
hepatic toxicity (Macias, Orihuela et al. 2009) and intracranial haemorrhage have also 
been reported  (Arbuthnot and Wilde 2008). Currently, it is prescribed only to adults 
who are not naïve to HIV treatment. Tipranavir is a CYP3A4 inducer and administered 
with twice the dose of ritonavir as a booster (De Clercq 2005). Darunavir is 
structurally similar to amprenavir but binds much more tightly to its target site than 
APV (King, Prabu-Jeyabalan et al. 2004).  Generally, it is well tolerated but adverse 
effects are similar to other PIs,  e.g. lipid metabolism disorder (McKeage, Perry et al. 
2009).  
1.3.5 Fusion inhibitors (FIs) 
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The fusion of the viral membrane into its target cell membrane is an essential process 
for the virus to infect its target cell (Colman and Lawrence 2003). HIV-1 viral particles 
contain surface proteins as part of their envelope which helps them to enter into the 
target cells by a fusion process (Eggink, Berkhout et al. 2010). These specialised fusion 
proteins, gp120 and gp41, contain 3 sub-units each and together make a glycoprotein 
envelope complex, generally known as Env, and arranged in the form of a trimer on 
the surface of the membrane (Eggink, Berkhout et al. 2010). gp41 has two important 
sub domains called HR1 and HR2 which coil together to bring viral and cellular 
membranes close enough to result in their fusion.  
The first fusion inhibitor, T20, or Enfuvirtide, is a peptide mimic of the HR2 sequence 
which binds HR1 and blocks the fusion process between the viral membrane and its 
target cellular membrane (Eggink, Berkhout et al. 2010). It is the only fusion inhibitor 
currently available for the treatment of HIV infection. Enfuvirtide is the only anti-HIV 
compound which has a polypeptide structure. Consequently it cannot be given orally 
and must be injected subcutaneously (Matthews, Salgo et al. 2004, De Clercq 2009). 
A second generation fusion inhibitor, T1249, has been through phase I and II clinical 
trials successfully but its further development was halted by Roche®, emphasising  
that, “current formulation of the T1249 is not suitable for large scale clinical use” 
(Martin-Carbonero 2004).  
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Table 1.2. FDA-approved HIV Medicines 
 
 
 
Type Drug Abbreviation Brand name Current Manufacturer FDA Approval  Date 
PIs Saquinavir 
Ritonavir 
Indinavir 
Nelfinavir 
Lopinavir 
Atazanavir 
Fosamprenavir 
Tipranavir 
Darunavir 
SQV 
RTV 
IDV 
NFV 
LPV 
ATV 
FPV 
TPV 
DRV 
Invirase® 
Norvir® 
Crixivan® 
Viracept® 
Kaletra® 
Reyataz® 
Lexiva® 
Aptivus® 
Prezista® 
Hoffmann-La Roche 
Abbott Laboratories 
Merk& Co.,Inc. 
Agouron 
Abbott Laboratories 
Bristol-Myers Squibb 
ViiV Healthcare 
BoehringerIngelheim 
Janssen Pharmaceuticals, Inc. 
Dec 6, 1995 
Mar 1, 1996 
Mar 13, 1996 
Mar 14,1997 
Sep 15, 2000 
Jun 20, 2003 
Oct 20, 2003 
Jun 22, 2005 
Jun 23, 2006 
NRTIs Abacavir 
Didanosine 
Emtricitabine 
Lamivudine 
Stavudine 
Tenofovir 
Zidovudine 
ABC 
ddl 
FTC 
3TC 
d4T 
TDF 
ZDV 
Ziagen® 
Videx® 
Emtriva® 
Epivir® 
Zerit® 
Viread® 
Retrovir® 
ViiV Healthcare 
Bristol-Myers Squibb 
Gilead Sciences 
ViiV Healthcare 
Bristol-Myers Squibb 
Gilead Sciences 
ViiV Healthcare 
Dec, 17 1998 
Oct 9, 1991 
Oct 31, 2000 
Jul 2, 2003 
Nov 17, 1995 
Jun 24, 1994 
Oct 26, 2001 
NNRTIs Delavirdine 
Efavirenz 
Etravirine 
Nevirapine 
Rilpivirine 
DLA 
EFV 
ETR 
NVP 
RPV 
Rescriptor® 
Sustiva® 
Intelence® 
Viramune® 
Edurant® 
ViiV Healthcare 
Bristol-Myers Squibb 
Janssen Pharmaceuticlas, Inc. 
BoehringerIngelheim 
JanssenPharmaceuticlas, Inc. 
Apr 4, 1997 
Sep 17, 1998 
Jan 18, 2008 
Jun 21, 1996 
May 20, 2011 
FIs Enfuvirtide T20 Fuzeon® Hoffmann-La Roche Mar 13, 2003 
EIs Maraviroc MVC Selzentry® ViiV Healthcare Aug 6, 2007 
IIs Dolutegravir 
Raltegravir 
Elvitegravir 
DTG 
RAL 
EVG 
Tivicay® 
Isentress® 
Vitekta® 
ViiV Healthcare 
Merk& Co., Inc. 
Gilead Sciences 
Aug 13, 2013 
Oct 12, 2007 
Sep 24, 2014 
33 
 
1.3.6 Co-receptor /Entry inhibitors (CRIs) 
Inhibition of HIV-1 virus co-receptor is a novel approach in pharmacological therapies 
for HIV. Maraviroc was the first entry inhibitor which binds to the CCR5 co-receptor 
and blocks the entry of HIV-1 particles into the cells (Lieberman-Blum, Fung et al. 
2008). It significantly improves the CD4 cell count and  decrease the number of the 
viral RNA molecules, but due to drug resistance concerns, it is indicated to be used 
only in salvage conditions. Maraviroc treatment also needs a costly tropism test 
(Hunt and Romanelli 2009) which gives information about the viral strain, indicating 
whether it is CXCR4 or CCR5 tropic (Edwards, Stucki et al. 2015). Tropism tests that 
are currently available for the detection of CCR5 strain of HIV-1 virus are not sensitive 
enough. Therefore, the possibility of patients receiving the wrong treatment is 
always there in the case of maraviroc (2010).  
1.3.7 Integrase inhibitors  
HIV integrase enzyme catalyses the process of integration of viral DNA into the host 
cell DNA in three steps. At first it makes a complex with viral DNA, then processes it, 
while cutting it at a suitable site 5’ from both ends, and finally transferring it into the 
nucleus and linking it into the host cell DNA (Gulick 2003). Integrase has emerged as 
a key drug target to reduce the viral replication (Fantauzzi and Mezzaroma 2014). 
There are three FDA approved integrase strand transfer inhibitors (InSTIs) available: 
raltegravir; elvitegravir; and dolutegravir. All of these InSTIs target different sets of 
viral mutations (Grobler and Hazuda 2014).  Raltegravir has been reported to be well 
tolerated both in children and adolescents over a period of 48 weeks and is also 
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available in chewable tablets making it easier to administer in children (Perry 2014). 
Cobicistat-boosted elvitegravir (EVG/c) is a combination of two drugs in which 
elvitegravir, an integrase inhibitor, is combined with a CYP3A inhibitor called 
cobicistat as a pharmacokinetic booster. Cobicistat has provided an alternative 
option to ritonavir as a booster with a once a day pill antiretroviral regimen. It can 
have adverse effects on the renal system and needs close continuous observation 
while being administered (Temesgen 2012). Dolutegravir has better pharmacokinetic 
properties and renders a once daily dose without the need for a pharmacokinetic 
booster. It has prolonged half-life at the cellular level  (Fantauzzi and Mezzaroma 
2014).  
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Figure 1.7; Various drug targets for therapeutic intervention for the treatment of 
HIV 
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1.4 Highly active antiretroviral therapy (HAART)  
Despite the huge success over the years in the treatment of HIV infection, it has been 
accepted that HIV virus cannot be eradicated with the use of currently available drugs 
(Eisele and Siliciano 2012).  This means that, unless advanced treatments are 
developed, HIV patients must continue taking drugs for their entire life. All currently 
licensed drugs have some adverse effects. The prolonged treatment of AIDS presents 
serious challenges of various kinds, from drug resistance due to mutations in the viral 
genome, to many diversified and complex adverse effects. The high rate of 
replication of HIV and inefficient proof-reading ability of reverse transcriptase are the 
key factors resulting in the continuous generation of new mutations in the HIV 
genome, consequently resulting in a much more resistant virus.  To tackle this 
problem, clinicians prescribe multiple HIV drugs simultaneously. In this way, viral 
ability to survive and replicate is reduced by targeting different stages of replication, 
using multiple HIV drugs from different classes. This method of prescribing and 
treating HIV patients with multiple drugs is called highly active antiretroviral therapy 
(HAART).  
Since the introduction of HAART in 1996 the mortality rate of HIV patients has 
reduced significantly (Mocroft, Vella et al. 1998). Since then HAART has been the 
mainstay in the treatment of HIV infected individuals and has dramatically improved 
the morbidity and mortality associated with HIV (Palella, Delaney et al. 1998). 
Previously it was not clear, and there were no clear guidelines, when exactly HIV 
patients should start receiving HAART (Mocroft and Lundgren 2004). However, there 
are now clear recommendations available from the National Institute of Health in the 
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United States and the British HIV association (Garin Escriva, Velasco Munoz et al. 
2014). 
HIV patients with CD counts <350 cells/mm3 are at the highest risk of opportunistic 
diseases. There is evidence that HIV patients receiving HAART having CD4 cell count 
<200 cells/mm3 improve in terms of survival rate and show a delay in disease 
progression with overall improvement in their CD4 cell count (Hammer, Squires et al. 
1997, 1999, Zolopa, Andersen et al. 2009). There is also evidence that patients who 
were deferred antiretroviral treatment (ART) until CD4 cell count dropped below 200 
cell/mm,3 had higher mortality rates than those who received ART at an early stage, 
when their CD4 cell count was between 200-350 cell/mm3 (Severe, Juste et al. 2010). 
Clinical evidence was put forward in the SMART study which demonstrated that HIV 
patients who received ART immediately, at the start of their treatment, showed 
significantly more improvement than those who deferred ART until CD4 cell count 
dropped below 250 cells/mm3. The most important and fundamental condition for 
improvement in cases of HIV is earlier diagnosis but, unfortunately, most patients are 
diagnosed quite late (Wolbers, Bucher et al. 2008, 2009, Grigoryan, Hall et al. 2009). 
Although there is an improvement in early detection the median count of CD4 cells 
remains 350 cell/mm3 (Althoff, Justice et al. 2010). Patients starting ART soon after 
HIV detection while having lower CD4 cell counts can improve but it can take up to 6 
years or more (Moore and Keruly 2007).  
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1.4.1 Adverse effects of HAART  
Antiretroviral drugs (ARVs), together with the virus itself, could result in various 
adverse effects such as hepatotoxicity, hyperglycaemia, diarrhoea, hypersensitivity 
(Wu, Li et al. 2014), Type 2 diabetes (T2DM) and an increased risk of cardiovascular 
disease (CVD) (Wand, Calmy et al. 2007). 
1.4.2 HAART related Hepatotoxicity  
Hepatotoxicity develops in patients receiving NRTIs, NNRTIs or PIs (Echenique and 
Rich 2013, Wu, Li et al. 2014). PIs cause endoplasmic reticulum stress by increasing 
the processing and activation of sterol regulatory element binding proteins (SREBPs) 
(Horton, Goldstein et al. 2002, Jeon and Osborne 2012), which results in the increase 
of lipid accumulation in the hepatocytes, consequently resulting in induced hepatic 
toxicity (Wang, Zhang et al. 2013). The mechanism of hepatic toxicity by nucleoside 
analogues is different than for PIs. Both NRTIs and NNRTIs are incorporated in the 
viral DNA and block the activity of human DNA polymerases, which is also required 
for mitochondrial DNA replication (Lewis and Dalakas 1995). Depletion of 
mitochondrial DNA results in the impairment of the cellular respiratory chain, 
starting the inhibition of pyruvate and fatty acid oxidation pathways. In cases of more 
severe NRTI induced liver toxicity, mitochondria appear large in size under the light 
microscope and this can lead to hepatomegaly or steatosis. In the worst case 
scenario, patients can suffer from lactic acidosis or liver failure (Moyle 2000).  
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1.4.3 HAART related hypersensitivity  
Hypersensitivity reactions (HSR) are another type of adverse effect resulting from 
treatment with a number of different antiretroviral drugs. Abacavir (ABC), a NRTI, 
and most of the NNRTIs, can cause hypersensitivity reactions. Some protease 
inhibitors and the fusion inhibitor can also produce similar symptoms, though they 
may not be the result of a true hypersensitivity reaction (Airo, Scarsi et al. 2009). The 
common manifestation of antiretroviral drugs hypersensitivity is a skin rash (Seth, 
Kamat et al. 2008) which may present as exanthema or drug hypersensitivity 
syndromes, typically manifesting as an erythematous, maculopapular confluent rash 
as shown in figure 1.8. It is accompanied by fever, rigors, myalgias, and arthralgias 
and is named as DRESS (drug reaction with eosinophilia and systemic symptoms) or 
DIHS (drug-induced hypersensitivity syndrome) (Chaponda and Pirmohamed 2011).  
A small proportion of patients treated with antiretroviral drugs may also present a 
hypersensitivity condition known as Stevens Johnson syndrome (SJS) or  toxic 
epidermal necrolysis (TEN) (Wolf, Orion et al. 2005).  
 
Figure. 1.8.  A typical maculopapular exanthema seen in hypersensitivity syndrome 
caused by antiretrovirals (Chaponda and Pirmohamed 2011). 
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Drug induced hypersensitivity in HIV is multi-factorial and has a complicated patho-
physiology which is related to a number of factors from the metabolic and 
immunologic host factors to the viral structural morphology. Studies have reported 
that drug hypersensitivity is indeed immune mediated with the clear involvement of 
T-cells (Pirmohamed and Park 2001). The actual mechanism by which drugs are 
presented in vivo is still unclear.  
Table 1.3. HIV drugs associated with drug hypersensitivity (Chaponda and Pirmohamed 
2011) 
Class Drug Hypersensitivity Reactions Frequency 
NRTI Zidovudine Exanthema Rare 
Abacavir Exanthema, HSR 2.3–9% 
Emtricitabine Rash 17% 
NNRTIs Efavirenz SJS, TENExanthema, 0.1 - 20% 
Nevirapine Exanthema, TEN, SJS, HSR, 0.3 – 32%  
Etravirine Rash, SJS, TEN 2 - 16%  
PIs Tipranavir Rash, dyslipidaemia 2 – 14%  
Atazanavir Rash 6%  
Fosamprenavir Rash, HSR 1–19%  
Lopinavir Rash 2–4% 
Darunavir Rash, HSR 6.7%  
Entry inhibitors Enfuvirtide Injection site reactions, HSR Rare 
Maraviroc Rash, cough, Rash 
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1.4.4 HAART related hyperglycaemia and insulin resistance  
Despite improved living standards and prolonged life span after receiving HAART, 
about 60% of HIV patients receiving regimens based on protease inhibitors, develop 
impaired glucose metabolism, leading to insulin resistance or type 2 diabetes 
(Visnegarwala, Krause et al. 1997, Lee, Walmsley et al. 1999). Protease inhibitors are 
associated with insulin resistance and reduce glucose uptake by adipocytes and 
skeletal muscle cells, consequently resulting in hyperglycaemia (Woerle, Mariuz et 
al. 2003, Honda and Oka 2006). The mechanism of PI induced insulin resistance is not 
clear but it has been suggested that the blockade of glucose transporter GLUT4 
translocation from cytoplasm to cell membrane and inhibition of insulin receptor 
substrate (IRS) are possible causes (Djedaini, Peraldi et al. 2009).  
It has been observed that insulin production from pancreatic β-cells is reduced after 
treatment with protease inhibitor treatment, which is another suggested cause of 
the hyperglycaemia. This is because all the cells need insulin as a signal to start 
absorbing glucose from the circulatory system  (Woerle, Mariuz et al. 2003). In 
another study, a comparison of lopinavir/ritonavir, darurnavir/ritonavir and 
atazanavir/ritonavir was observed and lopinavir was found as the worst offender in 
terms of causing insulin resistance, whereas darunavir showed the least association 
with development of insulin resistance.  Atazanavir showed an intermediate effect 
on insulin resistance (Capel, Auclair et al. 2012).  
1.4.5 HAART related hyperlipidaemia 
Hyperlipidaemia is a condition in which very low density lipoprotein (VLDL) and 
intermediate density lipoprotein levels are increased to levels higher than normal 
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(Stein, Klein et al. 2001). In a clinical study it was found that hyperlipidaemia in HIV 
patients receiving HAART is associated with PIs. Patients who received regimens 
having a PI based back bone had a higher risk of developing hyperlipidaemia (Smith, 
Martin et al. 2000). Besides atazanavir, which showed a better lipid profile, all other 
protease inhibitors showed considerably higher levels of lipids in the blood (Moreno, 
Hernandez et al. 2008, Estrada and Portilla 2011). This is because protease inhibitors 
interfere with the cellular mechanisms to maintain a balance between glucose and 
lipid metabolism. Protease inhibitors result in decreased  catabolism of VLDL and 
increase in their production.  
Another suggested mechanism is a decrease in the hydrolysis of triglyceride rich 
protein. Protease inhibitors can increase the production of certain enzymes in the 
liver which can up regulate the production of enzymes that take part in triglyceride 
production (Lenhard, Croom et al. 2000). One of the in vitro studies has shown that 
hepatocytes treated with PIs show increased secretion of intracellular apolipoprotein 
but in HIV patients treated with HAART, it has been shown that there is a decrease in 
apolipoprotein receptors. Therefore, higher levels of LDL in the circulation may be 
the result of this imbalance of over production of apolipoprotein (Estrada and Portilla 
2011).  
1.4.6 HAART related cardiovascular complications 
It is also known that long term treatment with ARVs increases the risk of myocardial 
infarction and atherosclerosis (Lo, Abbara et al. , Worm, Sabin et al.). It is suggested 
that HIV patients receiving ART are likely to develop lipodystrophy syndrome which 
includes dyslipidemia. Consequently, redistribution of fat in the body results in the 
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loss of fat in some parts of the body, e.g. arms and limbs, but greater storage in the 
abdominal area which also affects the vascular systems of the body. Increased fat in 
the walls of the arteries and veins due to lipodystrophy may lead to myocardial 
infarction (Troll 2011).  
1.4.7 HAART associated lipodystrophy 
The metabolic complications associated with HAART are broadly termed HIV 
lipodystrophy (HIVLD), HAART associated lipodystrophy (HALS), or fat redistribution 
syndrome. HIVLD is a clustering of morphologic and metabolic abnormalities such as 
peripheral fat loss (lipoatrophy), visceral lipid hypertrophy, insulin resistance and 
dyslipidemia (Fig 1.9) (Carr, Samaras et al. 1998).  Even though the use of newer ARVs 
has resulted in a reduction in the prevalence of HIVLD, it remains an issue as shown 
by the recent multicentre HIV-HEART Study (n=803), which reported HIVLD in 38.8% 
of HAART treated patients (Potthoff, Brockmeyer et al.). Another study in Australia 
showed that 53% of HIV patients undergoing ART developed lipodystrophy (Miller, 
Carr et al. 2003).  
When HIV lipodystrophy was first reported, clinicians relied upon patient’s self-
reporting, or on the basis of general observations, to make a diagnosis (Jeppesen, 
Hein et al. 1998). More accurate observations are now possible using more advanced 
methods and technologies, such as dual energy X-ray absorptiometry (DEXA) or 
computerized tomography (CT), to identify the exact parameters of the lipid content 
in a patient’s body. Single cut abdominal CT performed at the mid-L4 level vertebra 
can be used to estimate the areas of visceral adipose tissue (VAT), subcutaneous 
adipose tissue (SAT) and total adipose tissue content (TAT) (Miller, Carr et al. 2003). 
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HIVLD is a known risk factor for metabolic syndrome (MS) and T2DM (Potthoff, 
Brockmeyer et al. , Carr, Emery et al. 2003).  Cardiometabolic disease is a major public 
health problem worldwide. HAART-induced HIVLD increases the risk of 
cardiometabolic problems in HIV patients and further worsens the health and 
economic burden. Several mechanisms have been suggested to be responsible for 
HIVLD which include ARV-induced adipose toxicity, adipose gene expression 
derangements, mitochondrial toxicity, insulin resistance and genetic polymorphisms 
(Mallewa, Wilkins et al. 2008).  
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Figure 1.9(a); Characteristic facial lipoatrophy with loss of subcutaneous adipose 
tissue (SAT) from the buccal, periorbital and temporal regions, (b) Limb lipoatrophy 
showing loss of SAT from the extremities with prominence of veins, tendons and 
malleoli. (c) Visceral fat accumulation evidenced by the distended abdomen with 
lipoatrophy of the buttock region. (d) Fat accumulation in the dorsocervical region, 
also referred to as `buffalo hump'. (Mallon et al., 2001).  
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Therapeutic management strategies for HIVLD are limited and often symptomatic. 
Insulin sensitizers such as thiazolidinediones and metformin have not been very 
promising in terms of treatment for HIV lipodystrophy. They have been trialled in 
HIV+ patients and have shown mixed results (Benavides and Nahata 2004, Nissen and 
Wolski 2007). The FDA has recently approved tesamorelin, a growth hormone 
releasing factor analogue for the treatment of HIVLD (Traynor). Tesamorelin results 
in reduction of visceral fat with modestly beneficial effects on adiponectin; however 
no improvement in glucose parameters were observed (Falutz, Mamputu et al.). 
Interaction between ARVs and adipose tissue is important in HIVLD pathogenesis; a 
better understanding of the molecular mechanisms behind this interaction may lead 
to the identification of novel therapeutic targets and the development of clinical 
applications that might be beneficial in solving the problems related to HIVLD. 
Due to the stigmatisation of facial lipoatrophy, plastic surgery has gained popularity. 
Two studies have shown that poly-L-lactic acid (PLA) is well tolerated and effective in 
HIV patients with facial lipoatrophy, and that PLA persisted 18 months after the last 
injection (Valantin, Aubron-Olivier et al. 2003, Moyle, Lysakova et al. 2004). 
Therefore, the FDA have approved Sculptra, which is an injectable form of PLA. It is a 
biodegradable and biocompatible synthetic polymer of the alpha hydroxy acid family 
(Lam, Azizzadeh et al. 2006). Later in 2006, the FDA approved another material called 
Radiesse which is a semisolid cohesive implant consisting of synthetic calcium 
hydroxylaptile suspended in a gel carrier (Beer 2007).  
 
1.5 Mechanisms involved in the development of HAART related Lipodystrophy 
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Over the last few decades, adipose tissue was  considered inert and only a source of 
energy and storage for triacylgylcerols, which are released in the systemic circulation 
in the form of fatty acids when the body needs them for producing more energy 
(Kwon and Pessin 2013). However recent studies have shown that adipose tissue is 
also involved in the pathogenesis of HIVLD (Caron-Debarle, Boccara et al.). ARV-
induced adipose toxicity results in the inhibition of adipocyte differentiation and 
dysregulation of cellular metabolism and secretion of various adipose tissue-derived 
proteins known as adipokines (Caron-Debarle, Boccara et al. , Jones, Janneh et al. 
2005).  
ARVs downregulate adiponectin, an insulin sensitizer (Jones, Janneh et al. 2005), but 
increase the secretion of deleterious adipokines, such as IL-6 and TNF-α, which result 
in an imbalance of secreted adipokines (Jones, Janneh et al. 2005). ARVs also cause 
impairment of the insulin signalling pathway, leading to insulin resistance. However, 
the role of several other mediators that are involved in ARV-induced adipose toxicity 
are still unknown (Djedaini, Peraldi et al. 2009). In the following sections, some of the 
suggested pathways involved in ARVs adipocyte toxicity resulting in lipodystrophy 
are considered.  
1.5.1 Direct inhibition of glucose transporter GLUT 4 
Earlier studies identified that many first generation protease inhibitors target the 
insulin-responsive facilitative glucose transporter GLUT 4 (Murata, Hruz et al. 2002). 
Another recent study suggested that HIV protease inhibitors were responsible for 
ARV induced adipose toxicity in 3T3-L1 adipocytes via inhibition of GLUT 4 
transporters (Hresko and Hruz 2011). The molecular mechanism by which these 
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drugs block the intrinsic activity of GLUT4 is unknown, though the blockage of GLUT 
4 is acute and reversible. It is the peptidomimetic characteristics of the PIs found 
responsible which are shown to contribute to this effect (Hertel, Struthers et al. 
2004). 
Glucose transportation involves the intracellular translocation of the GLUT 4 to the 
cell membrane, where it facilitates the inward transport of glucose from the outside 
of the cell. In vitro studies have shown that physiological concentrations of the PIs, 
such as RTV and LPV, can result in immediate inhibition of glucose transportation by 
GLUT 4, which is reversed upon removal of the drug (Murata, Hruz et al. 2002). 
Impaired insulin signalling (Ben-Romano, Rudich et al. 2003, Kim, Wilson et al. 2006), 
reduced insulin secretion (Schütt, Zhou et al. 2004) and altered adipokine levels need 
further detailed investigation (Jones, Waitt et al. 2008). A recent study investigated 
the specific contribution of PI-mediated GLUT inhibition to altered glucose 
homeostasis and observed the effects of ARVs on glucose tolerance in transgenic 
mice lacking GLUT4 (G4KO). Their study suggested that GLUT4 inhibition is a primary 
mechanism that leads to changes in glucose tolerance, which contributes to 
derangements in the other molecular pathways that may influence insulin sensitivity 
(Vyas, Koster et al. 2010).  
1.5.2 Insulin resistance  
There are long-term adverse effects associated with HAART such as major alterations 
in metabolic parameters, including hyperlipidaemia and insulin resistance (IR); either 
of these occur in isolation or as part of the lipodystrophy. Among HIV-infected 
people, particularly those being treated with protease inhibitor therapy, insulin 
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resistance is a common phenomenon (Aboud, Elgalib et al. 2007), but the molecular 
mechanisms responsible for it are not completely understood yet (Aboud, Elgalib et 
al. 2007). Initial studies, using 3T3-L1 adipocytes, have established that PIs 
(specifically indinavir, ritonavir and amprenavir) are capable of acute induction of 
insulin resistance. Also GLUT4 was identified as the direct target of ARVs (Murata, 
Hruz et al. 2000). Later on these findings were confirmed in primary rat adipocytes 
at physiologically relevant drug levels (Murata, Hruz et al. 2002). Other tissues that 
have also shown PI-mediated insulin resistance in vitro include, rat skeletal muscle, 
on treatment with IDV (Nolte, Yarasheski et al. 2001),  human adipocytes, on 
treatment with RTV (Kim, Wilson et al. 2006) and human subcutaneous adipocytes 
upon treatment with both LPV and RTV (Noor, Flint et al. 2006). 
A study conducted in rats has shown that under euglycemic hyperinsulinemic clamp 
conditions, treatment with PIs (IDV, RTV, LPV) results in a dose dependent reduction 
of peripheral glucose disposal (Hruz, Murata et al. 2002, Yan and Hruz 2005). A better 
understanding of the individual HIV PIs that produce insulin resistance will allow the 
tailoring of individual treatment plans based upon the overall risk of diabetes. The 
experimental explanation of the molecular mechanisms for alterations in glucose 
homeostasis will facilitate the development of new HIV PIs that may maintain their 
clinical efficacy, without adding to the development of diabetes mellitus and other 
adverse effects (Hruz 2008).  
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Figure 1.10. Proposed mechanism of induction of insulin resistance in HIV-infected 
patients receiving protease inhibitors, CRABP-1: Cellular retinoic-acid binding protein 
type 1; LPR: low density lipoprotein receptor-related protein; GLUT4: glucose 
transporter type 4; IL6: interleukin 6; TNFα: tumor necrosis factor α.  
 
1.5.3 Role of antiretroviral induced mitochondrial toxicity in HIV Lipodystrophy 
Mitochondria are intracellular organelles present in all mammalian cells (except red 
blood cells) and contains  their own mitochondrial genome. The main function of 
mitochondria is to synthesize ATP through electron transport and oxidative 
phosphorylation. However, mitochondria are now recognised as being critical 
components of key cellular processes, such as apoptosis, and therefore play a pivotal 
role in the determination of life and death of  mammalian cells (Wallace 2005). 
HAART-related mitochondrial toxicity has been explained in the context of NRTIs. The 
exact mechanism of NRTI induced mitochondrial toxicity remains unclear and 
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probably differs between specific NRTI drugs (Feeney and Mallon 2010). NRTIs inhibit 
Pol-γ, which is the DNA polymerase responsible for the synthesis of mitochondrial 
DNA. Evidence points to a more complex relationship between these organelles and 
NRTIs and suggests many other mechanisms of mitochondrial interference, both 
related and unrelated to mtDNA, beyond the original “Pol-γ hypothesis” 
,(Apostolova, Blas-García et al. 2011). 
Longitudinal studies comparing subcutaneous fat in HIV-infected patients, before 
and after HAART initiation, show that six to eight months of treatment with NRTIs 
can change significantly the expression levels of several key mitochondrial electron 
transport genes in subcutaneous fat.  This leads to increased oxidative stress 
(Boothby, McGee et al. 2009) and a significant reduction in mitochondrial activity 
where depletion of mitochondrial DNA has also been observed (Nolan, Hammond et 
al. 2003). Several in vitro studies have shown that NRTIs such as zidovudine, 
stavudine, and didanosine may result in depletion of mitochondrial DNA (Chen, 
Vazquez-Padua et al. 1991). 
 
 
Table 1.3. Currently employed anti-HIV drug families and reported mitochondrial 
toxicity. Modified from(Perez-Matute, Perez-Martinez et al. 2013) 
 
Drug Family  Mitochondrial dysfunction  
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Nucleoside/nucleotide reverse 
transcriptase inhibitor (Abacavir, 
Didanosine, Emtricitabine, 
Lamivudine, 
Stavudine, Tenofovir, and 
Zidovudine) 
Inhibition of Pol-γ 
Depletion of mtDNA 
Reduction of mtDNA-encoded proteins 
Respiratory chain dysfunction 
Direct inhibition of ETC complexes (I, IV) 
Reduction of ATP levels 
ROS production 
Decrease in   
Impairment of ADP/ATP translocase 
Impairment of fatty acid oxidation 
 
Nonnucleoside reverse 
transcriptase 
inhibitor (Efavirenz, Etravirine, and 
Nevirapine) 
Respiratory chain dysfunction 
Reduction of ATP levels 
ROS production 
Decrease in Apoptosis 
 
Protease inhibitor (Atazanavir, 
Darunavir, Fosamprenavir, 
Lopinavir, 
Ritonavir, and Saquinavir) 
Inhibition of MPP (mitochondrial protease 
processing) 
Fragmentation of mitochondrial network 
Increase in mitochondrial Ca2+ 
accumulation 
Apoptosis 
ROS production 
 
 The severe adverse effects of NRTIs on mitochondria lead to increased production 
of reactive oxygen species (ROS) which may be directly involved in lipoatrophy. It is 
suggested that an early drug-induced mitochondrial dysfunction may result in an 
increase in subcutaneous fat; hence fat loss is associated with more advanced and 
severe mitochondrial dysfunction. Here it is important to note that, initially, mild 
mitochondrial toxicity shows an increased production of ROS resulting in the 
activation of mitochondrial biogenesis and adipogenesis leading to adipocyte 
hypertrophy. Mitochondrial dysfunction may lead to severe disturbances in 
mitochondrial bioenergetics, resulting in inadequate energy production. A decrease 
in adipocyte size and an increase in adipocyte death leads to clinical lipoatrophy 
(Caron-Debarle, Boccara et al. 2010). Consequently, clinicians may decide to change 
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the regimen altogether. However one study has shown that switching patients from 
stavudine to tenofovir improves fat mitochondrial function and decreases oxidative 
stress. The replacement of the older drugs with newer NNRTIs or new NRTIs allows 
partial recovery of lipoatrophy or sometimes may result in fat hypertrophy (Perez-
Matute, Perez-Martinez et al. 2013).  
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Figure 1.11. Proposed deleterious impact of mitochondrial dysfunction on adipose tissue (Caron-Debarle, Boccara et al. 2010) 
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1.5.4 Role of adipokines in HIV Lipodystrophy 
Body metabolism rate, energy homeostasis, weight regulation and many other 
biological processes are affected by adipokines (Carr, Workman et al. 2004). It is also 
reported that some important adipokines that play fundamental roles in metabolism, 
for example, adiponectin and leptin, are decreased in HAART treated patients (2003, 
Nagy, Tsiodras et al. 2003, Sweeney, Brennan et al. 2007).  Consequently adipokine 
replacement can be a potential therapy but it has not been approved by the FDA yet 
for treatment of any lipid metabolic disorder in HIV patients (Paruthi, Gill et al. 2013).   
a. Adiponectin 
Adiponectin is a novel adipocyte specific protein which acts like a classic circulating 
hormone, while inducing fatty acid oxidation, along with glucose uptake by the 
different cells of the body (Lee, Magkos et al. 2011). It is an anti-inflammatory 
cytokine and increases peripheral insulin sensitivity whilst suppressing 
gluconeogenesis by the liver (Kwon and Pessin 2013). Pro-inflammatory cytokines 
such as IL6 and TNFα were found to be upregulated in the serum of HIV patients 
when treated with ARVs (Lindegaard, Keller et al. 2004) which suppress the secretion 
of adiponectin from the adipocytes (Li, Shin et al. 2009). Studies in mice have shown 
that adiponectin can decrease levels of triglyceride in the liver and muscles by 
upregulating the oxidation of fatty acids (Fruebis, Tsao et al. 2001).  
Patients with type 2 diabetes, cardiovascular disease and obesity have lower levels 
of adiponectin (2002, 2005). Low serum levels of adiponectin have also been 
reported in HIV patients receiving HAART and are associated with insulin resistance 
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(Carol L. Addy 2003). Adiponectin can suppress the apoptosis of β cells and increase 
the expression of insulin,  thus suggesting its potential therapeutic value (Lee, 
Magkos et al. 2011). The anti-inflammatory and antiatherogenic properties of 
adiponectin show its immense potential as a new possible pharmacological 
treatment for enhancing insulin sensitivity in patients with metabolic syndrome and  
type 2 diabetes (Lihn, Pedersen et al. 2005).  However, further research is required 
to study the use of replacement adiponectin, or adiponectin analogues, and their 
potential effects, especially in patients  receiving HAART (Paruthi, Gill et al. 2013). 
The mechanism of action of adiponectin, through which it enhances insulin 
sensitivity, is still unknown (Ravussin 2002). 
Insulin sensitisers, such as thiazolidinediones and metformin, have been trialled in 
lipodystrophy but results from randomised clinical trials in HIV+ patients have shown 
mixed results (Benavides and Nahata 2004). Moreover, the associated adverse 
effects may limit their use in HIV+ patients (Nissen and Wolski 2007). Tesamorelin, a 
growth hormone releasing factor analogue, has been recently approved by the FDA 
for the treatment of HIVLD.  Tesamorelin mediated reduction in visceral fat was 
accompanied by a modest beneficial effect on adiponectin and but there was no 
improvement in glucose parameters (Falutz, Mamputu et al.) 
Adiponectin levels may be improved by the use of some pharmacological drugs such 
as telmisartan, which is an angiotensin receptor blocker and partial PPAR-γ receptor 
agonist. A recent in vitro study using 3T3L1 cells showed that levels of adiponectin 
secreted by mature adipocytes were improved after treatment with telmisartan 
whilst also causing a simultaneous reduction in the levels of IL6 and TNFα  (Kang, 
Yijun et al. 2014). Another in vivo study, conducted in type 2 diabetic rats, has shown 
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that treatment with telmisartan can improve the levels of adiponectin, adiponectin 
receptor 2 and GLUT4 levels (Guo, Zhang et al. 2012). A pilot clinical trial conducted 
in the United States in HIV infected patients with lipodystrophy failed to show any 
significant improvement in adiponectin levels with telmisartan therapy (Lake, Tseng 
et al. 2013) but it was conducted on a smaller scale with less number of patients 
taking part in it. Another large-scale, UK wide clinical trial called TAILoR (Telmisartan 
and Insulin Resistance in HIV), which is currently ongoing, is studying the detailed 
effects of telmisartan in terms of insulin resistance at different dose levels 
(http://www.tailortrial.org.uk/index.html).  
b. Leptin 
Leptin is an adipocyte specific hormone and is a regulator of energy homeostasis 
(Fruebis, Tsao et al. 2001, Wasim A. Haque 2002). It also regulates neuroendocrine, 
and immune functions (Moon, Dalamaga et al. 2013). It acts through hypothalamic 
pathways and signals when there is sufficient energy for the human body (Mantzoros 
1999). With weight loss, leptin levels decline and result in increased appetite and 
reduction in energy production in the body (Friedman and Halaas 1998). Leptin can 
show insulin sensitising effects by inhibiting gluconeogenesis in the liver and in 
adipose tissue and enhances the utilisation of glucose by skeletal muscles (Bluher 
and Mantzoros 2009). Leptin can also increase fatty acid oxidation inside muscle cells 
and reduce lipid accumulation while preventing lipotoxic effects (Petersen, Oral et al. 
2002).  
Small scale studies have shown that the use of leptin as a therapeutic tool can reduce  
insulin resistance, in the short term, in HIV patients with lipodystrophy (Lee, Chan et 
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al. 2006, Mulligan, Khatami et al. 2009); this  shows that recombinant leptin could 
possibly be used to treat lipodystrophy (Mantzoros 2009). At the moment a leptin 
analogue called metreleptin is available on the market for the treatment of the 
generalised lipodystrophy but not for HIV lipodystrophy. A clinical trial would need 
to be conducted for it to be approved for the use in HIV patients with lipodystrophy 
(Chou and Perry 2013).  
c. IL6 
Interleukin-6 (IL6), which was identified as a B-cell differentiation factor, is a 
multifunctional cytokine that regulates the immune response (Sehgal, May et al. 
1987). It plays a key role in haematopoiesis and regulates the acute phase response 
and inflammation. IL6 is secreted by many cell types including B cells, T cells, 
monocytes, keratinocytes, fibroblasts and adipocytes (Mihara, Nishimoto et al. 
2005). IL6 acts through two receptor molecules on the cell surface, IL6R and gp130 
(Hibi, Murakami et al. 1990). It has been reported that IL6 induces insulin resistance 
in adipocytes (Rotter, Nagaev et al. 2003). Resistance to insulin and obesity are 
closely associated and linked to low grade inflammation and IL6 has been found to 
be associated with inflammation linked to obesity (Mauer, Chaurasia et al. 2014). 
Macrophages secrete higher levels of IL6 when treated with ARVs (Chen, Jarujaron 
et al. 2009). Higher levels of IL6 have also been reported in the plasma of HIV patients 
receiving antiretroviral treatment (Crawford, Spritzler et al. 2010).  
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d. Tumour necrosis factor alpha (TNFα) 
Tumour necrosis factor was initially identified as an endotoxin induced glycoprotein 
in haemorrhagic necrotic sarcomas (Carswell, Old et al. 1975). It is mainly produced 
by activated macrophages and T-lymphocytes (Black, Rauch et al. 1997) but is also 
produced by adipocytes (Bradley, Fisher et al. 2008). It is a multifunctional cytokine 
that plays an important role in immune system regulation, cell proliferation, energy 
metabolism and apoptosis (Cawthorn and Sethi 2008). It is now known that TNF-α 
can induce insulin resistance in adipocytes (Ruan and Lodish 2003). Antiretroviral 
drugs can induce levels of TNFα in macrophages (Chen, Jarujaron et al. 2009). Also, 
HIV patients receiving combination antiretroviral therapy have shown higher serum 
levels of TNF-α (De Pablo-Bernal, Ruiz-Mateos et al. 2014). TNF-α levels were also 
reported to be higher in the plasma of HIV patients showing lipodystrophy 
(Lindegaard, Keller et al. 2004).  
e. Lipin1  
Lipin 1 is one of the members of the three proteins of the lipin family. It is mainly 
expressed in adipose tissue, skeletal muscle and testis (Peterfy, Phan et al. 2001). 
Lipin 1 acts like an enzyme and converts phosphatidate to diacylglycerol during 
triglyceride biosynthesis (Reue and Brindley 2008). When fatty acid levels are 
elevated, lipin 1 translocates from the cytosol to the endoplamic reticulum 
membrane and converts the phosphatidic acid to diacylglycerol (Reue and Brindley 
2008) and hence plays a key role in adipocyte maturation. Adipocytes lacking lipin 1 
cannot differentiate into mature adipocytes (Mitra, Chen et al. 2013). Levels of lipin1 
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were found to be low in HIV patients with lipodystrophy when compared to HIV 
patients without lipodystrophy. Also, lipin 1 levels were found to be correlated with 
limb fat where  higher levels of lipin 1 mRNA were demonstrated in their fat tissues 
(Lindegaard, Larsen et al. 2006).  
f. Interleukin-18  
Interleukin-18 (IL-18) is a proinflammatory, proapoptotic and proatherogenic 
cytokine that,  is suggested to play a pathogenetic role in various cardiometabolic 
and inflammatory conditions (Torre and Pugliese 2010). It is mainly produced by 
macrophages and is involved in both innate and acquired immune response and in 
tissue destruction (Kashiwamura, Ueda et al. 2002). It is synthesised as an inactive 
precursor and converted to the active form by IL-1β-converting enzyme (caspase-1). 
It elicits its action through heterodimeric receptors, IL-18Rα (ligand binding subunit) 
and IL-18Rβ (signal transducing subunit) (Kashiwamura, Ueda et al. 2002). Increased 
levels of IL-18 have been demonstrated in a range of cardiometabolic conditions such 
as obesity (Esposito, Pontillo et al. 2002), MS (Hung, McQuillan et al. 2005), T2DM 
(Esposito, Marfella et al. 2004, Hivert, Sun et al. 2009), myocardial infarction 
(Hartford, Wiklund et al.) and atherosclerosis (Torre and Pugliese). Esposito et. al. 
observed elevated plasma IL-18 levels in obese women which correlated with body 
weight and visceral fat. Interestingly, life-style induced reduction in body weight in 
these patients resulted in the reduction of IL-18 levels (Esposito, Pontillo et al. 2002).  
Increased IL-18 mRNA expression in the adipose tissue and adipocytes obtained from 
obese individuals has also been reported (Moschen, Molnar et al. , Bruun, Stallknecht 
et al. 2007). IL-18 was identified as an independent predictor of MS in subjects 
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without a history of diabetes (Hung, McQuillan et al. 2005); importantly IL-18 levels 
also showed correlation with hs-CRP and IL-6, which are two markers associated with 
metabolic disease. A further study in the same cohort showed IL-18 to be inversely 
correlated with adiponectin (Hung, McQuillan et al. 2008). This inverse relationship 
between IL-18 and adiponectin has been corroborated by other studies (Lee, Ng et 
al. , Straczkowski, Kowalska et al. 2007).  
g. Other adipokines 
A less studied adipokine called resistin was identified in 2001.  It was found that 
resistin levels in the blood decreased with anti-diabetic treatment but increased in 
diet-induced obesity and congenital lipodystrophy. It was thought that this hormone 
may connect diabetes with insulin (Steppan, Bailey et al. 2001); however later studies 
have failed to find any correlation between resistin and obesity or insulin resistance 
(Lee, Chan et al. 2003, Youn, Yu et al. 2004). In a recent study genetic variation in 
resistin was found to be associated with metabolic complications resulting from 
combination antiretroviral therapy in HIV positive individuals (Ranade, Geese et al. 
2008).  
Another adipokine, plasminogen activator inhibitor (PAI-1), which is extensively 
produced by adipocytes, is a key factor in regulation of fibrinolysis and catalyses the 
conversion of plasminogen into plasmin. Lower levels of PAi-1 were produced by 
visceral fat when compared to subcutaneous fat in obese individuals (Eriksson, Van 
Harmelen et al. 2000). Besides the fact that PAI-1 is produced both by visceral and 
subcutaneous fat, the data is contradictory about which source secretes more PAI-1 
hormone.   
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Ghrelin is mainly secreted by gastric cells but is also secreted by adipocytes. Over 
expression of ghrelin inhibits adipocyte maturation and proliferation via ghrelin 
receptors (Zhang, Zhao et al. 2004).  However, another study proposed that ghrelin 
stimulates insulin-induced glucose uptake in adipocytes (Patel, Stanley et al. 2006). 
Similarly, while one study showed higher levels of ghrelin in HIV patients receiving 
combination antiretroviral therapy (Falasca, Manigrasso et al. 2006), another study 
showed the opposite (Rietschel, Hadigan et al. 2001). These references suggest the 
need for further studies to evaluate the actual mechanism of action of ghrelin in ARV-
related metabolic adverse effects.  
1.6 Adipogenesis 
A complex and highly orchestrated programme of gene expression is involved in the 
formation of adipocytes from precursor stem cells. The basic network of transcription 
factors, as reported in different studies, that regulates adipogenesis has remained 
remarkably unchanged (Rosen and Spiegelman 2000, White and Stephens 2010) but 
with the continuous ongoing discovery of new factors and co-factors, our 
understanding of molecular mechanisms involved in the process of adipogenesis is 
improving (Lowe, O'Rahilly et al. 2011).  The understanding of the complexity of the 
process of adipogenesis contributes towards the development of therapeutic 
strategies for adipose tissue related diseases in the human body such as metabolic 
syndrome and obesity (Unger, Clark et al. 2010). Improvement in adipocyte function 
and the replacement of poorly functioning adipocytes can be beneficial in different 
metabolic diseases. Approximately 10% of new adipocytes are formed in adipose 
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tissue each year following differentiation of preadipocytes; this demonstrates the 
importance of adipogenesis in metabolic homeostasis. (Spalding, Arner et al. 2008).  
1.6.1   Adipocyte stem cells  
Adipogenesis in vitro follows a highly ordered and well characterised sequence. 
There are multiple sources of adipocytes which are used in research as described in 
figure 1.12. Several tissues, including adipose and muscle tissue, can provide 
adipocytes for research purposes but, especially useful are pluripotent mesenchymal 
stem cells (Rodeheffer, Birsoy et al. 2008).  Studies have shown that there are 
different precursor cells for brown adipose tissues, whereas previously it was 
thought that both of them originated from the same set of stem cells. The 
thermogenic brown adipocytes develop through the transcriptional activity of 
transcription factor PR-domain-containing 16 (PRDM16) from precursors and these 
can also give rise to myocytes (Seale, Bjork et al. 2008, Kajimura, Seale et al. 2009). 
The complex nature of adipose differentiation has made it difficult to dissect out the 
specific area in embryos to isolate the presumptive precursor fibroblast, which could 
then be transformed into mature adipocytes in an in vitro environment (Rosen and 
Spiegelman 2000). The isolation of adipocytes from a Swiss mouse, and their 
conversion into 3T3L1 and 3T3-F442A cell lines (Green and Kehinde 1975), helped to 
stream line the study of a variety of aspects of adipogenesis in vitro . 
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Figure 1.12. Various models used currently in research to study adipogenesis and 
related complications (Rosen and MacDougald 2006), Embryonic stem (ES), Mouse 
embryonic fibroblasts (MEFs). 
 
1.6.2 Initiation of adipocyte differentiation 
There are multiple factors involved in the initiation of differentiation of the 
adipocytes from stem cells. These include extracellular factors such as the insulin-like 
growth factor 1 (IGF1) (Kawai and Rosen 2010), fibroblast growth factor 1 (FGF1) 
(Widberg, Newell et al. 2009), bone morphogenetic proteins (BMPs) (Huang, Song et 
al. 2009), transforming growth factor β (TGFβ) (Zamani and Brown 2011),  interleukin 
17 (IL17) (Zúñiga, Shen et al. 2010), FGF2 (Xiao, Sobue et al. 2010) and activin 
(Zaragosi, Wdziekonski et al. 2010). Studies have reported that both in vitro and in 
vivo, the suppression of the WNT signalling pathway is essential for the adipocyte 
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differentiation (Christodoulides, Lagathu et al. 2009). Another pathway, known as 
the hedgehog (HH) signalling pathway,  may inhibit adipogenesis but its role is not 
yet clear (Pospisilik, Schramek et al. 2010). A study suggests that the WNT and HH 
pathways have receptors on the primary cilia which are normally present inside the 
microtubules in differentiating adipocytes, but formation of impaired cilia results in 
over expression of the PPARγ gene resulting in increased adipogenesis which leads 
to an obese phenotype (Marion, Stoetzel et al. 2009).  
Many other intracellular signalling pathways also affect the process of adipogenesis 
such as glutathione (Vigilanza, Aquilano et al. 2011) and the Janus kinase-signal 
transducer and activator of transcription 3 (JAK-STAT3) pathway (Zhang, Guo et al. 
2011). Retinoic acid inhibits adipogenesis via the SMAD signalling pathway (Tan, 
Leuenberger et al. 2011). Ribosomal protein S6 kinase 1 (S6K1) and components of 
the insulin signalling cascade, such as AKT and a newly discovered regulator of this 
pathway, inositol pyrophosphate, also have implications in adipogenesis (Zhang, 
Huang et al. 2009, Carnevalli, Masuda et al. 2010, Chakraborty, Koldobskiy et al. 
2010). In recent studies, the role of new transcriptional regulators of stem cells have 
been mentioned in terms of their role in adipogenesis which include, retinoblastoma 
protein (RB) (Calo, Quintero-Estades et al. 2010), p53(Molchadsky, Shats et al. 2008) 
and the proto-oncoprotein, MAF (Nishikawa, Nakashima et al. 2010). Apart from the 
external signals, the cell shape also influences the process of adipogenesis. Studies 
have shown that rounded mesenchymal stem cells (MSCs) are more likely to become 
adipocytes (Kilian, Bugarija et al. 2010). Similarly, in other studies, the importance of 
the extracellular matrix and its role in the remodelling of adipocytes and adipose 
tissue development are demonstrated (Mariman and Wang 2010); e.g. loss of the 
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membrane-bound matrix metalloproteinase MMP14 impairs adipogenesis (Chun, 
Hotary et al. 2006). This defect was apparent only in a three dimensional study. This 
clearly shows the constraints of two dimensional studies conducted in laboratories 
which can give us only a partial picture of the actual process of interaction between 
different pathways (Christiaens and Lijnen 2010). 
1.6.3   Regulation of gene expression during adipogenesis 
The process of terminal differentiation has been has been reviewed in detail by many 
authors (Farmer 2006, Rosen and MacDougald 2006, Tontonoz and Spiegelman 
2008). Here, only a brief description of regulatory mechanisms is provided. After 
receiving the stimulus to differentiate, expression of the key regulators of 
adipogenesis such as CAAT/enhancer-binding proteins (C/EBPs), C/EBPβ and C/EBPδ 
increases rapidly(Wang and Sul 2009). The key targets of C/EBPβ and C/EBPδ are the 
promoter region of genes encoding for the adipogenic transcription factors, C/EBPα 
and PPARγ, and the regulator of lipogenesis genes, SREBP1 (sterol-regulatory-
element-binding protein 1)(Rosen and MacDougald 2006). PPARγ targets the 
promoter of the gene encoding for C/EBPα and vice versa, resulting in the creation 
of a positive-feedback loop. In addition, PPARγ and C/EBPα together induce the 
expression of many genes that are involved in insulin sensitivity, lipogenesis and 
lipolysis, including those encoding for glucose transporter GLUT4, FABP4, adipocyte 
protein 2 (aP2), lipoprotein lipase (LPL), sn-1-acylglycerol-3-phosphate 
acyltransferase 2 (AGPAT2), perilipin and the secreted factors adiponectin and leptin 
(Nielsen, Pedersen et al. 2008).  
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PPARγ, a member of the nuclear receptor super-family is thought to be necessary 
and sufficient for adipogenesis and is considered as a master adipogenic regulator 
(Rosen and Spiegelman 2000). CCAAT-enhancer-binding proteins (C/EBP) are a group 
of proteins which belong to the leucine zipper class of transcription factors. In vitro 
both C/EBP- α and PPARγ are required for the middle and later part of the adipocyte 
differentiation whereas C/EBP β and δ are involved in the early differentiation 
process (Darlington, Ross et al. 1998, Choi, Ghaddar et al. 2014). PPARγ and C/EBPα 
also bind together on regulating a wide range of genes which are only expressed in 
the developing or mature adipocytes (Nielsen, Pedersen et al. 2008).  
There are some factors thought to be capable of both pro- and anti-adipogenic 
actions. For example,  the orphan nuclear receptor chicken ovalbumin upstream 
promoter-transcription factor II (COUP-TFII, also known as NR2F2) has been reported 
to promote pre-adipocyte lineage commitment by inhibiting Wnt signalling (Li, Xie et 
al. 2009) and it can also inhibit adipogenesis by repressing the expression of C/EBPα 
and PPARγ (Xu, Yu et al. 2008, Okamura, Kudo et al. 2009). Studies have found that 
many factors influencing adipogenesis may also affect its activity during 
adipogenesis.  For example, sirtuin (Sirt) SIRT2 inhibits PPARγ indirectly by reducing 
the amount of forkhead box O1 (FOXO1) acetylation and phosphorylation, which 
results in a rise in the nuclear localization of FOXO1, thereby repressing its 
transcription (Jing, Gesta et al. 2007) whereas SIRT1 acts as a co-repressor of PPARγ 
and impairs adipogenesis (Picard, Kurtev et al. 2004). There are numerous newly 
discovered inhibitors of PPARγ such as the cellular retinol-binding protein RBP1 
(Zizola, Frey et al. 2010) and cyclic phosphatidic acid (cPA) (Tsukahara, Tsukahara et 
al. 2010). Another means of regulation for PPARγ is its phosphorylation.  
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Phosphorylation results in inhibition of PPARγ by various mechanisms including 
impaired recruitment of transcriptional co-activators, along with increased binding 
to the circadian regulator, period homolog 2 (PER2), which consequently leads to the 
inhibition of PPARγ transcription (Grimaldi, Bellet et al. 2010). Overall there are many 
different pathways involved in adipogenesis consisting of a meshwork of 
communication between various genes at cellular level.  
1.6.4  Antiretroviral induced gene dysregulation in adipocytes  
In this era of HAART, there has been an improvement in the life span of HIV patients 
but the continuous and unavoidable use of antiretroviral drugs brings along some 
complexities such as lipodystrophy (Stanley, Joy et al. 2009). The underlying 
mechanisms resulting in metabolic abnormalities induced by ART are unclear, 
although various studies have shown adverse effects on adipocyte differentiation 
(Stankov, Schmidt et al. 2008), survival (Kim, Wilson et al. 2006), alteration in the 
secretion of variety of adipokines (Cianflone, Zakarian et al. 2006), mitochondrial 
dysfunction (Rudich, Ben-Romano et al. 2005) and oxidative stress (Lagathu, Eustace 
et al. 2007) induced by ARVs. It is quite possible that various ARVs might induce lipid 
abnormalities to a variable degree and also the actual mechanisms and properties of 
the metabolic side effects observed may also differ from one drug to another. Studies 
have shown evidence that some PIs inhibit degradation of adipogenic transcription 
factors such as SREBPs, C/EBP-a (Hirano, Yoshida et al. 2001, Bastard, Caron et al. 
2002, Lagathu, Eustace et al. 2007) and PPARϒ (Dowell, Flexner et al. 2000).  
In various studies, nucleoside reverse-transcriptase inhibitors (NRTIs) have been 
reported to cause mitochondrial dysfunction (Haerter, Manfras et al. 2004, Stankov, 
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Lucke et al. 2007) resulting in depletion of mitochondrial DNA and inhibition of its 
transcription. Lipid metabolism has been shown to be less affected by the newer 
generation of PIs along with integrase inhibitors while also having higher antiviral 
efficacy (Haerter, Manfras et al. 2004, Eron, Young et al. 2010). In a recent study 
conducted on 3T3-L1 cells inhibition of the expression of C/EBP-a, PPAR-ϒ, and 
SREBP-1c was reported after treatment with some PIs, whereas NNRTI mildly 
inhibited their expression. They also reported that NRTIs and some newer PIs such as 
ATV and RAL have minimal effects on the above mentioned adipogenic genes. The 
study also exhibited that RTV decreased lipid accumulation in mature 3T3-L1 cells 
more than in pre-differentiated cells, suggesting that the effect of RTV occurs 
relatively late in adipocyte differentiation. C/EBP-b, which is expressed only during 
early adipogenesis, was unaffected by ARVs treatment, suggesting that molecular 
targets affected by ARVs are probably downstream of this adipogenic transcription 
factor (Minami, Yamamoto et al. 2011). Some earlier studies have provided us with 
similar reports while suggesting that some ARVs block adipocyte differentiation by 
inhibiting the expression of those genes which are mainly expressed in the later part 
of adipogenesis, e.g. C/EBP-a and PPAR-ϒ (Parker, Flint et al. 2005, Stankov, Schmidt 
et al. 2008, Caron, Vigouroux et al. 2009) or by modulating SREBP-1 intranuclear 
localization (Bastard, Caron et al. 2002, Parker, Flint et al. 2005). These findings 
indicate that altered functions of PPARϒ, C/EBP-a, and SREBP-1c may play a role in 
ARV induced LD but it may not be limited to these genes only.  
A member of NFAT family of genes, NFATc4, is expressed in adipocytes and peri-
vascular tissue cells such as endothelial cells (Horsley and Pavlath 2002) and has a 
role in adipogenesis along with its role as a transcription factor. NFATc4 performs 
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transcription of many cytokine genes which are necessary for cell growth and 
adipogenesis. It modulates many important target genes while modulating a cell’s 
response to its environment especially in case of inflammation. PPARϒ is a master 
adipogenic transcription factor and NFATc4 modulates its response while binding to 
the gene promoter region (Yang, Xiong et al. 2002). Hence, there is a balance 
between these two transcription factors but ARVs differentially modulate the 
expression of PPARϒ and C/EBP, which is another important gene for adipogenesis 
affecting the metabolic pathways inside the cells, resulting in dysregulation of the 
adipogenesis (Gallego-Escuredo, Del Mar Gutierrez et al. 2010).  
PPARϒ is implicated in adipocyte differentiation and insulin sensitivity. Sterol 
regulatory element binding protein 1 (SREBP-1) is a transcription factor. PPARϒ and 
SREBP-1 are associated with both adipocyte differentiation and cholesterol 
homeostasis but SREBP-1 can control the transcriptional activity of PPARϒ (Fajas, 
Schoonjans et al. 1999). Both SREBP-1 and PPARϒ are down regulated by HIV-PIs 
(Hawkins, Robbins et al. 2008, Boccara, Auclair et al. 2010). The up regulation of 
NFATc4 by ARVs (Reyskens, Fisher et al. 2013) results in an increase in transcription 
of many pro-inflammatory cytokines such as IL6 and TNFα but down regulation of an 
insulin sensitizer called adiponectin (Kim, Kong et al. 2006, Nilsson, Sun et al. 2007). 
Protease inhibitors (LPV/r) and NNRTIs such as efavirenz reduce the expression of 
adiponectin and PPARϒ in human adipocytes and affect their maturation (Gallego-
Escuredo, Del Mar Gutierrez et al. 2010) leading to complications such as imbalance 
of body lipid profile resulting in lipodystrophy and later on cardiovascular disease 
(Morimoto, Simao et al. 2014). The above findings show that antiretroviral drugs 
dysregulate the metabolic pathways of adipocytes and can result in further 
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complications such as lipodystrophy. In the forthcoming chapters of this thesis  the 
role of some of the above mentioned transcription factors e.g NFATc4 and PPARϒ will 
be discussed in detail in relation to antiretroviral treatment in vitro.  
1.7 The role of genetic predispositions in development of HIVLD 
There have been various reports of variability amongst the intra and inter-individual 
response to pharmacological agents in the treatment of HIV infection (Michaud, Bar-
Magen et al. 2012) which suggest a role for genetic factors in HIVLD pathogenesis.  
However there is little data on this. One of the suggested mechanism involved in the 
development of lipodystrophy is  mitochondrial dysfunction which results in the 
blockage of the DNA polymerase-ϒ by NRTIs  (Shikuma, Hu et al. 2001, Cote, Brumme 
et al. 2002, Nolan, Hammond et al. 2003, McComsey, Libutti et al. 2008). Various 
studies have looked into the relationship between genetic variations in the mtDNA 
and lipodystrophy as summarised in table 1.4 below.  
McComsey et. al. 2002 did not find any evidence of an association between mtDNA 
mutations and HIVLD but this study used a small sample size (10 HIV infected patients 
who received NRTIs and had lipoatrophy and 10 healthy controls). Their findings were 
not replicated in another longitudinal study that found an association between 
lipoatrophy and the accumulation of mutations in the mtDNA (Martin, Hammond et 
al. 2003).  A study performed in the Swiss HIV Cohort suggests that mtDNA genetic 
variation has no role in the pathogenesis of NRTI-related lipoatrophy (Ortiz, Poloni et 
al. 2011). A cross sectional study involving 346 treated HIV-infected patients with 
lipodystrophy found that none of the nine European mtDNA haplo-groups were 
related to lipodystrophy (Nasi, Guaraldi et al. 2008). An explanation for these 
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discrepancies between studies is that most of them were conducted with a very small 
number of patients.   
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Table 1.4 Genetic studies which investigated the variation in mtDNA and lipodystrophy in HIV-infected patients treated with HAART 
 
 
Population assessed accessed for mtDNA dysfunction in 
relation to LD 
 
Conclusions 
 
Reference  
16 HIV-infected patients receiving cART and 5 presented LD Patients with LD developed changes in 
the mtDNA   
(Martin, Hammond et al. 2003) 
29 HIV-infected patients starting a first-line NRTI-based 
cART, 13 presented LA 
No accumulation of mtDNA mutations  (Ortiz, Poloni et al. 2011) 
346 HIV-infected patients with LD No association  (Nasi, Guaraldi et al. 2008) 
   
410 European-American HIV-infected  Mitochondrial haplogroup H associated 
with LD 
(Hendrickson, Kingsley et al. 2009) 
24 individuals: 10 healthy controls, 10 treated HIV-infected 
with LA and 4 untreated HIV-infected 
No association 
 
(McComsey, Tan et al. 2002) 
207 treated HIV-infected patients;  
69 with LD and 138 without 
Association b/w polymorphism in 
the E1143 and LD 
(Chiappini, Teicher et al. 2009) 
74 
 
Lipodystrophy is an inflammatory syndrome in which the role of cytokines cannot be 
neglected. The role of pro-inflammatory cytokines such as TNF-a,IL-1, IL-6 and IL-18 
has been studied in adipocyte (Johnson, Albu et al. 2004, Lindegaard, Hansen et al. 
2004, Cawthorn and Sethi 2008) which mimics the in vivo findings observed in 
adipose tissue samples of patients with lipodystrophy and other inflammatory 
diseases such as obesity, lipid abnormalities, atherosclerosis and cardiovascular 
diseases (Ledru, Christeff et al. 2000, Lindegaard, Hansen et al. 2004, Kishimoto 
2006).  
TNF-a gene polymorphisms have been studied to determine whether they are 
associated with the development of lipodystrophy but the results are inconclusive. 
TNF-α has a role in the pathogenesis of HIV and TNF-α inhibitors can have a significant 
impact on HIV disease progression (Kumar, Abbas et al. 2013). TNF-α also has a role 
in atherosclerosis which is common amongst HIVLD patients (Ntaios, Gatselis et al. 
2013). A British study found an association between the TNF-a -238G > A 
polymorphism and lipodystrophy but the authors suggested that this single 
nucleotide polymorphism (SNP) itself is neither sufficient nor absolutely necessary to 
produce lipodystrophy, though its presence may increase the risk of developing it 
(Maher, Alfirevic et al. 2002). However, many other larger longitudinal and cross-
sectional studies could not reproduce these findings (Tarr, Taffe et al. 2005, Asensi, 
Rego et al. 2008). In an Australian longitudinal study it was found that the same SNP 
was associated with an earlier start and a faster progression of lipodystrophy (Nolan, 
Moore et al. 2003) and another study in Indian HIV population replicated this 
association with HIVLD (Mahajan, Gaekwad et al. 2014).  
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A SNP in lipopolysaacride binding protein (LBP) was reported to be associated with 
HIVLD in a Spanish population cohort (Viladés, Escoté et al. 2014). A study in a Thai 
population cohort of HIV patients has shown a significant association between SNPs 
in FAS gene and HIVLD (Likanonsakul, Rattanatham et al. 2013). Another genetic 
study in HIV patients found significant association between HIVLD and SNPs in the 
estrogen receptor gene (Gasparotto, Sprinz et al. 2012).  
PPARϒ is a master transcription factor and is considered to be involved in obesity and 
the inherited form of lipodystrophy (Ahmed, Ziouzenkova et al. 2007). A study 
performed in Caucasians showed that a SNP in PPARϒ is associated with the potential 
risk of developing LD associated with cART (Saumoy, Veloso et al. 2009). Nuclear 
receptors such as PPARϒ are activated through certain ligands specific for their 
activation and play an important role in adipogenesis and whole-body lipid 
homeostasis, e.g. Liver X receptors (LXRα and LXRβ), peroxisome proliferator-
activated receptors (PPARα and PPARϒ), the farnesoid X receptor (FXR) and retinoid 
X receptors (RXRα, , RXRβ and RXRϒ) and regulate the activation of many other genes 
in different pathways involving cholesterol transport, cholesterol efflux and high-
density lipoprotein metabolism (Beaven and Tontonoz 2006). In a recent study, SNPs 
in RXRϒ (rs2134095, rs113471, and rs2194899) have been shown to be associated 
with HIVLD (Pushpakom, Owen et al. 2013). The above studies suggest that there is 
a possibility that genetic variants may play a role in conferring susceptibility to HIVLD. 
A detailed picture is described in chapter 6 of this thesis regarding genetic 
polymorphisms and association between HIVLD.  
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1.8 Aims of the Thesis 
HIV associated lipdystrophy is an adverse effect of cART. There has been a massive 
amount of research undertaken to understand its mechanisms because of its clinical 
importance, in longer term cardiovascular complications, as well as the reduction in 
the quality of life of HIV patients but its mechanism is still not clearly understood.  Its 
aetiology is complex and multifactorial, involving adipose tissue and skeletal muscle 
(Calza, Danese et al. 2014) as a target of ARVs and developing clinical phenotypes. 
New, emerging ARVs have only extended the life span of HIV patients and 
combination  ARVs have  made it difficult to determine the specific pathways 
involved in its appearance, particularly in relation to specific antiretroviral drugs. The 
main purpose of this work was to reduce the effect of these confounding factors and 
understand the actual mechanism of HIVLD by using both an in vitro model and 
patient samples. However, further elucidation of the mechanism of LD is required. 
Specifically the aims of this study were to understand the role of ARVs in the 
pathophysiology of HIVLD by: 
1. Characterisation of the effect of specific PIs and NNRTIs on adipogenesis and the 
expression of adipokines using an in vitro murine adipocyte model. 
2. Investigation of the potential of therapeutic molecules to reverse the 
adipotoxicity caused by ARVs. 
3. Understanding the molecular mechanisms that are responsible for the ARV-
mediated adipocyte toxicity. 
4. Studying the role of microRNAs in ARV -induced adipocyte toxicity 
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5. Determining the role of potential genetic variants in HIV patient DNA which might 
be responsible for the susceptibility and development of LD.  
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Chapter 2 
IL-18 and HIV associated Lipodystrophy   
 
Study of alteration in IL-18 gene response in murine 
adipocytes after treatment with protease inhibitors, NNRTIs 
and Telmisartan 
& 
Association between Genetic Variants in the IL-18 gene and 
HIV lipodystrophy 
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2.1 Introduction 
Interleukin-18 (IL-18) belongs to the IL-1 family of proteins and is produced by various 
types of cells including macrophages, dendritic cells (DCs), neutrophils, adipocytes, 
Kupffer cells, microglial cells, and neurons (Smith 2011). At the time of its discovery, 
it was known as an interferon gamma (IFN-γ) inducing factor produced by endotoxin-
activated Kupffer cells (Okamura, Tsutsui et al. 1995). This cytokine presents many 
biological effects such as multifunctional, pleiotropic, proinflammatory and 
proapoptotic actions (Iannello, Samaranil et al. 2009). It is not secreted in an active 
form but rather in the form of an inactive 24 KDa protein which needs further 
processing by another protein called IL-1β, a converting enzyme, more generally 
known as caspase-1. The mature and biologically active form of the IL-18 is only 18 
KDa (Gu, Kuida et al. 1997, Smith 2011). Caspase-1 itself requires activation from an 
assembly of multiunit complex, nucleotide-binding and oligomerization domain- 
(NOD-) like proteins, called inflammasomes (Chen, Shaw et al. 2009, Franchi, 
Eigenbrod et al. 2009).  
Expression of IL-18 is found to be higher than normal in many inflammatory diseases 
(Domingo, Gutierrez Mdel et al. 2014, Johansson, Eriksson et al. 2015, Tan, Yong et 
al. 2015). Increased production of biologically active IL-18 needs upregulation of IL-
18 gene expression at the mRNA and protein level whilst it also requires 
inflammasome assembly, caspase-1 activation, and, finally, the secretion of mature 
IL-18 by the cells (Kanneganti 2010, Davis, Wen et al. 2011). Initially IL-18 was held 
responsible for the Th1 type response only, which involves upregulation of IL-12 Rβ 
subunit on the T cell surface via IFN-γ (Okamura, Kashiwamura et al. 1998, Chang, 
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Segal et al. 2000), but then it was reported that it can also trigger Th2 responses 
(Nakanishi, Yoshimoto et al. 2001). Both Th1 and Th2 responses triggered by IL-18 
have been studied in HIV patients suffering from metabolic disorders resulting in 
lipodystrophy, which potentially highlights the importance of this cytokine as a 
therapeutic target (Iannello, Samarani et al. 2010).  IL-18 has a naturally present 
antagonist called IL-18 binding protein (IL-18bp). After binding, IL-18 becomes 
functionally inactive and cannot transduce signals through IL-18-specific receptors 
(Dinarello, Novick et al. 2013). For signal transduction, IL-18 must bind its receptor 
IL-18Rα and IL-18Rβ subunits. Initially, IL-18 binds IL-18Rα receptor subunit but its 
affinity is weak.  IL-18Rβ subunit is then recruited and this has a stronger affinity.  
 
 
Fig. 2.1. IL-18 signalling pathway; IL-18 receptor complex contains two receptor 
subunits α and β. Initially IL-18 binds to the IL-18 alpha chain (IL-18Rα) then IL-18 
receptor beta chain (IL-18Rβ) is recruited resulting in a high affinity complex which 
activates Toll-IL-1 receptor (TIR) domains. Toll-IL-1 binds MyD88 which 
phosphorylates IRAKs, TRAF-6, and finally results in activation of NFκB (Dinarello, 
Novick et al. 2013). 
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The complex of IL-18 with the IL-18Rα and IL-18Rβ results in the formation of a 
heterodimer which starts a series of changes downstream in the Toll-IL-1 receptor 
(TIR) domains. TIR recruits myeloid differentiation primary response gene 88 
(MYD88). MYD88 activates interleukin-1 receptor-associated kinases which degrade 
inhibitor of kappa Bα (IKBα) protein. This results in the release of NFKB (nuclear factor 
of kappa light polypeptide gene enhancer B) (Weber, Wasiliew et al. 2010) which is a 
transcription factor that takes part in the transcription of many pro-inflammatory 
cytokines such as IL-1, IL-6, IL-8, IL-11, and TNF-α (Gilmore 2006). 
2.1.1  IL-18 in Cardiometabolic disease 
As indicated in chapter 1, the morbidity and mortality associated with HIV has 
decreased with the advent of HAART.  However, this has also resulted in adverse 
effects including the development of metabolic complications including insulin 
resistance, cardiovascular disease and lipodystrophy.   Numerous pathways are 
potentially responsible for these metabolic complications. These include ARV-
induced adipose toxicity, resulting in dysregulation of expression of adipogenic 
genes, mitochondrial toxicity, development of insulin resistance and susceptibility 
due to the presence of various polymorphisms within disease-related genes 
(Mallewa, Wilkins et al. 2008). 
As mentioned earlier, it has been suggested that IL-18 may be involved in the 
complex pathogenesis of various cardio-metabolic and inflammatory conditions. It is 
a pro-inflammatory, pro-apoptotic and pro-atherogenic cytokine (Torre and Pugliese 
2010) and is associated with both innate and acquired immune response, while 
taking part in tissue destruction (Kashiwamura, Ueda et al. 2002). Adipocytes also 
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secrete IL-18, while TNF-α modulates its expression in human adipocytes during 
inflammation. It is suggested that IL-18 may have a role in the inflammatory cascade 
inside adipose tissue (Wood, Wang et al. 2005). Studies have reported increased 
levels of IL-18 in a range of cardiometabolic conditions such as obesity (Esposito, 
Pontillo et al. 2002), MS (Hung, McQuillan et al. 2005), T2DM (Esposito, Marfella et 
al. 2004, Hivert, Sun et al. 2009), myocardial infarction (Hartford, Wiklund et al.) and 
atherosclerosis (Torre and Pugliese).                                
Esposito et. al. observed elevated plasma IL-18 levels in obese women which 
correlated with body weight and visceral fat. Interestingly, life-style induced 
reduction in body weight in these patients resulted in the reduction of IL-18 levels 
(Esposito, Pontillo et al. 2002). Increased IL-18 mRNA expression in the adipose tissue 
and adipocytes obtained from obese individuals has also been reported (Moschen, 
Molnar et al. , Bruun, Stallknecht et al. 2007). The anti-lipolytic effect of different 
therapeutic agents on IL-18 was not observed until recently, but then a study 
focussed on HIV associated lipodystrophy found that acipimox (a niacin derivative 
and hypolipidemic agent) and insulin can be used as a potential tool to stop lipolysis. 
They also showed that upregulation of plasma levels of IL-18 in HIVLD patients can 
be reduced by the use of acipimox and insulin (Lindegaard, Ditlevsen et al. 2013). 
 IL-18 was also identified as an independent predictor of metabolic syndrome in 
subjects without a history of diabetes (Hung, McQuillan et al. 2005). More 
importantly IL-18 levels also showed correlation with hs-CRP and IL-6, two other 
markers associated with metabolic disease. Another study in the same cohort 
showed IL-18 to be inversely correlated with adiponectin (Hung, McQuillan et al. 
2008). This inverse relationship between IL-18 and adiponectin has been 
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corroborated by other studies (Lee, Ng et al. , Straczkowski, Kowalska et al. 2007). A 
large cohort study of 2093 women in the US, identified higher circulating IL-18 levels 
to be a significant predictor of T2DM after accounting for traditional risk factors 
(Hivert, Sun et al. 2009). In addition, various studies have also shown insulin 
resistance in obese and T2DM patients to correlate with IL-18 plasma levels 
(Esposito, Pontillo et al. 2002, Bruun, Stallknecht et al. 2007). IL-18 is also implicated 
in the pathogenesis of coronary heart disease; a recent meta-analysis and systematic 
review of various prospective studies identified IL-18 to be independently associated 
with CVD risk (Jefferis, Papacosta et al.).  
2.1.2 IL-18 in HIVLD 
Lindegaard et. al. were the first to report elevated plasma IL-18 levels in HIVLD 
(Lindegaard, Hansen et al. 2004). This study showed IL-18 levels to positively 
correlate with TNF-α, an adipokine suggested to have a pathogenetic role in HIVLD, 
and to negatively correlate with limb fat mass in HIVLD patients. A second study by 
the same authors found significantly higher expression of IL-18 mRNA in the 
subcutaneous adipose tissue of HIVLD patients and  it also correlated with waist-hip 
ratio, mRNA expression of IL-6, TNFα and IL-8 (Lindegaard, Hansen et al. 2004). 
Higher serum IL-18 levels in HAART-treated HIV patients with hypertriglyceridemia 
which correlated negatively with adiponectin levels have been demonstrated 
(Falasca, Manigrasso et al. 2006). 
In a recent study, conflicting outcomes were observed after treatment with regimens 
of different antiretroviral drugs received by HIV patients.  Patients who received PIs 
showed a decrease in the levels of IL-18 but on the other hand patients who received 
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NRTIs showed higher levels of IL-18 in fat tissue samples. This suggests that PIs may 
offer slightly less toxic regimen in the longer term when considering IL-18 expression 
as a lone parameter (Domingo, Gutierrez Mdel et al. 2014). Another study showed a 
difference in the levels of IL-18 amongst the visceral and subcutaneous fat tissue 
samples collected from HIV patients suffering from lipodystrophy. They observed 
significantly higher levels of IL-18 in subcutaneous adipose tissue samples when 
compared with visceral fat samples suggesting a possible role of IL-18 in fat loss and 
therefore in lipoatrophy (Gallego-Escuredo, Villarroya et al. 2013) but the mechanism 
of action of IL-18 in the development of lipoatrophy is not yet described clearly.  
Recently, different studies have looked into the involvement of genetic variants of IL-
18 in the development of HIVLD. A study conducted in a small cohort of HIV patients 
with and without LD in the Brazilian population assessed SNPs in the IL-18 gene in 
relation to the development of HIVLD. They found two SNPs, rs1946518 and 
rs187238, to be associated with HIVLD suggesting a possible role of IL-18 SNPs in 
conferring susceptibility to HIVLD (Castelar, Silva et al. 2010). However these SNPs 
were not found to be associated with HIVLD in a Spanish cohort (n=282) although the 
levels of IL-18 were found to be higher in the plasma of HIV patients both with and 
without lipodystrophy (Veloso, Escote et al. 2012). In another study, SNP rs5744292 
in IL-18 was found to be associated with higher levels of IL-18 protein in plasma of 
HIV+ individuals along with insulin resistance and metabolic syndrome (Presta, 
Andreozzi et al. 2009). Another SNP in IL-18, rs360719, has also been found to be 
associated with higher levels of IL-18 mRNA (Sanchez, Palomino-Morales et al. 2009). 
The brief summary of recent studies as described above highlights the possible role 
of IL-18 in HIVLD both from genetic and functional aspects. However, none of them 
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give a clear picture of its mechanism of action in the development of HIVLD and this 
requires further investigation. 
2.1.3 Rationale for the study 
IL-18 is secreted by adipose tissue (Bruun, Stallknecht et al. 2007) and its expression 
is increased in HIVLD (Lindegaard, Hansen et al. 2004). IL-18 induces secretion of 
adipokines, TNFα and IL-6 (Wang, Markel et al. 2008), which are linked to the 
pathogenesis of HIVLD (Caron-Debarle, Boccara et al.). IL-18 has also been shown to 
directly suppress adiponectin expression in adipocytes (Chandrasekar, Patel et al. 
2008). Adipose tissue accumulates ARVs (Caron-Debarle, Boccara et al.). These drugs 
induce adipocyte toxicity through apoptosis, inhibition of adipogenesis, inhibition of 
lipid droplet formation and downregulation of adiponectin (Caron-Debarle, Boccara 
et al. , Jones, Janneh et al. 2005). These effects are thought to result in insulin 
resistance and other metabolic abnormalities. IL-18 could be a critical mediator of 
ARV-induced adipocyte toxicity. If proven, this offers a novel therapeutic target 
which can be pharmacologically modulated to reverse ARV-induced adverse effects 
in the adipocyte.  
 
 
 
2.1.4 Hypotheses   
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The hypotheses for this study were: 
a) ARVs upregulate the expression of IL-18 in adipocytes and therefore, 
pharmacologic modulation of IL-18 may lead to reversal of ARV-induced adipose 
toxicity 
b) Genetic variants in IL-18 may predispose to the development of HIVLD in HAART-
treated HIV patients. 
2.1.5 Aims of the project 
1. To investigate whether ARVs modulate IL-18 expression and secretion in vitro 
in murine adipocytes. 
2. To utilise 3T3-F442A as an in vitro model to identify candidate molecules that 
can target IL-18 and investigate whether this strategy leads to the reversal of 
ARV-induced adipocyte toxicity. 
3. To determine genetic variants in IL-18 gene that might be associated with 
HIVLD in a UK HIV cohort.  
2.2 Methods  
2.2.1 Materials  
 Antiretrovirals,lopinavir (LPV), atazanavir (ATV), ritonavir (RTV), and efavirenz (EFV) 
were supplied by Santacruz Biotechnologies Ltd®. The angiotensin receptor blocker, 
telmisartan (Tel) was a gift from Boehringer Ingelheim GmbH, Germany. Insulin from 
bovine pancreas, methanol, Trypsin EDTA, chloroform and dimethyl sulfoxide 
(DMSO) were purchased from Sigma® Aldrich, UK. Fetal calf serum (FCS) and fetal 
bovine serum, Dulbecco’s modified eagle medium (DMEM), Hank's balanced salt 
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solution, rat tail collagen-I, reverse transcription kit, Tri-reagent for RNA isolation, 
FAM labelled IL-18, VIC labelled β-actin Taqman® gene expression assays and 
Taqman® gene expression master mix were purchased from Life technologies® USA. 
ELISA kits for IL8 were purchased from e-Bioscience® UK. 12 well and 6 well 
polystyrene plates, and T25, T75, T175 flasks and all other cell culture equipment 
were purchased from Thermo Fisher scientific ® USA. 3T3-F442A murine pre-
adipocyte cells were provided in-house at the Wolfson Centre for Personalised 
Medicine.  
2.2.2 Cell culture and drug incubations 
Cell culture media was prepared after filtering and adding 50 ml of FCS into 450 ml 
of Dulbecco’ Modified Eagle Medium (DMEM). 3T3-F442A murine adipocytes were 
cultured and maintained in T75 flasks using Dulbecco’s Modified Eagle Medium 
(DMEM), supplemented with 10% bovine calf serum. Upon reaching 75-80% 
confluence, cell culture media was discarded and the cells were washed twice with 
Hank's balanced salt solution. After washing, 5 ml of trypsin EDTA was added to the 
flasks and incubated for 5 minutes to detach the cells from the surface of the flask. 
The cells were detached by gentle tapping of the bottom of the flask. The cells were 
then poured into a 20 ml volume universal tube containing 15 ml of cell culture media 
to neutralize the trypsin and centrifuged  at 1000 rpm for 5 minutes at room 
temperature to obtain the cell pellet. After centrifugation, the supernatant was 
discarded and the cell pellet was suspended in 5 ml cell culture media. Cell counting 
was performed using Countess® cell counting chamber slides from Life Technologies 
UK. 10 µl of cell containing media was added into a 1.5 ml eppendorf tube with 10 µl 
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of trypan blue dye and mixed. Then a 10 µl mixture of cells and dye was loaded into 
a Countess cell chamber slide and inserted in the Countess cell counter. 1 X 10 6 cells 
were then sub-cultured in new T75 flasks for maintenance of the cell line and T175 
flasks were used large scale culturing of cells prior to freezing of the cells for future 
use.  
Once the cells were 70-80% confluent, 20,000 cells/well were cultured in pre-
collagen coated 12 well plates. Four sets of 12 well plates were cultured for each drug 
treatment experiment. After two days of incubation in a 5% CO2 incubator in 10% 
FBS, containing DMEM cell culture media, the media was replaced with 
differentiating media containing 100nM of insulin in all wells except the 
preadipocytes.  After 48 hours of differentiation, all media were replenished with 
fresh preadipocyte or differentiation media as the case may be.  Cells were treated 
with either the vehicle (methanol [5µl] in per ml differentiating media) or increasing 
doses of the drugs alone (1 µM, 10 µM and 20 µM of LPV, ATV, RTV and EFV) or in 
combination with 1 µM and 5 µM of Tel.  After 24 hours of treatment, conditioned 
media and cell lysates were collected in order to study adipokine levels and gene 
expression. Every experiment was replicated four times to check the reproducibility 
of the results and for statistical purposes. 
2.2.3 Expression of IL-18 using ELISA 
IL-18 solid phase sandwich ELISA kits were purchased from ebioscience, USA. Each 
standard and blank sample was duplicated but drug treated samples were assessed 
in triplicate. Microwell strips required for testing were washed twice with 
approximately 400 μl of the wash buffer per well with thorough aspiration of 
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microwell contents after every wash. After the last wash step, 100 μl of serial 
dilutions of IL-18 standards were added to the respective wells in the strips and then 
50 μl of sample diluent was added to all the sample wells, followed by the addition 
of the 50 μl of the sample in the respective wells. 50 μl of the biotin-conjugate was 
then added to all the wells. After incubation for 2 hours at room temperature, all the 
wells were washed three times using wash buffer and then 100 μl of streptavidin-
HRP solution was added to all the wells. After 1 hour of incubation at room 
temperature, streptavidin-HRP solution was discarded followed by three washes 
using wash buffer.  100 μl of TMB-substrate solution was then added to all the wells 
followed by an incubation period of 20 minutes in the dark at room temperature. 
Soon after the end of the last incubation period, 100 μl of the stop solution was 
added to all the wells and readings were made using a plate reader at 450 nm. Finally, 
IL-18 concentration levels in each sample were determined using the manufacturer’s 
instructions as described in the user manual.  
2.2.4 Isolation of mRNA  
After removing supernatants from the all the wells, cells were washed twice with 1 
ml of Hanks balanced salt solution.  500 µl of TRI reagent was then added to each 
well and cells were lysed and transferred into 1.5 ml autoclaved Eppendorf tubes. 
100 µl of chloroform was added to each tube and the tubes were gently inverted 
multiple times until the mixture appeared to be homogenised. They were then left 
for 10 minutes at room temperature. After 10 minutes, all the tubes were centrifuged 
at 14000 rpm for 15 minutes at 4°C to separate the RNA, DNA and protein into three 
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distinct layers. The top most transparent liquid contained RNA. The middle layer 
contained DNA and bottom layer contained proteins.  
The supernatant containing RNA was removed from each tube and transferred to 
new 1.5 ml Eppendorf tubes, each labelled with the same sample name. The 
remaining DNA and proteins in the tubes were discarded.  25 µl of isopropanol was 
then added to each tube containing RNA, which were then mixed using a vortex and 
left for 10 minutes at room temperature, followed by centrifuging at 12000 rpm for 
10 minute at 4°C. All of the supernatant from each Eppendorf was then transferred, 
(leaving any impurities at the bottom of the tubes) to new autoclaved 1.5 ml volume 
Eppendorf tubes which were labelled appropriately. 225 µl of isopropanol was then 
added to each of them and mixed using a vortex which was followed by an incubation 
period of 10 minutes at room temperature. After centrifuging all the tubes at 14000 
rpm for 10mins, all the supernatant were discarded, saving the pellet at the bottom 
of the tube.  100 µl of 75% ethanol was then added to each pellet and all the samples 
were centrifuged at 14000 rpm for 10 minutes and supernatant discarded, leaving 
the pellet at the bottom of the tube which contained total RNA for each sample 
respectively.  15 µl of RNAase/DNAase free water was then added to each RNA pellet, 
which was dissolved in the water by gentle tapping on the tube. Then each tube was 
centrifuged again to bring the whole sample to the bottom of the Eppendorf tube 
and it was then quantitated using a Nanodrop machine from Thermofisher Scientific® 
to check the quality and quantity of total RNA extracted. All the total RNA samples 
were stored at -20 ℃.  
2.2.5  Reverse transcription of total RNA 
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Total RNA was reverse transcribed using the Taqman® reverse transcription kit from 
Life Technologies USA. Each reaction contained 2 µl of total RNA from each sample, 
2.5 µl of Taqman 10X buffer, 5.5 µl of MgCl2, 5 µl of dNTPs, 1.25 µl of random 
hexamers, 0.5 µl of RNAase inhibitor, 0.875 µl of reverse transcriptase (RT scribe) and 
7.375 µl of RNAase/DNAase free water, making the total volume 25 µl for each 
sample in a 200 µl volume Eppendorf. Each of the tubes were mixed and centrifuged, 
and then placed on the heating block of the Veriti thermo-cycler from Applied 
Biosystems, UK. The thermocycler was programmed to run cycles of 25°C for 10mins,  
48°C for 30 min and 95°C for 5 min followed by incubation at 4°C for 1 hour,. At the 
end of the reverse transcription, the samples were mixed using a vortex and 
centrifuged again. The cDNA in each sample tube, formed as a result of reverse 
transcription, was then quantified using NanoDrop to check the quantity and quality 
of cDNA. Later on, cDNA from each tube was further normalised to 20 ng/ µl using 
RNAase/DNAase free water. 
2.2.6 IL-18 mRNA expression  level using real time PCR 
Real time quantitation detects the release of the fluorescent dye during the PCR 
extension phase of each cycle using the optical imaging system within the ABI 7900 
Fast Real Time PCR machine (Applied Biosystems® UK). FAM labelled IL-18, VIC 
labelled β-actin Taqman® gene assays and Taqman® gene expression master mix 
were used to perform duplex real time reactions to evaluate the levels of expression 
of mRNA for IL-18, relative to mRNA levels of β-actin as a house keeping gene, while 
employing cDNA, which was normalised to 20 ng/µl earlier for respective samples. 
Each reaction was replicated four times using cDNA from four biological replicates 
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for statistical purposes. In each well of the 384 well plates used for duplex real time 
PCR reactions, 1µl of FAM labelled IL-18 and 1 µl of VIC labelled β-actin gene 
expression assays, along with 10 µl of Taqman® gene expression master mix and 4 µl 
of RNAase/DNAase free water was added.  4 µl of 20 ng/µl normalised cDNA from 
the corresponding sample was then added to the respective wells. All reactions were 
carried out using standard cycling parameters 
(https://www.lifetechnologies.com/order/catalog/product/4329001) and 
quantitation of the target mRNA was carried out using the 2(-Delta Delta C(T)) 
Method (Livak and Schmittgen 2001).                                                                                             
2.2.7 Patient DNA  
 DNA had previously been extracted from blood samples collected from 180 HIV+, 
Caucasian patients, 124 of whom had HIVLD (HIVLD+) and 56 did not (HIVLD- 
controls). All patients were recruited between 1998 and 2004 from 13 centres: 
Northwick Park Hospital, London; Royal Bolton Hospital; Peterborough District 
Hospital; Gartnavel General Hospital, Glasgow; Countess of Chester Hospital, 
Chester; Newcastle General Hospital; Royal Victoria Hospital, Belfast Western 
General Hospital, Edinburgh; Kings Mill Hospital, Sutton in Ashfield; Royal Free 
Hospital, London; Norfolk and Norwich Hospital; Royal Hospital, Liverpool; and North 
Manchester General Hospital, MRC Clinical Trials Unit; (Pushpakom, Owen et al. 
2011). Local research ethics committee approvals were obtained for the study and 
written informed consent was obtained from all patients for the collection of 
blood/DNA samples and subsequent genetic analysis.  
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HIVLD was diagnosed by clinicians, based on the clinician's observation alone, or on 
patient self-reporting after the start of antiretroviral therapy. The cART mainly 
consisted of protease inhibitor backbone. Lipoatrophy (fat wasting of arms, face, 
legs, or buttocks), fat accumulation in the abdomen, over the dorsocervical region or 
breasts, and presence of associated metabolic abnormalities were considered as HIV 
lipodystrophy. All the patients in the study were of Caucasian ethnicity and all of 
them were treated with protease inhibitor for at least 12 months before recruitment. 
Patients recruited as controls in the study were also HIV+ but they did not show any 
features of HIVLD. All the patients were evaluated by the clinician at least three times 
during the period of one year. In a small sub group of 94 patients (69 with HIVLD and 
25 without HIVLD), the degree of lipoatrophy or lipohypertrophy was evaluated by 
the clinician as absent, mild, moderate or severe. Patients showing only mild signs of 
lipoatrophy were given a score of one and were classed as controls (HIVLD-), but 
others who exhibited more than one sign of severity of the condition, were assigned 
a higher score and hence were considered as HIVLD+ patients. In the rest of the 
patients, the decision of patient classification, as either controls or HIVLD+ patients, 
was made by clinicians or on the basis of patient self-report.  DNA samples were also 
obtained from 172 Caucasian HIV- healthy individuals with no known infectious or 
immune diseases to establish the population frequency of all allelic variants 
investigated. 
 
2.2.8 SNP selection  
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To find genetic association of IL-18 gene with HIVLD, 14 SNPs in IL-18 gene were 
selected which included haplotype-tagged SNPs selected from the CEPH/CEU 
HapMap dataset (phase III, release 27) and regulatory SNPs selected from the dbSNP 
database. SNPs with very low minor allele frequencies or without any available minor 
allele frequencies were selected due to the references from the previous 
publications. All selected SNPs are listed in Table 2.1.  
Table 2.1. SNP selection in IL-18 gene for genotyping 
Sl. NO. SNP ID Location Minor allele frequency 
1 rs549908 Exon (Tag SNP) 0.21 
2 rs1834481 Intron (Tag SNP) 0.09 
3 rs543810 3’UTR (Tag SNP) 0.25 
4 rs5744280 Intron (Tag SNP) 0.37 
5 rs1946518 (-607) 5' near gene (Tag SNP) 0.46 
6 rs5744290 Exon 0.013 
7 rs141853304 Exon ---- 
8 rs34229190 Exon ---- 
9 rs45497197 Exon ---- 
10 rs61734549 Exon 0.001 
11 rs187238(-137) Exon 0.22 
12 rs5744292 3’UTR 0.09 
13 Rs2115763 Intronic 0.28 
14 rs360719 5' near gene 0.22 
 
2.2.9 Genotyping  
SNP genotyping was performed using the Sequenom Mass ARRAY (MALDI-TOF) 
system (San Diego, California, USA). Sequence specific PCR primers and extended 
reaction oligonucleotides for each SNP were obtained from Metabion GmbH 
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(Martinsried, Germany). A multiplex SNP assays (14 plex) was designed using 
software made available by Sequenom 
(https://mysequenom.com/tools/genotyping/default.aspx) for genotyping using 
iPLEX chemistry with 10 ng of genomic DNA. For each assay, quality control 
procedures were performed and included the use of replicate samples and negative 
template controls on the same 384-well plate. Each SNP genotype cluster plot was 
manually checked and scored. Any sample with a call rate of less than 80% and any 
assay with a call rate of less than 90% were removed from subsequent analysis. 
2.2.10 Statistics 
All statistical analysis of gene expression and protein expression was performed using 
stats direct 2.7.9 software. Haploview software was used to evaluate Hardy–
Weinberg equilibrium and differences in allele, genotype and haplotype frequencies 
between HIVLD+ and HIVLD- patient groups and p-values of more than 0.05 were 
considered statistically insignificant. 
2.3  Results 
Differentiating 3T3-F442A cells were treated with increasing concentrations of ARVs, 
i.e. lopinavir (LPV), atazanvir (ATV), Ritonavir (RTV) and Efavirenz (EFV), to study their 
effects on IL-18 gene and protein expression.  3T3-F442A cells were also co-incubated 
with ARVs and Telmisartan (Tel). The results of expression of IL-18 both at gene and 
protein levels are presented below. 
 
97 
 
2.3.1. Effect of LPV and LPV/Tel on IL-18 gene and protein expression  
IL-18 gene showed a significant increase in expression following treatment with LPV 
and this was found to be concentration dependant. . Similar results were obtained 
when secreted IL-18 protein levels were studied. However, on co-incubation of 
differentiating adipocytes with 20 µM LPV and Tel (at 1 µM and 5 µM), a partial 
reversal of LPV-mediated IL-18 upregulation was observed. The effect was more 
pronounced for 5 µM Tel in comparison to 1µM Tel (fig 2.1).  
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Figure 2.1 A. Effect of LPV on IL-18 gene expression, B; effect of TEL coincubation on LPV-mediated IL1IL-18 gene expression, C; effect of LPV on IL-18 protein expression 
and D; effect of LPV and Tel on secreted IL-18 protein expression. Note: mean values were obtained from 4 independent repeats. *= p value < 0.05  
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2.3.2 Effect of ATV and ATV/Tel on IL-18 gene and protein expression  
ATV had a similar effect on the IL-18 gene expression when compared with LPV. A 
concentration-dependant increase in the IL-18 gene expression levels was observed 
with increasing concentrations of ATV with the 20 µM ATV having the maximum 
effect. When the differentiating adipocytes were co-incubated with 20 µM ATV and 
1 and 5µl of TEL,  a significant partial reversal of ATV-mediated increase in expression 
of IL-18 both at gene and protein levels were noticed (Fig 2.2). 
2.3.3 Effect of RTV and RTV/Tel on IL-18 gene and protein expression  
After treatment with RTV, both IL-18 gene and protein expression levels showed a 
significant dose-dependent increase as observed with LPV and ATV. It was also 
noticed that co-incubation with Tel, significantly reversed the RTV-mediated increase 
in expression of IL-18 both at gene and protein levels, as shown in fig 2.3. 
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and Tel on IL-18 protein expression. Note: mean values were obtained from 4 independent repeats. *= p value < 0.05  
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2.3.4 Effect of EFV and EFV/Tel on IL-18 gene and protein expression  
Although EFV is not from the same class of drugs as LPV, ATV or RTV, it was still 
important  to compare and find out its in vitro effect on expression, when compared 
with the earlier mentioned drugs,  because it is also used as a part of cART. EFV also 
resulted in a significant increase in IL-18 gene and protein levels and there was a 
concentration-dependant increase in IL-18 gene expression levels with increasing 
concentrations of EFV, as shown in fig 2.4. When co incubated with Tel, the 
expression of IL-18 both at gene and protein levels were brought down significantly. 
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Figure 2.4 A; effect of EFV on IL-18 gene expression, B; effect of EFV and Tel on IL-18 gene expression, C; effect of EFV on IL-18 protein expression and D; effect of EFV 
and Tel on IL-18 protein expression. Note: mean values were obtained from 4 independent repeats. *= p value < 0.05  
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2.3.5 Association between IL-18 SNPs and HIVLD  
DNA samples in this study were collected from 124 HIV patients with LD (HIVLD+) and 
56without HIVLD (HIVLD-). The clinical characteristics of the patients included in this 
study are described in table 2.2. HIVLD+ patient group with median age 40 years 
(range: 29–68 years) were comparable with HIVLD- patients group having a median 
age also 40 years with range between 24–65 years. Majority of the patients recruited 
in this study consisted of men. After the initial diagnosis of HIV, median time of the 
treatment was 7.6 years, in case of HIVLD- patients where as it was 7.4 years in case 
of HIVLD+ patients. CD4 counts were 321 mm3 in HIVLD- where as in HIVLD+ 
individuals it was 359 mm3, hence it was considered comparable between both 
HIVLD- and HIVLD+ groups. The protease inhibitors administered include IDV, RTV, 
SQV, NFV and LPV. The median time of exposure to protease inhibitors was also 
identical for both HIVLD+ (24.3 months; range: 13–53 months) and HIVLD- (24.5 
months; range: 12–67 months) groups. All patients in this study had also received 
NRTIs, of mainly including d4T, ZDV, and 3TC. The median exposure time to NRTIs 
was similar in both  cases of HIVLD+ (39 months; range: 10–133 months) and HIVLD- 
groups (39 months; range: 9–94 months). Demographic and clinical characteristics of 
study population are also described in table 2.2.  
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Table 2.2. Demographic and clinical characteristics of study population (n=180, 
HIVLD+, n=124, HIVLD−, n = 56) 
Patients Characteristics HIVLD+ HIVLD- 
Age at enrolment in years,  median 
(range) 
40 (29−68) 40 (24−65) 
Men    
             Women                                                                               
98 
26 
48 
8
Time since HIV diagnosis, median 
(range) 
7.4 yrs (2.0−19.3 
yrs) 
7.6 yrs (1.4−17.6 
yrs) 
CD4 cell count (mm3), Median (range) 359 (15−1218) 321 (3−750) 
Time of exposure to PIs, median 
(range) 
24.3 months            
(13-53 months) 
24.5 months            
(12-67 months) 
Time of exposure to NRTIs, median 
(range) 
39 months               
(10-133 months) 
39 months                
(9-94 months) 
 
14 SNPs in the IL-18 gene and promoter region were selected for this study. 
Genotyping was performed using a Sequenom mass array platform. None of the 9 
SNP markers were found to be significantly associated with HIVLD in this cohort of 
patients. A cluster plot was plotted for each of the SNPs genotyped as shown in Fig 
2.5 below, using low and high mass allele ratios.  
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Figure 2.5.  Example of a cluster plot for one of the SNPs studied in the IL-18 gene in 
our cohort of patients. 
 
 
 
 
 
 
Figure 2.6. Histogram of all 14 SNPs and corresponding allelic ratios in colours. Each 
colour represents one of the genotype calls made by the software where Red = no 
call, Blue = low molecular weight homozygous, yellow = heterozygous and green = 
high molecular weight homozygous.  
 
Hardy-Weinberg values and p-values were calculated using haploview software 
which was downloaded from the Broad Institute website 
(http://www.broadinstitute.org).       
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Table 2.3. p-values of SNPs evaluated in this study 
Sl No. SNP ID p-Values 
1 rs2115763 0.674 
2 rs360719 0.584 
3 rs1946518 0.235 
4 rs1834481 0.595 
5 rs549908 0.446 
6 rs5744280 0.652 
7 rs5744290 0.182 
8 rs5744292 0.210 
9 rs543810 0.487 
 
2.3.6 Characterisation of haplotypes 
Linkage disequilibrium was assessed in order to observe any patterns amongst the 
haplotypes.  One single LD plot comprising two individual smaller blocks was 
identified, as shown in the fig. 2.8 below.  
 
Figure 2.8.  Linkage disequilibrium (D’) across the selected SNPs in our cohort of 
study, in the IL-18 gene region. This LD plot was generated using data from 
genotyping done for this study in Haploview software version 4.1.  
 
IL-18 
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2.4 Discussion 
Several mechanisms contribute to the chronic inflammation present during infection 
by HIV-1, including the increased production of pro-inflammatory cytokines, such as 
IL-18 (Nasi, Alboni et al. 2014).  Important functions of IL-18 include the induction of 
IFN-Ү in T cells and natural killer cells, upregulation of Th1 cytokines and stimulation 
of the proliferation of activated T cells (Dinarello 1999). The direct link between the 
role of IL-18 and the mechanisms associated with the development of the HIVLD have 
not been elucidated. However, our results provide some insight towards the vicious 
cycle of antiretroviral induced toxicity at a cellular level in differentiating adipocytes.  
All the ARVs used in this study caused a significant increase in the production of IL-
18 by the adipocytes. This effect on IL-18 was concentration dependent and occurred 
with both a lipid friendly PI, ATV, and lipid-unfriendly agents, RTV and LPV.  It was 
also seen with EFV, a non-nucleoside reverse transcriptase inhibitor.  The reason why 
a disparate group of drugs were able to do this is unclear, but suggests a common 
mechanism.  Of course, the effect could be secondary to changes in other adipokines 
such as TNF-α or IL-6.  Alternatively, it could be due to a decrease in the level of its 
natural antagonists IL-18bp. However whether antiretroviral drugs can upregulate or 
downregulate IL-18bp has not yet been studied.  In addition, the effect of HIVLD on 
expression is unknown.  Both of these aspects need further investigation.  It is 
however important to note that HIVLD is a chronic inflammatory condition and IL-
18bp has been reported to be down-regulated in other chronic inflammatory 
conditions (Shimizu, Matsumoto et al. 2015).   One study showed that HIV infection 
itself can reduce the levels of IL-18bp, resulting in an imbalance between it and its 
antagonist IL-18.  However, the reduction in the levels of IL-18bp were reported to 
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be similar in the serum of HIV patients, both with HIVLD and without HIVLD, receiving 
HAART. It is therefore difficult to conclude whether antiretrovirals have any role in 
the downregulation of IL-18bp resulting in upregulation of IL-18 protein (Iannello, 
Boulassel et al. 2010).   
In previous studies, it has been reported that protease inhibitors interact with lipid 
metabolism and related pathways resulting in induced drug toxicity, which has been 
so serious that it sometimes posed greater danger to patients’ lives than HIV itself 
(Nolan, Reiss et al. 2005). In a clinical study, patients receiving antiretroviral 
treatments using protease inhibitors and nucleoside reverse transcriptase inhibitors 
as the backbone of the regime developed lipodystrophy and also showed higher 
serum levels of IL-18 (Lindegaard, Hansen et al. 2004). Similarly, the levels of IL-18 
mRNA in the adipose tissues obtained from  patients with HIVLD were found to be 
higher in comparison with fat obtained from HIVLD negative patients and healthy 
controls. (Lindegaard, Hansen et al. 2004). HIV patients with lipodystrophy being 
treated with protease inhibitors also showed apoptosis in the subcutaneous 
adipocytes, especially in lipoatrophic areas, resulting in lipolysis (Domingo, Matias-
Guiu et al. 1999).  These in vivo findings are consistent with our in vitro results.                           
Protease inhibitors induce lipolysis in vitro (Lenhard, Furfine et al. 2000). A recent 
study has also reported that IL-18 is interlinked with lipolysis in HIVLD+ patients and 
blockage of lipolysis can potentially reduce IL-18 expression (Lindegaard, Ditlevsen et 
al. 2013), which suggests that IL-18 may induce lipolysis and apoptosis in 
inflammatory conditions in adipocytes, while mechanistically playing a role in the 
development of lipodystrophy syndrome in HIV patients.  It is also important to note 
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that interference with lipid metabolism can be a possible cause of inflammatory 
signals resulting in an upregulation in IL-18 transcription and hence translation.  
Telmisartan is an angiotensin II receptor blocker and partial agonist at the PPARҮ 
receptor, which is a master adipogenic gene (Goyal, Bharti et al. 2011).  Previous 
studies have shown that PIs can over activate the renin angiotensin system (RAS) 
which potentially results in lipodystrophy syndrome and insulin resistance in HIV 
patients (Boccara, Auclair et al. 2010). Telmisartan as an angiotensin II type-1 
receptor  (AT1R) blocker can of course inhibit angiotensin II signalling through AT1R 
blockade and may thus improve insulin resistance, hypertension (Erbe, Gartrell et al. 
2006), lipid metabolism (Kakuma, Gotoh et al. 2010) and reduce the expression of 
pro-inflammtory cytokins, such as IL6 and TNFα via PPARγ (Kang, Yijun et al. 2014). 
Both in vitro and ex vivo studies have shown that PIs can reduce PPARγ expression 
and deregulate adipocyte lipid storage and adipokine secretion (Caron, Auclair et al. 
2001, Jones, Janneh et al. 2005, Lagathu, Eustace et al. 2007). This suggests that PI-
induced PPARγ dysfunction in adipose tissue might directly or indirectly participate 
in the upregulation of IL-18 secretion in HIV-infected patients.  This is in line with the 
in vitro findings of this investigation in relation to the modulation of IL-18 expression 
where it was also observed that telmisartan can significantly reduce IL-18 levels in 
cultured adipocytes in the presence of protease inhibitors.                 
A study in the Brazilian population reported that genetic variants within IL-18 are 
associated with the development of HIV associated lipodystrohy (Castelar, Silva et al. 
2010). However, this investigation failed to replicate any association between SNPs 
in the IL-18 gene and HIVLD. This could be due to a number of reasons. This particular 
study investigated Caucasian population and therefore the difference in ethnicity 
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may be one of the reasons for lack of replication of association between IL-18 genetic 
variants and HIVLD.   
In summary, the data show that IL-18 is upregulated in differentiating adipocytes by 
ARVs but the mechanism through which ARVs modulate IL-18 is still unknown. 
Further studies are needed to explore its role in ARV induced toxicity over a longer 
period of time, both in vitro and in vivo, which may potentially prove this cytokine a 
useful target for therapeutic intervention in patients suffering from lipodystrophy 
and metabolic syndrome.  
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Chapter 3 
Role of NFATC4 in ARV–induced adipocyte toxicity 
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3.1 Introduction 
The family of nuclear factors of activated T cells (NFAT) is an inducible nuclear factor 
that can bind the interleukin -2 (IL2) promoter region of activated T cells (Shaw, Utz 
et al. 1988). NFAT family members are expressed in every cell type including those in 
the central nervous system, blood vessels, heart, kidney and adipocytes. It is now 
known that the NFAT protein family consists of 5 members as shown in table 3.1 
(Crabtree and Olson 2002, Hogan, Chen et al. 2003, Macian 2005).  
 
Table 3.1. NFAT family of transcription factors 
NFAT family 
members 
Alternative names Regulation Expression in the 
immune system 
NFAT1 NFATc2 and NFATp Calcium-calcineurin Yes 
NFAT2 NFATc1 and NFATc Calcium-calcineurin Yes 
NFAT3 NFATc4 Calcium-calcineurin Yes 
NFAT4 NFATc3 and NFATx Calcium-calcineurin Yes 
NFAT5 TonEBP and OREBP Osmotic stress Yes 
 
 
NFAT3, also known as NFATc4 (Macian 2005), is phosphorylated in its inactive state 
and resides in the cytoplasm of the cell (Hogan, Chen et al. 2003). Upon antigen 
binding on the cell surface, tyrosine kinase receptors activate phospholipase Cϒ(PLCϒ), 
which hydrolyses phosphatidylinositol bisphosphate to release the second 
messenger, inositol 1,4,5-trisphosphate (IP3). IP3 binds to its receptor on the 
endoplasmic reticulum (ER) resulting in rapid release of Ca2+ from its stores (Feske, 
Giltnane et al. 2001). Ca2+ store depletion in the ER is sensed by an as-yet 
uncharacterised signalling pathway, which triggers the opening of the calcium 
release activated channels (CRAC) on the cell surface. This results in the “store 
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operated” influx of the Ca2+ from outside the cell (Hogan, Chen et al. 2003). In 
cytoplasm, a protein called calmodulin (CaM) binds Ca2+  and forms Ca2+/CaM 
complex, which activates a serine/threonine phosphatase enzyme called calcineurin 
(CN) (Stull 2001). Upon activation, Ca2+ /CaM dependent phosphatase enzyme CN 
dephosphorylates NFATc4 protein, thereby activating it. Activated NFATc4 
translocates to the nucleus and joins its partner transcription factors such as Fos/Jun 
to start transcription (Crabtree and Olson 2002).  
NFAT proteins are commonly present in all immune cell types but play different roles 
in cell types other than those in the immune system (Horsley and Pavlath 2002). 
NFATc4 has a role in adipogenesis (Ho, Kim et al. 1998, Yang, Suk et al. 2006). NFATc4 
combines with CCAAT/enhancer binding protein (C/EBPα) (Yang and Chow 2003, 
Yang, Suk et al. 2006) and modulates PPARϒ gene expression (Yang, Xiong et al. 2002). 
NFATc4 binds on the promoter region of the PPARϒ gene and increases its expression 
(Yang, Xiong et al. 2002). NFATc2−/−NFATc4−/− mice were found to possess a lean 
phenotype and exhibited a defect in fat accumulation, even after they were fed with 
a high fat diet when compared with control mice. It has also been reported that 
NFATc4 has a role in the transcription of adipokines such as resistin. NFATc2−/− 
NFATc4−/− mice showed increased insulin sensitivity and lower levels of resistin which 
indicates the role of resistin in glucose and insulin homeostasis (Yang, Suk et al. 
2006). An in vitro study has demonstrated that NFATc4 negatively regulates 
adiponectin gene expression in 3T3-L1 adipocytes (Kim, Kong et al. 2006). Another 
study reported an inverse relationship between two adipokines, IL-18 and 
adiponectin, and showed that this is mediated via NFATc4 phosphorylation in 
adipocytes (Chandrasekar, Patel et al. 2008). 
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Previous studies have shown that the NFAT protein family of genes is involved in the 
regulation of IL1, IL2, IL6, and TNFα gene expression (Nilsson, Sun et al. 2007, 
Lawrence, Naziruddin et al. 2011). NFATc4 increases its transcriptional activity in the 
absence of Lipin-1. In Lipin-1 depleted 3T3-L1 adipocytes, it has been observed that 
NFATc4 causes upregulation of expression of its target genes such as TNFα, resistin, 
FABP4 and PPARϒ. Similar results were also observed in the fat pads of Lipin-1 
deficient mice (Kim, Kumar et al. 2010). 
NFATc4 has a wide range of target genes which suggests it has a role in inflammatory 
conditions such as cardiac hypertrophy, lipodystrophy and obesity (Crabtree 1999). 
Elevated expression of PPARα can inhibit translocation of NFATc4 to the nucleus  
thereby preventing its association with nuclear factor kappa B (NF-kB) (Zou, Le et al. 
2013). Similarly, upregulation of PPARϒ by its agonist, rosiglitazone, resulted in the 
inhibition of translocation of NFATc4 from the cytoplasm to the nucleus. This 
suggests the existence of a feedback mechanism between the two genes and the 
potential use of PPARϒ as a therapeutic target when treating cardiac hypertrophy 
(Bao, Li et al. 2008) and HIV associated lipodystrophy. Treatment with 
lopinavir/ritonavir resulted in higher expression levels of NFATc4 in cardiac tissue 
samples of Wistar rats when compared with control rats (Reyskens, Fisher et al. 
2013); this may lead to the elevated transcription of target genes by NFATc4. A 
therapeutic agent called cyclosporine A (CsA) can inhibit the translocation of NFATc4 
from cytoplasm to nucleus (Feske, Giltnane et al. 2001).  However, this results in the 
arrest of adipocyte differentiation (Horsley and Pavlath 2002).  
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Figure 3.1. Schematic view of the NFAT activation cycle; Activation of the Ca2+ coupled cell surface receptors result in the activation of NFAT and 
Ca2+ also assist in activation of phosphorylation of NFAT by Calmodulin which is the key step in its translocation inwards to nucleus where it 
combine with FOS-JUN to perform transcription of different target genes.  
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3.1.1  Rationale for the study 
NFATc4 has been shown to be a negative regulator of adiponectin (Kim, Kong et al. 
2006). Studies have shown that the inverse relationship between two adipokines, IL-
18 and adiponectin, is mediated via NFATc4 in adipocytes (Chandrasekar, Patel et al. 
2008). It is also reported that PPARϒ is a target gene for NFATc4 and that it modulates 
its expression (Yang, Xiong et al. 2002). Results discussed in Chapter 2 show that 
antiretroviral drugs upregulate IL-18 expression levels in 3T3-F442A adipocytes. 
Given that ARVs modulate NFATc4 in other cell types (Reyskens, Fisher et al. 2013) 
and that ARVs inhibit adiponectin secretion from adipocytes, the role of NFATc4 in 
ARV-mediated adipocyte toxicity requires further investigation. This would help to 
delineate the importance of NFATc4 as a pharmacological drug target in reversing 
antiretroviral induced toxic effects.  
 
 
Figure 3.2. Schematic view of the potential interactions between NFATc4 and other 
mediators of adipogenesis as indicated by the literature (in black) and also with 
respect to the results outlined in chapter 2 (in red) 
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3.1.2  Hypothesis  
The hypotheses tested in this chapter are: 
1. ARVs upregulate the expression of NFATc4 in adipocytes, resulting in the 
development of features which could predispose to lipodystrophy, and 
pharmacologic modulation of NFATc4 may help in the reversal of ARV-induced 
adipose toxicity. 
2. ARV-induced upregulation of NFATc4, a transcription factor through which IL-18 
causes inhibition of adiponectin (a marker of insulin sensitivity), could be 
mechanistically important in the development of insulin resistance. 
3. The reversal of ARV-induced adverse effects by telmisartan is mediated through 
NFATc4. 
 
3.1.3 Aims and objectives  
The aims and objectives of this project were: 
1. To investigate whether ARVs modulate NFATc4 expression in vitro in adipocytes 
2. To observe the effect of ARV-induced toxicity after knock-down of NFATc4 mRNA 
while utilising 3T3-F442A as an in vitro model 
3. To identify pharmacological agents that may target NFATc4 and investigate 
whether this strategy leads to the reversal of ARV-induced adipocyte toxicity. 
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3.2 Methods  
3.2.1 Materials   
The antiretroviral drugs, lopinavir (LPV), atazanavir (ATV), ritonavir (RTV), efavirenz 
(EFV) and an angiotensin receptor blocker telmisartan (Tel), were supplied by 
Santacruz® Biotechnologies Ltd.  Insulin from bovine pancreas, methanol, Trypsin 
EDTA, chloroform and dimethyl sulfoxide (DMSO) were purchased from Sigma® 
Aldrich, UK.  Fetal calf serum (FCS), Dulbecco’s modified eagle medium (DMEM), 
Hank's balanced salt solution, rat tail collagen-I, a reverse transcription kit, TRI 
reagent for RNA isolation, FAM labelled NFATc4, VIC labelled β-actin and GAPDH 
Taqman® gene expression assays and Taqman® gene expression master mix were 
purchased from Life technologies® USA. ON-TARGETplus NFATc4, GAPDH and non-
targeting mouse siRNAs along with the transfection agent, Dharmafect-III, were 
bought from Dharmacon®, Thermofisher scientific Ltd. ELISA kits for IL6 and 
adiponectin were purchased from Life Technologies, NFATc4, PPARϒ, β-actin and 
GAPDH primary antibodies were purchased from Santacruz® Biotechnologies Ltd. 12 
well and 6 well plates along with T25, T75 T175 flasks and all other cell culture 
equipment was purchased from Thermo Fisher Scientific ® USA. 3T3-F442A murine 
preadipocyte cells were available in the Wolfson Centre for Personalised Medicine, 
the University of Liverpool.  
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3.2.2 Cell culture 
50 ml of FCS was filtered using 0.2 micron filters and added to 450 ml of Dulbecco’ 
Modified Eagle Medium (DMEM) to make cell culture media. 3T3-F442A murine 
preadipocytes were cultured and maintained in T75 flasks using cell culture media. 
At 75-80% confluence, the cell culture medium was discarded and the cells were 
washed twice with Hank's balanced salt solution. 5 ml of trypsin EDTA was introduced 
into the flask and incubated at 37℃ for 5 minutes for cell detachment. After 
incubation with trypsin, cells were detached from the surface of the flask by gently 
tapping its base. Cells, along with trypsin, were poured into a 20 ml volume universal 
tube containing 15 ml cell culture medium to neutralize the trypsin. The universal 
tube was then centrifuged at 1000 rpm for 5 minutes at room temperature to obtain 
the cell pellet. After centrifuging, the supernatant was discarded and the cell pellet 
was suspended in 5 ml of cell culture medium. Cell counting was performed using a 
Countess cell chamber. 10 µl of cell suspension was added into a 1.5 ml eppendorf 
tube along with 10 µl of trypan blue dye and mixed using a 10 µl pipette to get a 
homogenised mixture of cells and the dye. 10 µl of this mixture of cells and dye was 
then loaded into a countess cell chamber and inserted into a countess cell counter 
provided by Invitrogen®. Only the required number of cells were sub-cultured into 
new T75 flasks to maintain the cell line for further use.  T175 flasks were used to 
freeze cells for future work.  
3.2.3 Drug incubations 
12 well plates coated with rat tail collagen-I (100 µg/ml) were seeded with 20,000 
cells per well. An appropriate number of 12 well plates were employed for every 
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experiment for statistical reasons. Preadipocytes were maintained in standard cell 
culture media as described in section b. Differentiating adipocytes were incubated in 
differentiating cell culture media containing 100nM of insulin. After 48 hours of 
incubation at 37°C, in a 5% CO2incubator, fresh culture medium was added to wells 
containing preadipocytes and differentiating medium was added to wells with differentiating 
adipocytes. Different concentrations of drugs, as described below, were added to wells 
designated for drug treatment; methanol (100%) was used as a vehicle.  LPV, ATV, RTV, 
and EFV were used in concentrations ranging from 1 µM to a maximum of 20 µM. 
Combinations of 20 µM of LPV, ATV, RTV and EFV with 1 µM / 5 µM Tel 
concentrations were also part of the experimental plan. All the drug treatments were 
carried out for 24 hours only. After 24 hours of each treatment conditioned media 
and cell lysates were collected in order to study adipokine levels and gene expression 
levels. Every experiment was replicated four times to check the reproducibility of the 
results and for statistical analyses. 
3.2.4 Supernatants and lysates collection  
After 24 hours of each treatment, supernatants and cell lysates were collected. 
Supernatant was collected in 1.5 ml eppendorf tubes and stored at -20° C and later 
used to study the expression of secreted adipokines. All the wells were washed with 
Hank’s balanced salt solution before some cell lysates were collected using 500 µl of 
Tri-reagent to study gene expression levels, while others were collected using 100 µl 
of Ripa buffer and were employed in western blotting studies to determine protein 
expression levels. Every experiment was replicated appropriately to check the 
reproducibility of the results and for statistical analyses.  
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3.2.5 NFATc4 knock-down using siRNA 
Small interfering RNA (siRNA) assays were used according to manufacturer’s 
guidelines. The stock siRNA tubes were diluted to 20 µM concentration using 1X 
buffer provided by the manufacturer. Initially, 15 and 25 nanomole (nmol) 
concentrations of siRNA were employed for optimisation purposes only. A ratio of 
1:500 concentration (i.e. 1 µl of dharmacfect-III transfection reagent in 500 µl of cell 
culture medium) was used to transfect the adipocytes.  75% knock-down was an ideal 
target at gene expression levels but 85.19% knock-down was achieved using 25 nmol 
concentrations of NFATc4 siRNA.  
Table 3.2; Experimental plan for NFATc4  Knock-down along with drug treatment 
Day 0 1 2 3 4 5 
Action  
 
Cell plating 
 
---- 
Insulin 
+ cell Culture 
Media 
NFATc4 
Knock-down 
assay 
 
Drug 
addition 
Supernatant 
And  
Cell lysates collection 
 
After the optimisation of siRNA, Dharmafect III transfection agent and 25 nM final 
concentration of each siRNA were used to perform the assay. 15,000 preadipocytes 
per well were cultured in 12 well polystyrene plates. After two days differentiating 
medium was added to all the wells.  24 hours after the initiation of differentiation 
appropriate siRNA solutions were added into the designated wells. After 24 hours 
incubation with scrambled GAPDH and NFATc4 knock-down assays, cells were 
treated with vehicle (100% methanol) and 20 µM LPV, with or without 5 µM Tel. In 
one lane of wells, NFATc4 knock-down was used as a treatment on its own for 
comparison purposes. Differentiated adipocytes and preadipocytes were also 
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included in the study for comparison. The detailed experimental plan is shown below 
in Figure 3.4. After 24 hours, conditioned medium was collected from all wells; cells 
were washed twice with Hank’s balanced salt solution and lysates were collected 
using Tri-reagent for gene expression studies and RIPA buffer for western blotting. 
Lysates were stored at -80 °C and supernatant were stored at -20° C for further 
studies.  
3.2.6 ELISA 
In order to study the expression of IL6 and adiponectin in the supernatant collected 
from the different experiments in this project, ELISA kits were purchased from Life 
Technologies and were performed according to the manufacturer’s guidelines set in 
the default protocol.  
3.2.7 Protein isolation 
Cell lysates were collected from each well in 100 µl of RIPA buffer (purchased from 
Sigma®) and incubated on ice for 45 minutes. All the samples were sonicated at 5% 
intensity for 10 seconds.  All the samples were then centrifuged at 14,000 rpm for 30 
minutes. The supernatant from each sample tube was transferred to a new 1.5 ml 
eppendorf tube while leaving the pellet at the bottom of the tube. The supernatant 
contained the total cell protein.  
3.2.8 Protein measurement using western blotting  
A DC Protein Assay Kit was purchased from Bio-rad® and used according to the 
manufacturer's guidelines to quantitate the total protein in all the samples. Briefly, 
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20 µl of reagent S was added to 1 ml of reagent A to prepare a working reagent A.  5 
µl of protein standards and all the samples were added to the microtitre plate.  25µl 
of the working reagent A was then added to all the standards and each sample, 
followed by 200 µl of reagent B.  The plate was then placed on the shaker for 1 minute 
to mix all the reagents and then, after 15 minutes of incubation at room temperature, 
the readings were measured  using a plate reader at 550 nm wavelength. A standard 
curve was then plotted and the protein concentration in each sample was calculated  
using the formula obtained from the standard curve. Only 20 µg of the protein was 
used from each sample in western blotting to study the expression of the target 
proteins.   
3.2.9 Western blotting 
1D gel electrophoresis was performed using freshly made 1.5 mm thick 8% gels. For 
the SDS-gel electrophoresis, a discontinuous gel, consisting of a stacking gel and 8 % 
separation gel, was prepared.  To make the 8% separation gel, 2.3 ml distilled 
deionised water, 1.3 ml 30 % acrylamide mix, 1.3 ml 1.5M Tris (pH 8.8), 50 µl 10% 
SDS, 50 µl 10% APS and 3 µl TEMED were mixed. The separation gel was overlaid with 
0.1 % SDS solution. After polymerisation of the separation gel for approximately 30 
minutes, 0.68 ml distilled deionised water, 0.17 ml 30% acrylamide mix, 0.13 ml 1M 
Tris/HCl (pH 6.8), 0.01 ml 10% SDS, 0.01 ml 10% APS and 0.001 ml TEMED were added 
and then poured on top of a polymerized separation gel to form a stacking gel layer 
for sample loading. A 10 well comb was inserted into the stacking gel immediately 
before polymerization.  
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Samples were prepared using the isolated protein as described in section “f” above. 
20 µg isolated protein was mixed with 3 µl of 5 X sample buffer and 2 µl 1M DTT. The 
samples were denatured at 95 °C for 15 minutes and cooled on ice. After cooling , 
the samples were centrifuged for 1 minute at 14,000 rpm and loaded onto the SDS 
gel. Lane 1 was loaded with a pre-stained protein ladder marker (abcam®) and 
samples were loaded in all the remaining wells. The gel was run at 90 volts in 1X 
running buffer (100ml of 10X running buffer + 900 ml of distilled deionised water), 
until the marker dye ran out of the gel. 
After 1D-Gel electrophoresis, the gel was blotted in blotting buffer (100 ml of 10 X 
running buffer, 200 ml ethanol, 700 ml deionised water) at 110V for 1 hour. The 
proteins were transferred to a nitrocellulose membrane. The membrane was blocked 
in 5% milk/PBST solution (2.5mg milk in PBST) for 1 hour to avoid any non-specific 
binding of the antibodies. The primary antibody for NFATc4 was diluted at 1:400 in 
5% milk/TBST and was incubated overnight at 4°C. After incubation with the primary 
antibody, the nitrocellulose membrane was washed with TBST for 1 hour and 
incubated with the secondary antibody (goat anti mouse HRP conjugated at 1:1000 
in 5% milk) for 1 hour. The membrane was washed with TBST for 1 hour. Enhanced 
chemiluminescence substrate was then applied and the membrane was developed 
on X-ray film. After different exposure times the film was developed for 2 minutes, 
washed in water, fixed for 2 minutes, washed again and dried. The western blot film 
was compared with the marker on the nitrocellulose membrane. The films were 
densitometry scanned using a Bio-Rad GS-800 scanner and quantified using the 
software, Quantity One. 
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3.2.10 Total RNA extraction and reverse transcription 
Total RNA extraction and reverse transcription was performed as described earlier in 
section 2.2.4 of chapter 2.  
3.2.11 Statistical analysis  
Statistical analysis of the results from the gene expression and protein expression 
experiments were performed using Stats Direct 2.7.9 software provided by the 
University of Liverpool.  Paird T-test was employed to compare the values of the 
replicates. Results were considered significant if the p-value was <0.05.  
3.3 Results  
All the in vitro studies were performed while treating differentiating adipocytes with 
ARVs along with Tel to study their effects on NFATc4 gene expression.  
3.3.1 Effect of LPV and LPV/Tel on NFATc4 gene expression  
Differentiating adipocytes were treated with 1 µM, 10 µM and 20 µM concentrations 
of LPV with or without 1 µM and 5µM Tel respectively. There was a dose dependent 
increase observed in NFATc4 gene expression with LPV. However, co-incubation of 
differentiating adipocytes, with Tel (both 1µM and 5 µM), resulted in a reversal of 
the results observed with LPV alone. 1 µM Tel showed a lesser effect on NFATc4 when 
compared with 5µM Tel (Figure 3.4).  
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Figure 3.4 A; Effect of LPV on NFACTc4 gene expression, B; effect of LPV and Tel on 
NFATc4 gene expression. Mean values were obtained from 4 independent repeats. 
*= p value < 0.05.  
 
3.3.2 Effect of ATV and ATV/Tel on NFATc4 gene expression levels 
Similar to LPV, treatment with ATV (1 µM, 10 µM, 20 µM) resulted in a concentration 
dependent increase in NFATc4 gene expression levels. 20µM ATV had the maximum 
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effect. Differentiating adipocytes were also co-incubated with 1µM Tel and 20µM 
ATV where a significant decrease in the gene expression levels of NFATc4 was noted. 
Co-incubation of 5 µM concentration of Tel with 20µM ATV resulted in a further 
decrease in the expression of NFATc4 mRNA levels as shown in Figure 3.5. 
 
Figure 3.5 A. Effect of ATV on NFACTc4 gene expression, B; effect of ATV and Tel on 
NFATc4 gene expression. Mean values were obtained from 4 independent repeats. 
*= p value < 0.05.   
 
 
Conc. of ATV (µM) 
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3.3.3 Effect of RTV and RTV/Tel on NFATc4 gene expression levels 
NFATc4 gene expression levels were observed to be similarly upregulated after 
treatment with RTV (1 µM, 10 µM, 20 µM) in a concentration dependent fashion 
when compared with LPV and ATV. Co-incubation of 20 µM RTV with both 1 and 5 
µM Tel resulted in a significant reduction in the gene expression levels of NFATc4 
(Figure 3.6). 
 
Figure 3.6 A Effect of RTV on NFACTc4 gene expression, B; effect of RTV and Tel on NFATc4 
gene expression. Mean values were obtained from 4 independent repeats. *= p value < 
0.05. 
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3.3.4 Effect of EFV and EFV/Tel on NFATc4 gene expression levels 
Differentiating adipocytes were treated with 1 µM, 10µM and 20µM concentrations 
of EFV with and without 1µM and 5µM Tel respectively. There was a concentration-
dependent increase observed in NFATc4 at gene expression levels. All three different 
concentrations of EFV resulted in the upregulation of NFATc4 gene expression levels. 
However, co-incubation of differentiating adipocytes with Tel (both 1µM and 5 µM) 
resulted in reversal of the results observed with EFV alone. 1 µM Tel showed a lesser 
effect on NFATc4 when compared with 5µM Tel (Figure 3.7).  
3.3.5 Effect of LPV and LPV/Tel on NFATc4protein expression  
Protein expression of NFATc4 in differentiating adipocytes was investigated for 20µM 
LPV with and without 5µM Tel and was compared against the vehicle-treated cells. . 
In comparison with the vehicle, 20µM LPV showed significantly increased expression 
of NFATc4 protein. The LPV-mediated increase in NFATc4 protein expression was 
partially, although significantly, reversed following co-incubation with Tel as shown 
in Figure 3.8, A. These results correlate with those observed for NFATc4 gene 
expression after treatment with LPV and Tel, shown in Figures. 3.4 A and B. It also 
shows that the effect of the drugs on NFATc4 is similar, both at gene and protein 
levels.  
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Figure 3.7 A; Effect of EFV on NFACTc4 gene expression, B; effect of EFV and Tel on 
NFATc4 gene expression; mean values were obtained from 4 independent repeats. 
*= p value < 0.05  
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Figure 3.8, A, B and C; Western blots and graphs showing effect of 20 µM LPV (20LPV) and 20 µM LPV+5 µM Tel (20LPV+5T) on NFATc4 after 
24 hours. GAPDH was used as endogenous control,* = p-value less than 0.05 
A 
B 
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3.3.6 Optimisation of NFATc4 Knock-down 
After 48 hours of starting differentiation in adipocytes, the siRNA technique was used 
to knock-down NFATc4 gene expression in 3T3-F442A adipocytes for a maximum of 
a 24 hour time period. Western blots showed significant reduction in NFATc4 protein 
expression resulting from knock-down of mRNA levels as shown in Figures 3.10 A and 
B.  
 
 
Figure 3.9.  A; NFATc4 gene expression knockdown in adipocytes, B;  NFATc4 gene 
expression knock-down in terms of percentage.  
 
 
A 
B 
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Figure 3.10, A; NFATc4 protein expression in lysates collected after knock-down 
assay, B; Percentage knock-down of NFATc4 protein 
3.3.7  Effect of LPV on NFATc4 protein expression levels after NFATc4 mRNA 
Knock-down 
Adipocytes were treated with 20 µM LPV for 24 hours, with and without knock-down 
of NFATc4 gene. Cells treated with 20 µM LPV without NFATc4 knock-down showed 
a significant increase in NFATc4 protein expression levels. Whereas, in adipocytes 
treated with knocked-down NFATc4, LPV treatment could not induce the expression 
of NFATc4 protein. These results show that LPV has little effect on NFATc4 protein 
A 
B 
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expression levels after 24 hours of NFATc4 mRNA knock-down treatment using siRNA 
(Figure 3.11).  
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A 
B 
A 
Figure. 3.11. A; Western blots showing treatment results with 20 µM LPV for 24 hours both with and without knock-down (KD) of NFATc4 gene, B; graph 
showing comparison of different treatments in the experiment and line graph showing the pattern of NFATc4 protein expression levels in adipocytes in 
response to different treatments with and without NFAtc4 knock-down. GAPDH was used as an endogenous control.*=p value less than 0.05 
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3.3.8 Effects of LPV and Tel on Adiponectin protein expression levels 
with/without NFATc4 knock-down  
The differentiating adipocytes were employed to observe the effects of LPV on 
adiponectin with and without knocking-down NFATc4. The combined effect of LPV 
with Tel on adiponectin was also studied in comparison to the effects of LPV on 
adiponectin without Tel. Adiponectin protein expression levels in adipocytes after 
just NFATc4 knock-down were also studied.  
Adipocytes, when treated with 20 µM LPV, showed a significant reduction in 
adiponectin protein expression levels. When compared with adipocytes treated with 
20 µM LPV after NFATc4 knock-down; there was a significant increase in the levels of 
adiponectin protein. Adipocytes, when co-incubated with 20 µM LPV with 5 µM Tel, 
showed a significant increase in adiponectin levels. NFATc4 knock-down treatment 
on its own had no effect on adiponectin expression in adipocytes. There was a 
significant increase in adiponectin levels in adipocytes when compared with its levels 
in preadipocytes.  
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Figure 3.11; ELISA results showing expression levels of adiponectin protein in the supernatants collected after different treatments or no treatment at all as 
described under each bar of the column graph. The graph shows significant reduction in adiponectin levels after treatment with 20 µM LPV and 20 µM LPV 
with scrambled NFATc4 siRNA. There was significant increase in adiponectin levels when adipocytes were treated with 20 µM  LPV after NFATc4 knock-
down. Co-incubation of 20 µM LPV and 5 µM  Tel also increased the levels of adiponectin expression significantly. Also a significant increase in adiponectin 
levels was found in adipocytes when compared with preadipocytes. * = p value less than 0.05. All the experiments were repeated in three replicates to 
check the reproducibility and for statistical reasons. 
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3.3.9 Effects of LPV and Tel on IL6 protein expression levels with/without NFATc4 
knock-down  
Adipocytes, when treated with 20 µM LPV, showed a significant increase in IL6 
protein expression levels but adipocytes treated with 20 µM LPV after NFATc4 knock-
down, showed a significant decrease in the levels of IL6 protein. Co-incubated with 
both 20 µM LPV and 5 µM Tel resulted in a significant decrease in IL6 levels. NFATc4 
knock-down treatment on its own had no effect on IL6 levels in adipocytes. There 
was no significant increase in IL6 levels in adipocytes when compared with 
preadipocytes (figure 3.12).  
3.3.10 Effects of LPV and Tel on PPARϒ protein expression levels with/without 
NFATc4 knock-down  
Adipocytes, when treated with 20 µM LPV, showed a significant decrease in PPARϒ 
protein expression levels but adipocytes treated with 20 µM LPV after NFATc4knock-
down, showed a significant increase in the levels of PPARϒ protein. Upon co-
incubation with 20 µM LPV with 5 µM Tel, there was a significant increase in PPARϒ 
protein levels. NFATc4 knock-down treatment on its own had a significant effect on 
PPARϒ protein levels in adipocytes. There was a significant increase in PPARϒ protein 
expression levels in adipocytes when compared with preadipocytes (figure 3.13).  
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Figure 3.12; ELISA results showing expression levels of IL6 protein in the supernatants collected after different treatments, or no treatment at all, as described 
under each bar of the column graph. The graph shows significant increase in the IL6 levels after treatment with 20 µM LPV and 20 µM  LPV with scrambled 
NFATc4 siRNA. There was a significant decrease in IL6 levels when adipocytes were treated with 20 µM  LPV after NFATc4kn ock-down. Co-incubation of 20 
µM  LPV and 5 µM  Tel also reduced the levels of IL6 expression significantly. There was no significant difference between IL6 levels secreted by adipocytes 
when compared with preadipocytes. * = p value less than 0.05. All the experiments were repeated in three replicates to check the reproducibility and for 
statistical reasons.  
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Figure 3.13,A; Western blots showing PPARϒ protein expression levels in lysates collected after different treatments, or no treatment at all. B; The graph shows significant 
decrease in the PPARϒ levels after treatment with 20 µM LPV. There was significant upregulation in PPARϒ protein levels when adipocytes were treated with 20 µM LPV after 
NFATc4 knock-down. Co-incubation of 20 µM LPV and 5 µM Tel also induced the levels of PPARϒ significantly. There was a significant decrease in PPARϒ levels in the adipocytes 
after NFATc4 knock-down. PPARϒ levels were induced in adipocytes  when compared with preadipocytes. * = p value less than 0.05. All the experiments were repeated in 
three replicates to check the reproducibility and for statistical reasons.  
A 
B 
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3.4 Discussion  
Every tissue requires the acquisition of certain phenotypic characteristics which 
involves the expression of certain genes to define the fate and function of the cells. 
All genes require regulation and this regulation can be at multiple levels. The NFAT 
family of genes have specific roles in different cell types. NFATc4 is expressed in 
adipocytes and peri-vascular tissue cells, such as endothelial cells (Horsley and 
Pavlath 2002). NFATc4 has a role in cytokine gene transcription and adipocyte 
differentiation. It also modulates many important target genes, while modulating a 
cell’s response to its environment, especially in the case of inflammation. PPARϒ is a 
master adipogenic transcription factor and NFATc4 modulates its response while 
binding on the gene promoter region (Yang, Xiong et al. 2002). NFATc4 also takes 
part in the transcription of an important adipokine and insulin sensitizer called 
adiponectin, whilst regulating it negatively (Kim, Kong et al. 2006). Further, NFATc4  
modulates the expression of IL6 which is a pro-inflammatory cytokine (Nilsson, Sun 
et al. 2007). The literature suggests that modulation of biological markers, such as 
adiponectin and IL6, by NFATc4 may be due to the effect of ARVs. Therefore the 
effects of antiretroviral drugs on NFATc4 gene expression were investigated and a 
significant induction of NFATc4 gene expression levels by all four ARVs (LPV, RTV, 
ATV, EFV) was found. 
Antiretroviral drugs, especially protease inhibitors such as LPV and RTV, are known 
to cause insulin resistance and reduce adiponectin levels in HIV patients (Omar, Dave 
et al. 2014). Both protease inhibitors (LPV/r) and NNRTIs, such as efavirenz, reduce 
the expression of adiponectin in human adipocytes and affect their maturation 
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(Gallego-Escuredo, Del Mar Gutierrez et al. 2010). This leads to further complications 
such as an imbalance of the lipid profile body resulting in lipodystrophy which is a 
risk factor for cardiovascular disease (Morimoto, Simao et al. 2014). Telmisartan is 
an angiotensin receptor blocker and PPARϒ partial agonist (Goebel, Clemenz et al. 
2009, Boccara, Auclair et al. 2010, Goyal, Bharti et al. 2011) and recent studies 
suggest that PPARϒ may modulate NFATc4 (Bao, Li et al. 2008) but is itself also a 
target gene for NFATc4  (Yang, Xiong et al. 2002). This investigation showed that Tel 
can reduce NFATc4 expression in the presence of ARVs and suggests that modulation 
of NFATc4 expression may lead to a change in the expression of its target genes, such 
as IL6 and adiponectin. 
Earlier, in chapter 2, it was demonstrated that targeting IL-18 using Tel in the 
presence of ARVs can result in a reduction of secreted IL-18 protein from the 
adipocytes. Furthermore, the effects of the downregulation of IL-18 by Tel on the 
expression of adiponectin were investigated and significant induction in its secretion 
was found suggesting that IL-18 may negatively regulate adiponectin secretion. This 
is in line with earlier published literature by Chandrasekar et al. (2008). It was also 
suggested that downregulation of adiponectin by IL-18 was carried out via NFATc4 
(Chandrasekar, Patel et al. 2008). However, this study has demonstrated that both 
IL-18 (chapter 2) and NFATc4 are upregulated by ARVs. Further, it has previously been 
observed that ARVs downregulated adiponectin levels in HIV patients (Omar, Dave 
et al. 2014), suggesting that ARVs cause upregulation of IL-18 and NFATc4, resulting 
in subsequent downregulation of adiponectin.                                                                             
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The data presented in this chapter confirms that NFATc4 knockdown can block the 
effect of ARVs on adiponectin, IL6 and PPARϒ in terms of their expression, as shown 
in Figures 3.11, 3.12 and 3.13. Similarly, this study has shown that Tel can also be 
used as an alternative pharmacological strategy in these cells to improve adiponectin 
and PPARϒ expression in the presence of ARVs.   Our data is also consistent with the 
notion that NFATc4 is the key mediator between IL-18 and adiponectin and also that 
the inverse relationship between IL-18 and adiponectin is maintained through 
NFATc4 (Chandrasekar, Patel et al. 2008). The findings of this study confirm that the 
blockade of NFATc4 can block the negative effect of IL-18 on adiponectin (Figures 
3.11, 3.12, 3.13). 
In an earlier study, IL6 was found to be upregulated in HIV lipodystrophy patients 
who received cART (Lihn, Richelsen et al. 2003). Also, in 3T3-F442A adipocytes after 
being treated with ARVs, higher IL6 levels were observed. However, upon co-
incubation with rosiglitazone, an agonist for PPARϒ (Tungsiripat, El-Bejjani et al. 
2012), and ARVs, there was partial decrease in IL6 expression (Jones, Janneh et al. 
2005).  This investigation suggests that ARVs downregulate adiponectin while 
simultaneously upregulating IL6 via NFATc4, as shown in Figures 3.11 and 3.12. This 
is in line with the previously published literature suggesting that IL6 is a target gene 
for NFATc4 and inhibition of NFATc4 by CsA (cyclosporin A) results in downregulation 
of IL6 (Nilsson, Sun et al. 2007). The use of the PPARϒ partial agonist, Telmisartan, 
showed a significant decrease in IL6 protein levels in adipocytes after the co-
incubation treatment with LPV and Tel, when compared with treatment with 
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Lopinavir alone, suggests that Telmisartan can also reduce the levels of IL6 in 
3T3F442A adipocytes, as shown in Figure. 3.12.  
PPARϒ as a master adipogenic gene has a central role in adipocyte maturation (Ali, 
Hochfeld et al. 2013). Antiretroviral drugs cause significant reduction in the 
expression of PPARϒ in human adipocytes. This may have implications in the 
pathogenesis of HIV lipodystrophy but the mechanism for this is unclear (Gallego-
Escuredo, Del Mar Gutierrez et al. 2010). The results of this investigation do not give 
much insight in respect of the effect of ARVs on PPARϒ. This may be due the fact that 
this study was conducted at an early stage of differentiation and transcription of the 
PPARϒ gene and it may not be active enough at the early stage of adipocyte 
differentiation.  
The results presented in this chapter certainly highlight the importance of NFATc4 as 
a potential pharmacological drug target for the treatment of HIV lipodystrophy and 
complications associated with it.  The successful knockdown of NFATc4 was key to 
understanding its role in a broader context while understanding its position in the 
transcription and regulation of its target genes. In reviewing the overall picture of the 
complex meshwork of adipokines and the transcription factor, NFATc4, it is clear that 
antiretroviral drugs play a major role in the dysregulation of adipocyte gene 
regulation at the transcription level.  This study has shown that blockade of NFATc4 
transcription activity can reverse the antiretroviral induced adipose toxicity, while 
resulting in the upregulation of adiponectin, PPARϒ and the downregulation of IL6. 
Further studies are still needed to understand the pathways connecting PPARϒ with 
NFATc4 and the various mediators which are assocaited. 
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Effects of antiretroviral drugs on the miRNA 
profile of 3T3-F442A adipocytes 
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4.1 Introduction 
MicroRNAs (miRNAs) are a novel group of endogenous small RNAs consisting of 20 
to 30 nucleotides which post-transcriptionally regulate expression of various genes. 
There is growing evidence of the role of miRNAs in regulation of multiple pathways 
in adipose tissue relating to adipogenesis, insulin resistance and inflammation (Zhou 
and Li 2014). It has been shown in many high-throughput studies that several miRNAs 
are differentially expressed in adipose tissue during adipogenesis and various 
pathological conditions (Piva, Spandidos et al. 2013). Several miRNAs have been 
identified and characterised functionally in terms of their targets and actions (van 
Rooij 2011). The discovery of let-7 and its homologous genes proved to be a stimulus 
to discover and study more miRNAs in detail. In 2002, Calin et. al showed a 
correlation between miRNA abundance and human disease. They showed an 
association between the loss of miR-15 and -16 and the occurrence of B-cell 
leukaemia (Calin, Dumitru et al. 2002). In terms of miRNAs research, there was no 
major discovery until 2006   when a cardiac miRNA-profiling study showed an 
association between cardiac remodelling in both mice and humans with 
dysregulation of many different miRNAs (van Rooij, Sutherland et al. 2006).   
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Figure 4.1. Time line of the various discoveries related to miRNAs (van Rooij 2011). 
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Today microarray analysis and deep-sequencing approaches have enabled 
researchers to correlate the changes in expression levels of miRNAs to the 
progression of different diseases across various species (van Rooij 2011). The genome 
of all the multicellular animals is highly conserved through  evolution and they all 
contain miRNAs having similar or an almost conserved sequence across the species 
(Friedman, Farh et al. 2009). miRNAs are non-coding transcripts which are 
transcribed by RNAase polymerase II (Kim, Han et al. 2009). They may have an origin 
from either intron or exon referring to their class as intronic or exonic miRNAs 
respectively (Krol, Loedige et al. 2010).  
After transcription, a primary miRNAs consisting of thousands of bases is cleaved by 
an enzyme called Drosha resulting in a precursor miRNA consisting of around 70 
nucleotides containing a stem loop structure (Hilton, Neville et al. 2013). Precursor 
miRNA is transported into the nucleus, by a protein called exportin (Orom, Nielsen et 
al. 2008), where it is processed further by another enzyme called Dicer (Lee, Ahn et 
al. 2003). The result is a short double stranded miRNA which requires further 
processing by a complex of proteins called the Argonaut protein complex (Fang and 
Rajewsky 2011), which separates the mature miRNA from the messenger miRNA 
strand (Meister 2013). The mature miRNA then gets incorporated in RNA-induced 
silencing complex (RISC) which guides it to  target miRNA according to its 
complementarity with its target sequence (Selbach, Schwanhausser et al. 2008). The 
messenger strand of the miRNA double strand is normally degraded (Vasudevan, 
Tong et al. 2007). miRNAs normally have a predefined target and they act like 
modulators of the genes (Baek, Villen et al. 2008). Mostly the sequences of miRNAs 
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are conserved across the species (Mukherji, Ebert et al. 2011). The detailed 
processing of the miRNAs is also depicted in the figure 4.2.  
 
 
Figure 4.2. Process of biogenesis and mechanism action of the miRNAs (Piva, 
Spandidos et al. 2013). 
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The adipose tissue consists of three types: brown, beige and white. Beige adipose 
tissue is considered as the intermediate stage between white and brown adipose 
tissue. It also has the capability to convert to both white and brown adipose tissues. 
Brown adipose tissue has thermogenic properties whereas white adipose tissue has 
insulating energy storage and endocrine properties (Peirce, Carobbio et al. 2014). 
miRNAs have been presented as an integral part of tissue formation along with their 
key regulatory role in its primary function (Mukherji, Ebert et al. 2011). Studies have 
already demonstrated that various miRNAs and related cell machinery have a role in 
adipogenesis. For example, the inhibition of key miRNA processing enzymes, Drosha 
and Dicer, can result in the halting of adipogenesis (Lim, Lau et al. 2005, Oskowitz, Lu 
et al. 2008). In an animal study, it was observed that mice that lack the Dicer enzyme 
could still develop white adipose tissue; however, the brown adipose tissue lacked 
thermogenic gene activity (Mudhasani, Puri et al. 2011). In another study it has been 
shown that miR-14 has significant involvement in the triglyceride and diacylglycerol 
metabolism where animals lacking miR-14 showed higher levels of triglycerides and 
diacylglycerol (Xu, Vernooy et al. 2003). A study conducted in drosophila reported 
that miR-278 null drosophila had higher insulin levels in their circulation as well as 
higher levels of glucose   (Teleman, Maitra et al. 2006). miR-8 knock out drosophila 
model  were also found to have a defective insulin pathway (Hyun, Lee et al. 2009). 
The role of miRNAs has been reported in the inhibition of adipogenesis in many 
studies;  miR-21, miR-130, miR-138, miR-145, miR-155 have all been shown  to be 
negative regulators of adipogenesis (Lee and Dutta 2007, Kim, Hwang et al. 2009, 
Sun, Fu et al. 2009, Liu, Yang et al. 2011). Similarly some miRNAs have been reported 
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as positive regulators of adipogenesis: miR-371 up regulates ADIPOQ and FABP4 
whereas miR-30 promotes adipogenesis through the negative regulation of 
SREBP1P2, ACVR1 and RUNX2 genes.  It has also been reported that individual 
miRNAs which target various genes and show positive  or negative effects on 
adipogenesis but, actually,  very little is known about the whole pathway which 
regulates the  metabolism of the fat cell (Xie, Lim et al. 2009, Ortega, Moreno-
Navarrete et al. 2010).  
Various studies have shown that visceral adipose tissue has many miRNAs that are 
differentially expressed within it (Vohl, Sladek et al. 2004, Dahlman, Forsgren et al. 
2006, Klimcakova, Roussel et al. 2011). A study conducted on the profile of 155 
miRNAs in visceral fat tissue found 16 miRNAs that were highly upregulated in 
omental fat and a further investigation revealed that 12 of these 16 miRNAs were 
dysregulated in individuals with obesity and type 2 diabetes (T2DM)  (Kloting, 
Berthold et al. 2009). Dysregulation of miRNAs may result in insulin resistance and 
many miRNAs have been reported to be involved in insulin resistance in studies 
focussed on rodent, human and mouse adipocytes (Trajkovski, Hausser et al. 2011, 
Rottiers and Naar 2012, Honardoost, Sarookhani et al. 2014). Lower levels of miR-
221  are reported to be associated with elevated levels of the TNF-α; miR-221 has 
also been shown to be a negative regulator of the ADIPOR1 (receptor of adiponectin) 
and this  may contribute to insulin resistance (Chou, Wang et al. 2013, Meerson, 
Traurig et al. 2013).  
Inflammation is another important component of obesity, T2DM and metabolic 
syndrome; several miRNA are also reported to play a role in this.   miR-26b is thought 
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to be associated with the infiltration of macrophages in adipose tissue and miR-99a 
along with miR-325 have been found to be negatively correlated with IL6 secretion 
in omental and subcutaneous fat (Kloting, Berthold et al. 2009). miR-132 has been  
associated with increased secretion of IL6 and IL18 (Strum, Johnson et al. 2009, Estep, 
Armistead et al. 2010) whereas miR-145, miR-26a and let-7d are reported to be 
involved in lipolysis in adipocytes through various mechanisms which include 
production and processing of TNF-α (Lorente-Cebrian, Mejhert et al. 2014). Network 
diagram of miRNAs interacting with a complex meshwork of signalling pathways 
involving various genes involved in adipogenesis (Son, Ka et al. 2014) is shown in 
Figure 4.3 below.    
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Figure 4.3. Showing various microRNAs targeting genes involved in adipogenesis and other patways (Son, Ka et al. 2014). 
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4.1.1 Rationale for the study 
There is very little known about the effects of antiretroviral drugs  (ARVs) on the 
miRNA profile of adipocytes; given that ARVs cause adipocyte toxicity in HIV patients, 
understanding the interactions between ARVs and miRNAs is important. We decided 
to perform a screening study to study the effects of ARVs on miRNAs regulation in 
differentiating 3T3F442A adipocytes.  Using the in vitro adipocyte model which has 
been used throuhgout this project, we designed a study to screen for differentially 
regulated miRNAs when treated with various ARVs with or without telmisartan.  
Some studies have reported implication of miRNAs in insulin resistance e.g. miR-103 
and miR-107 had been shown to regulate insulin sensitivity in primary mouse 
adipocytes. They both targeted Cav-1 gene (Trajkovski, Hausser et al. 2011) which 
acts as an essential constituent protein of adipocyte caveolae (Palacios-Ortega, 
Varela-Guruceaga et al. 2014). miR-103 is upregulated in differentiating adipocytes 
(Li, Liu et al. 2015). The above described details regarding miR-103 and miR-107, 
provided rational to investigate their role further in adipogenesis in our in vitro model 
before and after adipogenesis. Hence, we decided to investigate the effects of ARVs 
and Tel on the expression of miR-103 and miR-107, along with Cav-1, during 
adipogenesis over a period of 10 to 16 days in separate experiments while replicating 
them independently.  
 
 
4.1.2 Aims and Objectives of the study 
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The aims of the studies included in this chapter were; 
1) To use global miRNA profiling to investigate the effects of ARVs on differentiating 
3T3-F442A adipocytes.  
2) To validate selected miRNA targets using the 3T3-F442A in vitro model 
3) To characterise selected miRNAs by investigation of expression of their target 
genes 
4.2 Method 
4.2.1 Materials  
TaqMan® rodent microRNA-A Arrays v2.0, megaplex reverse transcription primers, 
TaqMan® universal master mix and Taqman reverse transcription kit were 
purchased from Life Technologies UK. Antiretrovirals i.e. lopinavir (LPV), atazanavir 
(ATV),  efavirenz (EFV) and an angiotensin receptor blocker telmisartan (Tel) were 
supplied by Santacruz® Bio-technologies Inc. Insulin from bovine pancreas, 
methanol, Trypsin EDTA, chloroform and dimethyl sulfoxide (DMSO) were 
purchased from Sigma® Aldrich, UK. Fetal calf serum (FCS) and fetal bovine serum, 
Dulbecco’s modified eagle medium (DMEM), Hank's balanced salt solution, rat tail 
collagen-I, reverse transcription kit, tri-reagent for RNA isolation, FAM labelled 
Caveolin-1, microRNA 103, microRNA 107 and snRNA U6, VIC labelled β-actin 
Taqman®  gene expression assays and  Taqman® gene expression master mix were 
purchased from Life Technologies® USA. Caveolin-1 and GAPDH primary and 
secondary antibodies were purchased from Santacruz® Bio-technologies Inc. 12 
well, 6 well plates along with T25, T75, T175 flasks and all other cell culture 
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equipment were purchased from Thermo Fisher Scientific ® USA. 3T3-F442A murine 
pre-adipocyte cells were kindly provided by Dr. Sudeep Pushpakom based at the 
Wolfson Centre for Personalised Medicine, University of Liverpool, UK.  
4.2.2 Cell culture 
3T3-F442A murine preadipocytes were cultured as described in Chapter 2 of this 
thesis. Cells were differentiated on Day 2 and after 48 hours post-differentation, cells 
were treated with either vehicle or 20 µMs of LPV, ATV, and EFV with or without 
telmisartan (1 and 5 µM) for 24 hours and RNA was extracted as described before. 
For the validation studies, longitudinal samples were collected after 16 and 10 day 
drug treatment periods respectively. Lysates for total RNA extraction and western 
blotting were collected from preadipocytes, differentiating adipocytes and drug 
treated samples at appropriate time intervals according to the design of the studies. 
Different treatments used in the miRNAs screening study are described in the Table 
4.1 below; 
Table 4.1. Drug treatment plan for cells in the microRNA screening study. 
Sl 
# 
Samples without drug 
treatments 
Sample receiving 
single Drug 
Treatments 
Sample receiving  
drug combination 
treatment 
1 Preadipocytes 20 µM Lopinavir 
(LPV) 
20 µM Lopinavir (LPV) 
+ 
5 µM 
Telmisartan 
2 Differentiating adipocytes 
(After 48 hours of 
differentiating ) 
20 µM Efavirenz 
(EFV) 
20 µM Efvavirenz 
(EFV) 
+ 
5 µM 
Telmisartan 
3  
 
20 µM Atazanavir 
(ATV) 
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4.2.3 Collection of lysates and total RNA extraction from drug treated cells 
After 24 hours of each treatment, supernatants were collected from all the wells and 
cells were washed twice with 1 ml of Hank's balanced salt solution. 500 µl of TRI-
reagent was then added to each well. Cell lysates were collected using a pipette and 
transferred into 1.5 ml autoclaved Eppendorf tubes. 100 µl of chloroform was added 
to each tube and they were gently inverted multiple times until the mixture appeared 
to be homogenised. They were then kept at room temperature for 10 minutes. After 
10 minutes, all the tubes were centrifuged at 14000 rpm for 15 minutes at 4°C to 
separate the RNA, DNA and protein in three distinct layers. The top, most transparent 
layer contained RNA. The middle, cloudy layer, contained DNA and the bottom, pink 
layer, contained proteins.  
The supernatant containing RNA was removed from each tube and transferred to 
another 1.5 ml Eppendorf tube. The remaining DNA and proteins in the tubes were 
discarded. 25 µl of isopropanol was then added to each tube containing RNA and 
mixed well by gentle tapping before they were left for 10 minutes at room 
temperature. They were then centrifuged at 12000 rpm for 10 minute at 4°C. The 
supernatants from each of the Eppendorfs were then transferred, leaving any 
impurities at the bottom of the tube, to a new autoclaved 1.5 ml volume Eppendorf 
tubes.  225 µl of isopropanol was then added to each of them, mixed using a vortex 
and, incubated for 10 minutes at room temperature. After centrifuging all the tubes 
at 14000 rpm for 10mins all the supernatant was discarded while saving the pellet at 
the bottom. 100 µl of 75% ethanol was then added to each pellet. All the samples 
were centrifuged at 14000 rpm for 10 minutes and all the supernatant was discarded 
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leaving the pellet at the bottom of the tube, which contained total RNA for each 
sample respectively. After the addition of 15 µl of the RNAase/DNAase free water to 
each RNA pellet   they were dissolved by gentle tapping on the tube. Each tube was 
then centrifuged again to bring the whole sample to the bottom of the Eppendorf 
tube.  It was then quantitated using the Nanodrop machine from Thermofisher 
Scientific ® to check the quality and quantity of total RNA extracted. All the total RNA 
samples were stored at -20 ℃ for further analysis.  
4.2.4 Real Time PCR using TaqMan Low density Array (TLDA) 
Taqman low density arrays were employed to analyse a wide spectrum of miRNAs in 
preadipocytes and differentiating adipocytes samples treated with or without the 
drugs. The overall sequence of the procedure is described in a flow chart in Figure 
4.4, below; 
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Figure 4.4. Flow chart showing steps involved in the overall sequence of miRNAs 
screening experiment. 
Samples were carefully selected after quantitation and quality checked using 
Nanodrop. Total RNA from all the selected samples were normalised between the 
ranges of 800 – 900 ng / µl. Reverse transcription was performed using 3 µl of total 
RNA and 4.5 µl of a master which was prepared from different reagents of Taqman 
miRNA reverse transcription kits as described in Table 4.2.  
 
 
 
 
 
RNA normalisation between 800 ng / µl to 900 ng / µl 
Reverse Transcription for cDNA generation  
Real Time PCR analysis using TLDAs 
Interpretation of results 
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Table  4.2. Composition of the master mix used for reverse transcription of Total 
RNA for TLDAs only. 
Sl No Reverse Transcription reaction mix Components Volume for one sample 
(µLs) 
1 Megaplex ™ RT primers  0.80 
2 dNTPs with dTTP  0.20 
3 Multiscribe ™ reverse transcriptase  1.50 
4 10X RT Buffer 0.80 
5 MgCl2 0.90 
6 RNAase Inhibitor  0.10 
7 Nuclease free water 0.20 
Total Volume  4.50 
 
For reverse transcription purpose 4.5 µl was added in to 3 µl of the total normalised 
RNA from each sample, making a final volume of 7.5 µl only. The conditions set up 
for reverse transcription on thermocycler are described in  Table 4.3 below; 
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Table 4.3. Parameters used for reverse transcription. 
 
Sl No Stage Temperature Time 
1  
40 Cycles 
16 °C 2 min 
42 °C 1 min 
50 °C 1 sec 
2 Hold 85 °C 5 min 
3 Hold 4 °C ∞ 
 
To run a real time PCR reaction on TLDA arrays, 6 µls of sample (cDNA) was mixed 
with 450 µls TaqMan ® universal PCR master mix, No Amperase® UNG, 2X and 444ul 
of Nuclease free water to obtain 900ul of reaction mix.  
Out of the 900 µl preparation for each sample, 100 µl was loaded into each of the 8 
ports of a TLDA array, hence each array received only one sample for studying 384 
miRNA transcripts. After loading the sample, each array was centrifuged at 1200 rpm 
for 1 min. The array was then sealed using a sealer Filling reservoirs were then 
trimmed off the array. The array was finally loaded on to the 7900HT Fast Real Time 
PCR machine and standard settings were used to perform the real time PCR as 
described by the manufacturer. After running the array reactions, data was exported 
to Microsoft Excel spread sheets and analysed accordingly.  
4.2.5 MiRNA and gene expression analysis for validation of selected targets using 
real time PCR 
Total RNA was reverse transcribed using the Taqman® reverse transcription kit from 
Life Technologies USA. Each reaction contained 2 µl of total RNA from each sample, 
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2.5 µl of Taqman 10X buffer, 5.5 µl of MgCl2, 5 µl of dNTPs, 1.25 µl of random 
hexamers, 0.5 µl of RNAase inhibitor, 0.875 µl of reverse transcriptase (RT scribe) and 
7.375 µl of RNAase/DNAase free water, making the total volume 25 µl for each 
sample in a 200 µl volume Eppendorf tubes respectively. Each of the tubes were 
mixed and centrifuged then placed on the heating block of the Veriti® thermo-cycler 
from Applied Biosystems® UK. The thermo cycler was programmed and run at 25°C 
for 10mins, 48°C for 30 min, 95°C for 5 min, 4°C for one hour for one whole cycle 
only. At the end of the reverse transcription, the samples were mixed using vortex 
and centrifuged again. Then cDNA in each sample tube formed as a result of reverse 
transcription was quantified using NanoDrop™ to check the quantity and quality of 
cDNA. Later on, cDNA from each tube was further normalised to 20 ng / µl using 
RNAase /DNAase free water.  
FAM, labelled Cav-1 and VIC, labelled β-actin Taqman® gene assays and Taqman® 
gene expression master mix were used to perform duplex real time reactions to 
evaluate the levels of expression of miRNA for Cav-1 relative to miRNA levels of β-
actin which was used as a house keeping gene while employing cDNA, which was 
normalised to 20 ng/µl earlier for respective samples. Also, FAM labelled gene 
expression assays for miRNA 103 and 107 were used to study their relative 
expression in comparison with endogenous expression of snRNA U6 gene.  
All the reactions were replicated four times using cDNA from four biological 
replicates for statistical purposes. All reactions were carried out using standard 
cycling parameters 
(https://www.lifetechnologies.com/order/catalog/product/4329001) and 
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quantitation of the target mRNA was carried out using the 2(-Delta Delta C(T)) 
Method. (Livak and Schmittgen 2001).                                                                                         
4.2.6 Western blotting 
1D gel electrophoresis was performed as described in chapter 3 of this thesis to 
study the expression of Caveolin-1 protein in the 20 µM LPV treated cells. The 
western blotting films were scanned using a Bio-Rad GS-800 scanner for 
densitometry purpose and quantification was performed using the software 
Quantity One.     
4.3 Results 
4.3.1 Differential expression of miRNAs with ARVs: 
Taqman® low density array (TLDA) was used to perform a screening study to find 
the expression levels of various microRNAs in different samples included in the 
experiment. The comparisons studied are described below in Table 4.4; 
Table 4.4. Comparisons studied using miRNA expression data from TLDA 
experiment. 
Sl #  Different comparisons studied 
1 Pre adipocytes vs Differentiating adipocytes 
2 Vehicle vs 20 µM LPV 
3 Vehicle vs 20 µM ATV 
4 Vehicle vs 20 µM EFV 
5 20 µM LPV vs 20 µM LPV + 5 µM Tel 
6 20 µM EFV vs 20 µM EFV + 5 µM Tel 
 
169 
 
4.3.1.1 microRNAs significantly modulated in differentiating adipocytes  
In total, 24 microRNAs were significantly differentially regulated in adipocytes 
undergoing differentiation in comparison with preadipocytes (Table 4.5).  
Table 4.5. MiRNAs significantly regulated in differentiating adipocytes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sl # microRNAs Fold Change p - value  
1 mmu-miR-429-001077 1.461 0.0266 
2 mmu-miR-34a-000426 2.394 0.0230 
3 mmu-miR-331-5p-002233 3.163 0.0162 
4 mmu-miR-139-5p-002289 3.385 0.0230 
5 mmu-miR-130b-000456 4.295 0.0140 
6 mmu-miR-744-002324 4.479 0.0295 
7 mmu-miR-93-001090 4.697 0.0418 
8 mmu-miR-34c-000428 4.948 0.0163 
9 mmu-miR-26b-000407 4.991 0.0357 
10 mmu-miR-145-002278 5.000 0.0478 
11 mmu-miR-19b-000396 5.063 0.0373 
12 mmu-let-7f-000382 5.137 0.0249 
13 mmu-miR-96-000186 5.156 0.0141 
14 mmu-miR-872-002264 5.618 0.0151 
15 snoRNA202-001232 5.653 0.0062 
16 mmu-miR-210-000512 5.716 0.0184 
17 mmu-miR-425-001516 7.436 0.0460 
18 mmu-miR-324-3p-002509 7.461 0.0061 
19 mmu-miR-497-001346 7.640 0.0157 
20 mmu-miR-103-000439 7.806 0.0258 
21 mmu-miR-200b-002251 7.827 0.0080 
22 mmu-miR-503-002456 8.308 0.0306 
23 mmu-miR-328-000543 9.312 0.0001 
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Figure 4.5. MiRNAs significantly differentially regulated in differentiating adipocytes as compared to preadipocytes, p value < 0.05
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There were various miRNAs which were not detected in preadipocytes and, similarly, 
a few were not detected in differentiating adipocytes. The miRNAs detected only in 
preadipocytes and differentiating adipocytes samples are described in tables 4.11 
and 4.12 respectively; 
 
Table 4.8. MiRNAs which were expressed in preadipocytes only. 
 
 
Sl # miRNAs expressed only in preadipocytes 
1 mmu-miR-466h-002516 
2 mmu-miR-139-3p-002546 
3 mmu-miR-615-5p-002353 
4 rno-miR-347-001334 
5 ath-miR159a-000338 
 
These miRNAs are potentially downregulated during differentiation and therefore 
does not express in differentiated adipocytes. 
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Table 4.9. MiRNAs which were expressed in differentiating adipocytes but not 
expressed in preadipocytes 
miRNAs expressed only in differentiating adipocytes 
1 mmu-miR-32-002109 21 mmu-miR-450b-5p-001962 
2 mmu-miR-124-001182 22 mmu-miR-467e-002568 
3 mmu-miR-127-000452 23 mmu-miR-501-3p-001651 
4 mmu-miR-129-3p-001184 24 mmu-miR-542-3p-001284 
5 mmu-miR-135b-002261 25 mmu-miR-582-3p-002567 
6 mmu-miR-141-000463 26 mmu-miR-582-5p-002566 
7 mmu-miR-150-000473 27 mmu-miR-590-5p-001984 
8 mmu-miR-181c-000482 28 mmu-miR-669a-001683 
9 mmu-miR-202-3p-001195 29 mmu-miR-671-3p-002322 
10 mmu-miR-204-000508 30 mmu-miR-742-002038 
11 mmu-miR-215-001200 31 mmu-miR-871-002354 
12 mmu-miR-216b-002326 32 mmu-miR-883a-3p-002461 
13 mmu-miR-223-002295 33 mmu-miR-883b-3p-002565 
14 mmu-miR-290-3p-002591 34 mmu-miR-452-001032 
15 mmu-miR-297c-002480 35 mmu-miR-468-001085 
16 mmu-miR-297b-5p-001626 36 mmu-miR-670-002020 
17 mmu-miR-302a-000529 37 mmu-miR-675-3p-001941 
18 mmu-miR-345-3p-002529 38 mmu-miR-377-000566 
19 mmu-miR-367-000555 39 mmu-miR-410-001274 
20 mmu-miR-376a-001069   
 
4.3.1.2 Differential expression of miRNAs in differentiating adipocytes with LPV 
In total 13 miRNAs were significantly modulated in adipocytes when treated with 
20 µM LPV; fold changes  and respective p values are described in the Table 4.10 
and graphical representation can be found in Figure 4.6 A, B, C.  
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Table 4.10. MiRNAs differentially regulated by 20 µM LPV in differentiating 
adipocytes. 
Sl # microRNAs modulated by  
20 µM LPV 
Fold Change  p-value  
1 mmu-let-7c-000379 1.209 0.012 
2 mmu-miR-182-002599 2.666 0.005 
3 mmu-miR-143-002249 9.971 0.015 
4 mmu-miR-15b-000390 10.122 0.024 
5 mmu-miR-145-002278 19.114 0.006 
6 mmu-let-7i-002221 20.322 0.050 
7 mmu-miR-26a-000405 21.102 0.002 
8 mmu-miR-106b-000442 22.208 0.001 
9 mmu-miR-26b-000407 23.083 0.010 
10 mmu-miR-30b-000602 41.965 0.007 
11 mmu-miR-106a-002459 43.428 0.003 
12 mmu-miR-140-001187 76.386 0.008 
13 mmu-miR-465a-5p-001082 362.964 0.046 
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Figure 4.6, A, B. MiRNAs differentially regulated after treatment with 20 µM LPV in adipocytes as compared to Vehicle.  p value < 0.05 
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Figure 4.6 C. MiRNAs differentially regulated after treatment with 20 µM LPV in adipocytes as compared to Vehicle.  p value < 0.05 
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4.3.1.3 Differential expression of microRNAs in differentiating adipocytes following 
coincubation of Tel with LPV 
Tel significantly partially reversed LPV-induced downregulation of 5 miRNAs in 
differentiating adipocytes( Table 4.11 and Figure 4.7).  
 
Table 4.11. miRNAs differentially regulated by 20 µM LPV + 5 µM Tel in comparison 
with 20 µM LPV 
 
 
 
Sl # miRNAs Fold change with  
20 µM LPV 
Fold change with 
20  µM LPV + 5 µM 
Tel 
p-
values 
1 mmu-miR-125b-5p-
000449 78.121 21.176 0.007 
2 mmu-miR-29c-000587 7.511 2.169 0.017 
3 mmu-miR-146a-000468 7.788 4.336 0.032 
4 mmu-miR-425-001516 6.222 2.338 0.033 
5 mmu-miR-151-3p-
001190 2.111 1.268 0.046 
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Figure 4.7. microRNAs differentially regulated after treatment with 20 µM LPV + 5 µM Tel in adipocytes as compared to Vehicle, p  < 0.05
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4.3.1.4 microRNA significantly modulated with EFV 
4 miRNAs were found to be significantly modulated on treatment with 20 µM EFV 
after 24 hours treatment and these are described in Table 4.12. The graphical 
representation of the data from table 4.12 is shown in the figure 4.8.  
Table 4.12. MiRNAs differentially regulated by 20 µM EFV in adipocytes. 
Sl # miRNA Fold Change  p-values 
1 mmu-miR-106b-000442 10.443 0.025 
2 mmu-miR-140-001187 19.858 0.032 
3 mmu-miR-30b-000602 20.270 0.021 
4 mmu-miR-106a-002459 42.294 0.020 
 
 
Figure 4.8. microRNA differentially expressed after treating adipocytes with 20 µM 
EFV,  p < 0.05 
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4.3.1.5 Differential expression of miRNAs in differentiating adipocytes following 
coincubation of Tel with EFV 
When we co-incubated 5 µM Tel with 20 µM EFV we found that Tel significantly 
partially reversed EFV-mediated changes in expression of 3 different miRNAs in 
differentiating adipocytes(Table 4.12 and Figure 4.9).  
Table 4.13. MiRNAs significantly regulated by Tel coincubation with EFV 
 
Sl # 
 
miRNAs 
Fold change with  
20 µM EFV 
Fold change with 
20  µM EFV + 5 µM 
Tel 
 
p-values 
1 mmu-miR-21-000397 10.863 39.276 0.025 
2 mmu-miR-146a-
000468 2.009 1.047 0.050 
3 mmu-miR-743a-
002469 1.315 0.111 0.013 
 
 
Figure 4.9. Showing miRNAs differentially regulated after treatment with 20 µM 
EFV + 5 µM Tel in adipocytes as compared to 20 µM EFV, p < 0.05 
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4.3.1.6 Differential expression of miRNAs ATV 
There were 3 miRNAs which were significantly modulated in differentiating 
adipocytes after 24 hours of 20 µM ATV treatment. MiR-351 was the least 
upregulated whereas the highest upregulation was in the expression of miR-140. The 
details of the p values are shown in table 4.14 and graphical representation is 
depicted in figure 4.10; 
Table 4.14. MiRNAs significantly differentially regulated in differentiating 
adipocytes following treatment with 20 µM ATV 
 
Sl # miRNA Fold Change p-values 
1 mmu-miR-351-001067 5.358 0.019 
2 mmu-miR-106b-000442 22.605 0.003 
3 mmu-miR-140-001187 77.079 0.013 
 
 
Figure 4.10. MiRNA differentially expressed after treating adipocytes with 20 µM 
ATV in comparison with vehicle, p < 0.05. 
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4.3.1.7 MiRNAs significantly modulated by all three drugs (ATV, LPV and EFV)  
Two miRNAs were significantly differentially regulated across all three drug 
treatments used in this screening study. These were miR-140 and miR-106b as shown 
in Table 4.15.   
Table 4.15. MiR-106b and miR-140 shown significant differential regulation across 
all 3 drug treatments 
 
miRNAs Fold change 
With 
20 µM ATV 
p-
values 
Fold 
change 
With 
20 µM LPV 
p-
values 
Fold 
change 
With 
20 µM EFV 
p-values 
miR-106b 22.605 0.003 22.208 0.001 10.443 0.025 
miR-140 77.079 0.013 76.386 0.008 19.858 0.032 
 
 
 
 
Figure 4.11. Data from table 4.15 showing fold change comparison of miR-106b and 
miR-140, after treating adipocytes with different drugs (20 µM ATV, LPV and EFV), p 
< 0.05 
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4.3.1.8 Common microRNAs significantly modulated by TEL on coincubation with 
ARVs in adipocytes 
One miRNA was found modulated by TEL irrespective of the ARV used. . This was 
mmu-miR-146a-000468 (Fold change: 4.336; p = 0.032 [when coincubated with LPV]; 
fold change:1.047; p value=0.05 [with EFV)  
 
 
 
Figure 4.12. Showing common differentially expressed microRNAs between 
treatments with 20 µM LPV + 5 µM Tel and 20 µM EFV + 5 µM Tel, p < 0.05 
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MiR-103, miR-107 and their target gene, Caveolin 1 were selected for validation 
studies in differentiating adipocytes using LPV as an exemplar drug.   
4.3.2.1 Effect of antiretroviral drugs on miR-103, miR-107 and Cav-1 expression in 
differentiating adipocytes  
To study the effects of the antiretroviral drug (Lopinavir) on miR-103 and miR-107 
and their common target Cav-1 mRNA, a multiple time point study was initially 
conducted over a period of 16 days. The gene expression levels of miR103, miR107 
and Cav-1 were investigated. Only LPV was used to study its effect in differentiating 
adipocytes over a period of 16 days. Treatment with LPV resulted in the 
downregulation of miR103 and miR107 in differentiating adipocytes across all the 
time points studied.  Two different concentrations of LPV (10 µM and 20 µM) were 
included. 10 µM LPV was less effective but 20 µM LPV made significant reduction in 
the expression of miRNAs at various time points as shown in figures 4.9 to figure 4.15. 
All the results are the mean of four independent repetitions of the process.  
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Expression levels of miR-103 at various time points 
 
 
Figure 4.13. Showing gene expression levels of miR-103 at all time points after various treatments, 
(All the results are the mean of four independent repeats.), *= p < 0.05 
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Expression Levels of miR-107 at various time points
 
Figure 4.14. Showing gene expression levels of miR-107 at all time points after various treatments, 
(All the results are the mean of four independent repeats), *= p < 0.05 
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Expression Levels of Cav-1 at various time points 
 
Figure 4.15. Showing gene expression levels of Cav-1 at all time points after various treatments, 
(All the results are the mean of four independent repeats), *= p < 0.05 
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4.3.2.2 Effect of coincubation of telmisartan with LPV on miR-103, miR-107 and Cav-
1 in differentiating adipocytes 
It was observed that LPV caused a significant reduction in the levels of miR-103, miR-
107 and Cav-1 simultaneously at all time points during ongoing adipocyte 
differentiation. Since we have already observed Tel to partially reverse the results of 
ARVs in the in vitro model, we investigated the effect of Tel coincubation on LPV-
induced changes in these targets.  Tel significantly partially reversed the effect of LPV 
on both miRNAs and Cav-1 mRNA under investigation at all time points. The changes 
observed in the Cav-1 mRNA were also validated at the protein level in cell lysates 
using Western blots. (Figure 4.17, 4.19 and 4.21.)  
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Expression levels of miR-103, miR-107 and cav-1 at 24 hours of various treatments (Day 3 of adipocyte differentiation) 
 
Figure 4.16. Showing gene expression levels of miR-103, miR-107 and cav-1 at 24 hours of treatment with 20 µM LPV and 20 µM LPV + 5 µM 
Tel, (Day 3 of differentiation), All the results are the mean of four independent repeats. *= p < 0.05. 
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Expression levels of cav-1 protein at 24 hours of various treatments (Day 3 of adipocyte differentiation) 
 
 
 
 
 
 
 
Figure 4.17. Showing Cav-1 western blot results after treatment with 20 µM LPV and 20 µM LPV + 5 µM Tel at 24hours 
(day 3 of adipocyte differentiation). All the results are the mean of 3 independent repeats. *= p < 0.05. 
 
 
 
Expression levels of miR-103, miR-107 and Cav-1 at day 4 of various treatments (Day 6 of adipocyte differentiation) 
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Figure 4.18. showing gene expression levels of miR-103, miR-107 and cav-1 at day 4 of treatment with 20 µM LPV and 20 µM LPV + 5 µM 
Tel(Day 6 of differentiation). All the results are the mean of four independent repeats. *= p < 0.05. 
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Expression levels of miR-103, miR-107 and Cav-1 at 48hours of various treatments (Day 6 of differentiation) 
 
 
 
 
 
Figure 4.19. Showing Cav-1 western blot results after treatment with 20 µM LPV and 20 µM LPV + 5 µM Tel at Day 4  
(Day 6 of adipocyte differentiation) All the results are the mean of 3 independent repeats. *= p < 0.05. 
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Expression levels of miR-103, miR-107 and Cav-1 at day 8 of various treatments (Day 10 of adipocyte differentiation) 
 
 
 
Figure 4.20. showing gene expression levels of miR-103, miR-107 and cav-1 at day 8 of treatment with 20 µM LPV and 20 µM LPV + 5 µM Tel 
(Day 10 of differentiation). All the results are the mean of four independent repeats. *= p < 0.05. 
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Figure 4.21. showing Cav-1 western blot results after treatment with 20 µM LPV and 20 µM LPV + 5 µM Tel at day 8 
(day 10 of adipocyte differentiation). All the results are the mean of 3 independent repeats. *= p < 0.05. 
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4.4 Discussion  
HIV associated Lipodystrophy (LD) is a complex collection of diseases with a 
pathophysiology spanning from obesity and metabolic disturbances to insulin 
resistance (Bindlish, Presswala et al. 2015). cART based on various antiretroviral 
drugs has been implicated in the pathogenesis of HIVLD. In recent research, miRNAs 
have emerged as naturally existing regulators of metabolism at cellular level; they 
are also reported to regulate adipogenesis and other functions of adipocytes 
(McGregor and Choi 2011). In a study performed using C.elegans, various miRNAs 
have been reported to be involved in direct metabolic pathways leading to the 
maturation and development of tissues (Lagos-Quintana, Rauhut et al. 2001). In vitro 
and in vivo studies have reported that miRNAs regulate adipogenesis at the 
transcription level and their sequences are highly conserved across various multi-
cellular species (Son, Ka et al. 2014).  
In this study, it has been demonstrated that various miRNAs are modulated during 
adipogenesis in response to ARVs. In a microarray study conducted on samples 
collected from non-obese, obese and T2DM women, miR-34a was found to be 
upregulated in mature adipocytes. miR-34a levels were also found to be higher in 
adipocytes obtained from obese individuals when compared to adipocytes from lean 
individuals (Ortega, Moreno-Navarrete et al. 2010).  Our results also show that miR-
34a is upregulated in differentiating adipocytes and supports its suggested role in 
adipocyte maturation. mir-26b is reported to be highly expressed in both mature 
mice and human adipocytes and was found to be associated with adipokine secretion 
in adipocytes (Xu, Shi et al. 2014). In another study, miR-26b inhibition can result in 
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the halting of adipogenesis in adipocytes suggesting its key role in adipogenesis 
(Song, Xu et al. 2014) and its role in modulation of insulin sensitivity makes it a 
potential therapeutic target (Xu, Ji et al. 2015). Results here show similarities with 
other miRNA studies conducted.  
This study shows that miR-19b is upregulated in differentiating adipocytes which 
indicates its role in adipogenesis. In previous studies it has been reported that miR-
19b is situated in the third intron of the C13orf 25 gene and it has been shown that 
it is upregulated in 3T3-L1 adipocytes during differentiation (Wang, Li et al. 2008). 
3T3-L1 is very closely related to the 3T3-F442A in vitro model which we have used in 
this study. Inhibition of miRNAs using the antisense technique has been employed by 
many studies and few have reported an effect on the target gene expression. 
Similarly, in the case of miR-34c, antisense inhibition did not affect the expression 
levels of any of the adipogenic markers such as PPARϒ. However, during adipogenesis 
its expression was noted to be upregulated which is similar to other results. It has 
been reported here that miRNA 34c is upregulated in the adipogenesis and it is 
mainly in differentiating adipocytes. This study did not include the expression of miR-
34c at a mature adipocyte stage but it would be interesting to see if its expression 
remains higher in the mature adipocytes and also to determine if there is any 
association between its expression levels and other adipogenic markers e.g. PPARϒ 
and CEB/P-α.  
This study also showed the upregulation of another important positive regulator of 
adipogenesis, miR-210, which has been previously reported by other studies as 
having the ability to enhance the adipogenesis in 3T3L1 adipocytes. Blockade of miR-
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210 results in inhibition of adipogenesis, whereas the over expression of miR-210 is 
reported to modulate adipogenesis positively via the PI3/Akt pathway by targeting 
SHIP1 which is a negative regulator of PI3/Akt.  (Liang, Wang et al. 2013).  
The differentiation of preadipocytes into mature adipocytes requires highly complex 
changes in gene expression. Many transcription factors have been identified that 
may modulate the adipocyte maturation process but the molecular mechanisms 
responsible for these changes at different stages of adipogenesis are not completely 
known.  The results from our array study also found let-7 to be upregulated in 
maturing adipocytes; this is in line with previous findings about let-7 in adipocytes. 
The upregulation of let-7 transcription during 3T3L1 adipocyte differentiation has 
already been reported; the study also mentioned that let-7 blockade results in the 
inhibition of maturation of adipocytes at the terminal stage. Furthermore, they noted 
downregulation of HMGA2 expression in differentiating adipocytes (Sun, Fu et al. 
2009). HMGA2 is a target gene for let-7 and it binds on 6 different sites on the HMGA2 
untranslated region to block its translation (Mayr, Hemann et al. 2007).Loss of 
HMGA2 also results in the loss of fat tissue in mice and  (Zhou, Benson et al. 1995). 
Therefore, the relationship between let-7 and its target genes is of great significance 
in adipogenesis.  
Our study also observed that miR-200b is upregulated in differentiating adipocytes 
in line with other studies (Seale, Bjork et al. 2008). MiR-200b is pro-adipogenic 
microRNA but its expression is reduced in   in obese and diabetic individuals along 
with ob/ob and leptin deficient mice (Oger, Gheeraert et al. 2014). These findings 
suggest the need to study the predicted targets of miR200b in more detail and the 
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potential opportunities for therapeutic modulation of its expression which could 
possibly help with the issue of obesity.  
This study also screened any potential miRNAs which are observed only in 
preadipocytes and therefore are those which may be involved in adipogenesis 
programme. Five miRNAs were not detected in differentiating adipocyte samples, 
suggesting that these miRNAs are possibly silenced completely during adipogenesis.  
These include miR-139-3p  which is important in due to its involvement with various 
pathways (Hill, Sheppard et al. 2006, Alemdehy, Haanstra et al. 2015),  miR-466h, 
miR-615-5p, miR-347 and miR159a.  (ref; Table #4.9).  
There were 46 miRNAs as described in Table 4.12 which were detected exclusively in 
differentiating adipocytes. One example is miR-1, which was initially considered 
skeletal muscle specific (Nakajima, Takahashi et al. 2006) although a  later  study has 
reported that it has a role in the development of brown adipose tissue (Lin 2015).  
Another example, miR-32, has been reported as a regulator of SLC45A3 in lipid and 
glucose metabolism of brain cells and myelin (Shin, Howng et al. 2012) however no 
role for this miRNA has been described in adipocytes until now.  
miR-124 has been found to have  a slow and gradual upregulation in adipogenesis 
(Son, Ka et al. 2014) but there has been no study reporting its presence in pre-
adipocytes. In a study focussed on obesity related microRNAs it was reported that 
miR-127 is highly expressed in islet cells in comparison with their expression in 
adipose tissue and liver cells (Zhao, Keller et al. 2009). Another microRNA, miR-129-
3p, was reported to be upregulated in growth arrested NIH/3T3 cells (Bengestrate, 
Virtue et al. 2011) but its expression was very low in mesenchymal stem cells which 
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is in line with  the findings in this studymiR-135b was reported elsewhere (Wang, Xu 
et al. 2015) but there was no study showing its significance in preadipocytes or 
adipocytes. All those microRNAs observed in this study that were expressed only in 
adipocytes would need further investigations in terms of their role in adipogenesis 
individually.  
This was the first study into the effects of antiretroviral drugs on microRNA profile of 
differentiating adipocytes; our study observed miR-145 to be upregulated 19-fold 
after treatment with LPV. miR-145 is known to inhibit adipocyte differentiation (Guo, 
Chen et al. 2012) and given that LPV also inhibits adipogenesis (Vernochet, Azoulay 
et al. 2003), this may  suggest the possibility of LPV inhibiting adipogenesis via 
upregulating various anti- adipogenic microRNAs such as miR-145. Another miRNA, 
miR-182 was upregulated in  LPV treated differentiating adipocytes in this study; this 
miRNA  has been characterised as an oncomiR which promotes inflammation and 
related markers (Ma, Yu et al. 2013). It has also been reported that miR-182 is 
involved in the induction of a proinflammatory cytokine, IL-2 (Stittrich, Haftmann et 
al. 2010) and human adipocytes have been shown to secrete proinflammatory 
cytokines TNF-α, IL6 and IL2 during inflammatory conditions (Meijer, de Vries et al. 
2011). This may suggest potential role for LPV-mediated miRNAs in the regulation of 
inflammatory cytokines resulting in disturbances in adipocyte metabolism.  
The effect of a non-nucleoside reverse transcriptase inhibitor, Efvavirenz (EFV) on the 
microRNA profile of the differentiating adipocytes observed 5 different microRNAs 
to be significantly upregulated by EFV. MiR-106a is reported to be involved in the 
balance between osteogenic and adipogenic differentiation of adipose derived 
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mesenchymal stem cells (Li, Li et al. 2013).  This study observed a 42-fold increase in 
the expression of miR-106a in adipocytes after being treated by EFV although the 
role played by miR-106a is not clear. The significant upregulation of miR-106a by EFV 
could possibly suggest a role for EFV to increase an imbalance in the stem cell 
commitment towards the adipocyte lineage, resulting in lipid hypertrophy in some 
parts of the body. The individual investigation of miR-106a expression in 
differentiating adipocytes and adipose tissue from HIV lipodystrophy patients would 
be required to clearly explain its role.   
All three ARVs studied in this exercise upregulated miR-140 and miR-106b 
significantly. In  this study miR-140 is upregulated multiple-fold by all 3 ARVs; miR-
140 is involved in promoting adipocyte lineage commitment from stem cells towards 
both white and brown adipose tissue by  suppression of Ostem1 gene (Liu, Zhang et 
al. 2013). miR-106b was the other miRNA which was found upregulated mainly by 
the protease inhibitors used in this study. miR-106b is a negative regulator of brown 
adipocyte only and its levels were found to be downregulated in white adipose tissue 
in mice (Wu, Zuo et al. 2013). Brown adipose tissue cells originate from the same 
stem cells as skeletal muscle cells (Sacks and Symonds 2013). 
In the  intervention study,  differentiating adipocytes were co-incubated with ARVs 
and Telmisartan (Tel), which is known to be a partial agonist of PPARϒ (Kang, Yijun et 
al. 2014), to see if Tel had any effect on miRNA profile in differentiating adipocytes . 
TEL caused a change in the expression of various ARV-mediated miRNAs but only 
miRNA-146a was common amongst the two treatments (i.e. 20 µM LPV + 5 µM Tel 
and 20 µM EFV + 5 µM Tel ). MiR-146a is reported to be involved in adipocyte 
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differentiation by targeting C/EBP-β and apoE genes (Tanaka, Yoshida et al. 1997, 
Huang, Gu et al. 2009). Besides miR-146a, 20 µM LPV + 5 µM Tel treatment 
significantly reversed the LPV-mediated upregulation of 4 other miRNAs (miR-125b-
5p, miR-29c, miR, miR-425 and miR-151-3p). Recent studies have revealed in other 
in vitro models that miR-29c is implicated in obesity (McGregor and Choi 2011) and 
miR-125b-5p plays role in adipogenesis while promoting differentiation of 3T3-L1 
from preadipocytes (Ouyang, Ye et al. 2015). We also observed differential 
upregulation of miR-210 and miR-19b as result of 5 µM Tel treatment in combination 
with EFV whereas both these miRNAs have been reported to have a positive 
regulatory role in adipogenesis (McGregor and Choi 2011, Liang, Wang et al. 2013).  
It was observed that miR-103 was upregulated significantly in differentiating 
adipocytes; a recent study by a Swiss group also found that miR-103 and miR-107 
were involved in the regulation of insulin resistance. Here it is important to note that 
miR-103 and miR-107 are closely related as they have only one nucleotide difference 
in their sequence and both have a common target gene, caveolin-1 (Trajkovski, 
Hausser et al. 2011). It was reported that upon silencing miR-103 and miR-107 the 
expression of Cav-1 improves which results in better insulin tolerance in ob/ob 
mouse primary adipocytes in vitro (Trajkovski, Hausser et al. 2011). While considering 
both this study's screening results and the Swiss study,  the change in gene 
expression levels of miR-103, miR-107 and Cav-1 on ARV treatment were investigated 
over a period of 16 days of adipocyte differentiation .  The results of this study 
contradicted the Swiss study in that miRNA-103 and miR-107 were found 
downregulated following treatment with LPV. The results from the current study 
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makes sense from an adipogenesis angle; these miRNAs were shown to be 
upregulated during adipogenesis in previous studies and LPV being an inhibitor of 
adipogenesis is expected to downregulate the expression of miR-103 and miR-107.  
However, it contradicts the Swiss study from an insulin resistance angle; the 
difference between our results and the Swiss group's laboratory results may mainly 
be due to the use of two different cell types. The Swiss group used ob/ob primary 
cells which are leptin deficient and are destined to be obese and develop insulin 
resistance (Liu, Nakagawa et al. 2003) whereas we used a normal mouse adipocyte 
cell line. Moreover we also found Tel, a molecule that has been shown to reverse the 
anti-adipogenic effects of LPV, to result in reversal of LPV’s effects on these miRNAs 
and Cav-1.                                 
This is the first study into the effects of ARVs on the miRNA profile of differentiating 
adipocytes. This study, along with previously published literature may suggest a role 
for miRNAs in the development of adipocyte toxicity and the resultant complications 
such as HIVLD and other metabolic disturbances. However, several of the miRNAs 
identified in this study need independent validation first in appropriate adipocyte 
models and then in HIVLD patients. Some of these miRNAs, given they are validated 
may serve as potential biomarkers of disease and toxicity.  
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5.1 Introduction 
Combination antiretroviral therapy (cART) has multiple adverse effects (Fellay, 
Boubaker et al. 2001) which results in the regimens being switched during the course 
of therapy in almost half of HIV cases (Dieleman, Jambroes et al. 2002, Chen, Westfall 
et al. 2003). Adverse effects associated with ARVs threaten adherence to medication 
and treatment success . In the longer term, metabolic complications of cART result 
in dyslipidemia and impaired glucose tolerance leading to major cardiovascular 
concerns.  There is therefore a need to investigate the mechanisms of metabolic and 
other toxicities of cART treatment (Hammer, Saag et al. 2006).  
The contribution of genetic background of patients to susceptibility to adverse 
reactions is termed pharmacogenetics or toxicogenetics, with variability in response 
to cART between individuals being increasingly linked to it (Owen 2006, Owen, 
Pirmohamed et al. 2006). Toxicogenetics mainly addresses the questions of why 
certain ARVs result in severe toxicities in one patient but milder toxicities in another, 
and why certain toxicities are observed in fewer, but not all, patients despite them 
receiving the same ARV exposure, with similar immunological, virological and 
demographic characteristics (Haas 2005, Haas 2006, Martin, Nolan et al. 2006, 
Barreiro, Fernandez-Montero et al. 2014).  
Recent research in HIVLD has resulted in the identification of some key facts which 
are consistently replicated in many studies; of importance is the proatherogenic 
dyslipidemia and insulin resistance that are often associated with lipodystrophy 
(Caron-Debarle, Lagathu et al. 2010). Mitochondrial damage, along with an increase 
in subcutaneous adipocyte apoptosis, is associated with the use of nucleoside 
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analogue reverse transcriptase inhibitors (NRTIs) such as stavudine (Villarroya, 
Domingo et al. 2005). With the use of newly developed antiretroviral drugs, the 
incidence of lipoatrophy has reduced in the short term but still needs to be studied 
in the long term (Vidal, Domingo et al. 2011).  Protease inhibitors which are still one 
of the most commonly used class of antiretrovirals used in current clinical practice 
interfere with adipocyte differentiation process and cause HIVLD (Caron-Debarle, 
Boccara et al. 2010). Diagnosis of HIVLD is not streamlined across the world due to 
many reasons such as the lack of appropriate guidelines for diagnosis and a lack of  
resources in poor countries. It has been suggested that genetic variants play an 
important role in the development of  lipodystrophy (Vidal, Domingo et al. 2011).  
The rationale for genetic testing prior to ARV treatment is to avoid adverse drug 
reactions by selecting the ‘right drug for the right patient’.  However, a genetic 
association may also provide important insights to potential pathogenesis.  Although 
pharmacogenetic studies are conducted in many areas, it is important to note that in 
many cases, initial reports of genetic association have not been confirmed by later 
studies (Ioannidis, Ntzani et al. 2001, Hattersley and McCarthy 2005). This is due to a 
number of reasons including inadequate sample size, population stratification and 
publication bias ((Pirmohamed 2014). . Ideally in a study, the total number of SNPs 
studied, frequencies of the genotype and important comparisons made should all be 
clearly defined and initial results should be replicated in independent patient cohorts 
(Vidal, Domingo et al. 2011). Gene association studies should also have a large 
sample size to avoid bias (Hattersley and McCarthy 2005) and inclusion of gene dose 
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effects in case of severe phenotypes should be adjusted for multiple comparisons 
and longitudinal data sets (Tarr, Taffe et al. 2005).  
Genetic associations with non-metabolic ART complications and pharmacokinetic 
parameters of ARTs have been extensively reviewed (Rotger, Csajka et al. 2006, 
Naidoo, Chetty et al. 2014). There has been several studies investigating the role of 
various genetic variants in HIVLD; this review attempts to conduct a systematic 
literature search, collate, analyse and present the current evidence on the role of 
genetic variants in the development of HIVLD; it will also discuss the issues that need 
to be addressed in order to bring pharmacogenetics knowledge on HIVLD to clinical 
practice.  
5.2 Methods  
5.2.1 Primary research question 
The primary research question addressed by this systematic review is whether 
genetic variants play a role in the development of HIVLD and if so, which are the 
major contributors.  
5.2.2.Aims: 
The aims of this systematic review were:  
1. To identify and summarise  existing literature on the topic;  
2. To clarify the relative strengths and weaknesses of the existing literature;  
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3. To evaluate the strengths (or weaknesses) of associations of various genetic 
variants with the development of HIVLD; and 
4. To providing evidence (wherever possible) on the role of genetic variants that are 
important in the development of HIVLD.  
5.2.3. Protocol 
A detailed research protocol was developed to address the above aims and to 
formulate the questions and methods of the review before retrieving the literature. 
The section below explains the various components of the protocol: 1) Study 
selection criteria; 2) outcomes; 3) Study design; 4) Inclusion and exclusion criteria; 5) 
search strategy; 6) data collection; and 7) assessment of study quality.  
5.2.4. Study selection criteria 
 This review included all studies which involved the recruitment of HIV patients on 
combination therapy with protease inhibitors, NRTIs and NNRTIs with genetic variant 
data associated with lipodystrophy. HIVLD diagnosis methods were recorded which  
included anthropometric methods and imaging techniques such as Dual-energy X-ray 
absorptiometry (DEXA), MRI and Computed tomography (CT scan). The phenotypes 
studied include lipoatrophy, lipohypertrophy and the mixed phenotype, 
lipodystrophy.   
5.2.5.  Study design 
It was anticipated that the design of the majority of studies included would either be  
retrospective, prospective cohort studies or case-control studies. However 
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randomised controlled trials and other study types were also included in our analysis, 
where available. 
5.2.6. Inclusion criteria  
HIV patients treated with highly active antiretroviral therapy in general and protease 
inhibitors (PIs) in particular are known to be associated with HIVLD. It was 
contemplated that drug studies including regimens of HAART consisting of PIs, NRTIs 
and NNRTIs must be included in the review as all  three classes of drugs  are known 
to be associated with HIVLD.  
5.2.7. Exclusion criteria  
This review was limited to HIVLD associated genetic polymorphisms. Studies 
comprising of sample sizes smaller than 15 were excluded. Case reports were  also 
omitted from this review owing to the high potential for  bias. Studies in which the 
duration of HIV therapy was less than 6 months were also excluded. Studies about 
HIV patients with ages below 16 years have been excluded. Only studies available in 
English language were included. All non-English language studies were were 
excluded from full analysis due to lack of translation facilities. Only those studies 
available in full text format were included. 
5.2.8. Medical Subject Headings (MeSH) Terms and search strategy  
Studies included in the systematic review were searched using Medline, Scopus, Web 
of Science and the HuGENet databases. The initial search was conducted using 
individual MeSH terms and the  search results were merged using boolean operators 
(or, and, not, both, either, do not) in various combinations. MeSH terms used in this 
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systematic review are described in  Table 5.1 along with boolean operators. The 
reference lists from these searches were compiled, titles which appeared relevant 
were screened and relevant studies were reviewed . Conference proceedings 
including British HIV association (BHIVA), European AIDS clinical society (EACS), 
International aids society (IAS) and Conference on Retroviruses and Opportunistic 
Infections (CROI) were searched online.  
In cases where the availability of texts was limited or  only abstracts were available, 
efforts were made to obtain the full text prior to considering whether to include or 
exclude the results in the systematic review. Once potentially relevant papers were 
identified through the search strategies, all reference lists were merged and 
duplicates identified for removal. After initial screening of titles and abstracts the 
combined list was checked against the inclusion and exclusion criteria to determine 
their relevance to this study. This process of inclusion and exclusion was carried out 
by the author independently and was then independently reviewed by a second 
reviewer. Care was taken in reviewing the papers to identify the authors, 
geographical location and time period of the study to minimise the risk of including 
the same data sets more than once in the review.  
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Table No. 5.1. Mesh Terms used in this systematic review 
MeSH terms associated to HIVLD MeSH terms associated to HIV treatment MeSH terms associated to genetic studies 
HIV Lipodystrophy, 
HIV associated Lipodystrophy, 
HIV associated Lipodystrophy syndrome, 
HIVLD, HALS, 
Lipoatrophy, Lipohypertrophy 
Fat redistribution, Hyperlipidaemia 
Hypercholesterolemia, 
Hypertriglyceridemia, 
Insulin Resistance, Hyperglycaemia 
Metabolic syndrome, Diabetes 
Body fat redistribution, Adiposity 
Adipose, Abdominal fat, 
Buffalo hump,Temporal fat wasting, 
Fat wasting 
Highly Active Antiretroviral Therapy 
Antiretroviral Therapy, HAART 
Protease inhibitors, Atazanavir(ATV) 
Darunavir (DRV), Fosamprenavir (FPV)  
Lopinavir(LPV), Nelfinavir (NFV) 
Ritonavir (RTV), Saquinavir (SQV) 
Tipranavir(TPV), Indinavir (IDV) 
NnRTIs, Abacavir (ABC), Didanosine (ddI) 
Emtricitabine (FTC), Lamivudine (3TC) 
Stavudine (d4T), Tenofovir (TDF) 
Zidovudine (AZT/ZDV), NRTIs, 
Delavirdine(DLV), Efavirenz (EFV) 
Etravirine (ETR), Nevirapine (NVP) 
Rilpivirine (RPV), Fusion inhibitors, 
Enfuvirtide (ENF), Enfuvirtide (T20) 
Integrase inhibitors, Maraviroc (MVC) 
Raltegravir(RAL) 
Single Nucleotide Polymorphysims 
SNPs, Gene polymorphisms, 
Genetic Variants, Microarray, 
Genome wide association study, 
GWAS 
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5.2.9. Data collection 
After studies which met the inclusion criteria were identified  data was included in 
the design of the study. Size of the population, treatment regimens, the schedule of 
dosing, the index of HAART regimens, the method used for the diagnosis of HIVLD, 
the quality of genotyping conducted, putative genetic variants explored and evidence 
of an association were all documented.  
5.2.10. Assessment of study quality 
The study quality was assessed using a detailed proforma developed with references 
to both the HuGENet Reviews Handbook (Boyce, Beggs et al. 1991) and a specialist 
review of methodological issues in pharmacogenetic studies (Add Jorgensen AL, 
Williamson PR). This was carried out by the reviewers independently and evaluated 
with consideration of the following issues: 
1) Why the particular genetic variants were chosen for exploration. Was there 
evidence of a rational approach to selection and was this explained and justified? 
2) Was the method described adjusted for multiple testing? 
3) Recording of the samples size was very important and it was also assessed 
whether the sample sizes and power calculations were provided. 
4) In case-control studies evaluation of the clear definitions of both groups was 
noted while consideration was given to whether they were genotyped in mixed 
batches in order to reduce bias. 
5) Study designs had to have outcomes clearly defined.   
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6) The evaluation of the reporting of the genotyping procedure was also very 
important to see whether the primers were clearly described and if there were 
any quality control measures taken, and, if so, then what was the outcome of the 
quality control methods?  
7) The evidence for the blinding of genotyping personnel was also considered to 
determine if the outcome status of the subjects affected the final outcome of the 
study. 
8) If human inference is required by the method of the genotyping are there 
measures in place to ensure this was carried out by more than one person?  
9) Where genotyping results compared to previously reported genotype 
frequencies and was this referenced? 
10) Is any missing data reported, to what extent, and what reasons for the absence 
are provided? Are checks for absent data carried out and are the results 
reported? If so what is done about missing data?; Is it imputed? Does the paper 
state what the effects of the missing data may be in terms of the number of 
patients affected in each analysis?  
11) Is cryptic population stratification considered and adjusted for if present? 
12) How was Hardy Weinberg equilibrium (HWE) tested for and are outcomes 
provided? Is a p-value threshold applied to determine deviation from HWE? How 
are any SNPs that deviate from HWE explored and dealt with in the analysis? 
13) Is the mode of inheritance assumed? If so, is this justified and, if not, are the 
limitations discussed? 
14) The extent of clinical heterogeneity in the studies and accuracy of phenotypes. 
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The pro-forma included a table with questions addressing these issues and was 
completed for each study included in the review. 
5.3 Results and discussion              
This systematic review, has collected and compiled the most recent information 
published about the genetic variants and their possible role as described in various 
journals in terms of their association with lipodystrophy after undergoing cART 
treatment. After identifying the studies, on Medline, Scopus, Web of Science and 
HuGenet, the review has aimed to include all the studies published before July 2015. 
All the studies found have been dually scrutinised by two independent authors and 
then included in this review. All the MeSH terms used to search the related papers 
have already been described in table 5.1.  
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Figure. 1. Schematic diagram of systematic literature review and identification of 
relevant publications  
The details of the studies, together with their findings are presented in table 5.2 and 
5.3. Our initial search identified 10,535 publications that reported original data on 
SNPs associated with HIVLD (figure 1). After screening titles, 10,135 duplicates were 
removed; further 365 articles were excluded after scanning the abstracts. 
Consequently, only 37 studies were left to be included in our final review tables. Out 
of these 29 studies were case control studies and 8 were cohort studies.  
5.3.1 Characteristics of included studies 
8 studies focussed on mtDNA mutations/haplotypes associations with LD (Table 5.2) 
whereas 29 studies focussed on genetic variants other than mtDNA. Of the 37 
included studies included (table 5.2 and 5.3) a total of 8957 patients of which 4059 
10535 titles identified 
Medline ( n = 2691) 
Scopus (n= 3562) 
Web of Science (n = 4231) 
HuGenet (51) 
 
 
10,135 duplicates 
removed 
402 potential eligible papers 
 
37 full text articles selected for review 
review  
 
365 articles excluded  
Not in English (n = 1)  
Other drug article (n = 240)  
No access (n = 1) 
Reviews articles (n = 90) 
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HIVLD +ive and 3554 HIVLD –ive individuals were genotyped for different SNPs in 
various genes. Quality criteria are discussed below.  
5.3.2 Sample size  
The media sample size across all the studies was 216 (interquartile range: 103-329) 
and none of the studies performed a sample size calculation before analysis. 
5.3.3 Hardy-Weinberg equilibrium 
 Only 20/37 studies performed Hardy-Weinberg equilibrium (* see tables 5.2 and 
5.3). 
5.3.4 Genotyping Data 
34/37d studies described the technique used in genotyping of the SNPs. All  the 
studies described rational for the selection of the SNPs. 12/37c studies mentioned 
quality checks for genotyping. Similarly, minority of the studies (12/37b) described 
the primer sequences for genotyping or attached reference for the sequence used. 
None of the studies described any details regarding missing data. Only 5/37a studies 
performed multiple testing for further evaluation of the data. 
5.3.4 Population and outcomes 
Out of 8 studies focussing on mtDNA, only one defined phenotype after fat 
redistribution as lipoatrophy (Ortiz, Poloni et al. 2011) while half of the studies 
employed dual energy X-ray absorptiometry (DEXA) and remaining study groups 
relied upon patient’s self-report plus clinician’s observational skills to define 
lipodystrophy in HIV patients. In case of studies focussing on genetic variants other 
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than mtDNA, both lipoatrophy and lipohypertrophy were used for defining 
lipodystrophy. Whereas in terms of diagnosis of LD, only 9 studies used DEXA and 
one study also used MRI scans but remaining studies were dependent upon clinical 
observations made by clinicians and also upon patient’s self-report. 
5.3.5 mtDNA polymorphisms 
Some researchers have reported the development of mitochondrial dysfunction 
following cART, with this contributing to the development of lipoatrophy in HIV 
patients (Bogardus, Concato et al. 1999, Tarr, Taffe et al. 2005, Margolis, Heverling 
et al. 2014). The replication and repair of mitochondrial DNA (mtDNA) is interrupted 
via inhibition of polymerase gamma (POLG) by NRTIs. Patients treated with NRTIs 
have shown a reduction in mtDNA in the peripheral blood mononuclear cells and this 
phenomenon reverses when the offending drug treatment is stopped (Côté, Brumme 
et al. 2002). A similar reduction in mtDNA has been observed in  patients with 
lipodystrophy (Shikuma, Hu et al. 2001, Nolan, Hammond et al. 2003, McComsey, 
Libutti et al. 2008). There is no consensus upon the sensitivity of the mtDNA content 
of a cell as a marker of its well-being; nevertheless it has been suggested that mtDNA 
content could be used as a measure of the cellular homeostasis of a particular cell 
type (Walker, Bickel et al. 2002, de Mendoza, Sanchez-Conde et al. 2004).  
In a study, conducted by Grace McComsey et al., no evidence of NRTI association with 
mtDNA depletion was found in leukocytes where they compared data extracted from 
10 samples collected from HIV patients with lipoatrophy who received NRTIs against 
4 untreated HIV patient samples and 10 healthy controls (McComsey, Tan et al. 
2002); however these findings were not replicated. In another study, conducted at a 
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later date, mitochondrial DNA mutations were found in association with the 
development of lipoatrophy (Martin, Hammond et al. 2003). However, in a Swiss HIV 
cohort, mtDNA variations were not found to be associated with the development of 
lipoatrophy in HIV infected patients receiving NRTIs (Ortiz, Poloni et al. 2011). A study 
focussing on haplogroups and lipodystrophy investigated 346 HIV patients with and 
without HIVLD for differences in frequencies of 9 most common mtDNA haplogoups. 
However the distribution of these haplogroups were not found different between 
groups (Nasi, Guaraldi et al. 2008).  In another study, after 96 weeks of follow up, 
50% of patients (n=10) having mtDNA haplogroup I, developed lipoatrophy (Hulgan, 
Haubrich et al. 2011).  
 
 
 
 
219 
 
Table 5.2. Studies that have assessed the association between the genes that encode for mitochondrial polymorphisms and lipodystrophy in 
HIV infected patients treated with HAART 
References Ethnicity of 
the 
population 
Type of study Drugs used in 
cART 
Total 
number 
of 
patients 
HIVLD 
+ive 
(cases) 
HIVLD 
 -ive 
(control) 
Gene (s) 
studied 
Diagnosis 
method 
Significant  
p-values 
OR  Final outcome  
(McComsey, Tan et al. 
2002)b,c,d 
White 
Caucasian 
Cross-sectional/ 
case control 
NRTI 
 
24 10 4 mtDNA 
mutations 
Clinical 
observation 
NA NA No evidence of 
association  
(Martin, Hammond et al. 
2003)b,c,d 
White/ 
Caucasian 
Longitudinal / 
Case control 
d4T / 3TC / 
IND / AZT / 
ddl / NVP 
16 5 11 mtDNA 
mutations 
Clinical 
observation 
0.031 NA Association 
between HIVLD and 
mtDNA sequence 
(Nasi, Guaraldi et al. 
2008) 
Caucasian 
(Italian ) 
Cross-sectional ddl, d4T 
 
346 346 0 mtDNA 
haplogroups 
DEXA NA NA No evidence of 
association 
(Hendrickson, Kingsley et 
al. 2009)d 
White 
/Caucasian 
Cross-sectional AZT, d4T 410 410 0 mtDNA 
haplogroups 
Clinical  
observation 
Arms: 0.007 
Legs: 0.037 
Buttocks: 0.1 
 
1.77 
1.54 
1.41 
mtDNA Haplogroup 
H associated with 
LD 
(Hulgan, Tebas et al. 
2008)d 
White Longitudinal / 
Case control 
ddl, ZDV, 3TC, 
EFV, 
96 46 50 mtDNA 
haplogroups
/HFE -187 
C/C 
DEXA 0.02 NA No association with 
mtDNA but with 
HFE-187 C/C 
(Chiappini, Teicher et al. 
2009)d 
White 
(French) 
Cross-sectional/ 
case control 
ddl, d4T 
 
207 69 138 POLϒ Clinical  
observation 
E 1143; 
0.048 
NA Association 
between LD and 
E1143 amino acid 
residue  
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Table 5.2 (continued) 
References Ethnicity of 
the 
population 
Type of study Drugs used in 
cART 
Total 
number 
of 
patients 
HIVLD 
+ive 
(cases) 
HIVLD 
 -ive 
(control) 
Gene (s) 
studied 
Diagnosis 
method 
Significant  
p-values 
OR  Final outcome  
(Ortiz, Poloni et al. 
2011)*,b,c,d 
White Longitudinal / 
Case control 
ZDV, 3TC , 
d4T, DDI, EFV, 
NFV, LPV, 
IND, SQV, RTV 
29 13 16 mtDNA 
mutations/ 
deletions 
DEXA Peri.Fat:0.54 
Total 
fat:0.41 
NA  
NA 
No evidence of 
association 
(Hulgan, Haubrich et al. 
2011)d 
White 
European 
Longitudinal / 
Case control 
EFV, LPV/r, 
d4T, TDF, ZDV 
 
231 39 192 mtDNA 
haplogroups 
DEXA H: 0.8 I: .08, 
J: 0.5, K: 0.9, 
T:0.9,U:0.4,
W:0.2, X:0.8 
NA Greater risk of 
developing LD with 
haplogroup I 
DEXA; Dual-energy x-ray absorptiometry, 3TC, lamivudine; APV, amprenavir; AZT, zidovudine; D4T, stavudine; HIVLD – , highly active 
antiretroviral therapy-treated HIV + patients without lipodystrophy; HIVLD +, highly active antiretroviral therapy-treated HIV + patients with 
lipodystrophy; IDV, indinavir; LPV, lopinavir; NFV, nelfinavir; NRTI, nucleoside, reverse transcriptase inhibitor; PI, protease inhibitor; RTV, 
ritonavir; SQV, saquinavir. *= study tested Hardy-Weinberg equilibrium, a = multiple testingperformed, b = primer sequence /reference 
mentioned, c = studies with quality control checks  d=studies with description of genotyping technique  
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Table 5.3. Studies that have assessed the association between the single nucleotide polymorphisms in various genes and lipodystrophy in HIV infected patients 
treated with HAART 
 
References Ethnicity of 
the 
population 
Type of study  Drugs 
used in 
cART 
Total 
number 
of 
patients 
HIVLD 
+ive 
cases 
HIVLD 
-ive 
control 
 
Gene (s) 
studied 
Diagnosis 
method 
p-values OR Final outcome 
(Asensi, Rego et al. 
2008) *,d  
Caucasians 
(Spanish) 
 
Cross-
sectional 
/case control 
d4T, 
LPV/RTV 
243 90 153 IL-1β, IL-1α , 
IL-6, TNF-α, 
TLR4, NOS2 
and NOS3 
 
Clinical 
observation 
IL-1β; -3954C/T; 0.03 
 
1.68  
(1.03-2.77) 
IL-1β (3954C/T) may 
protect against LD  
(Uttayamakul, Oudot-
Mellakh et al. 2015) 
*,c,d 
 
Thai Cross-
sectional 
/case-control 
/replication of 
GWAS 
d4T 326 142 184 DLGAP1  
Clinical 
observation 
rs12964965; 0.0001 2.46 
(1.56-3.88) 
SNP in DLGAP1 is 
associated with Fat 
loss (lipoatophy) 
(Veloso, Olona et al. 
2011) *,d 
 
Caucasians 
(Spanish) 
Cross-
sectional 
/case control 
ddI, 3TC, 
ABC, TFV, 
EFV, NVP, 
SQV, IDV, 
RTV, NFV, 
APV, LPV, 
ATV 
 
286 
 
133 
 
153 
 
TNF-α 
 
Clinical 
observation 
TNF-α 
-238,   p = 0.86 
-308,   p = 0.04 
-863,   p = 0.11 
NA TNF-α SNP -308 is 
associated with LD   
(Domingo, Cabeza et al. 
2011) *,c,b,d 
Caucasians 
(Spanish) 
Cross-
sectional 
/case control 
d4T +PIs, 
NNRTIs, 
NRTIs 
33 NA NA TS, MTHFR, 
DHFR, RFC1, 
SLC19A1 
 
DEXA 
 
TS (2R/3G, 3C/3G, and 
3G/3G); 
0.0032 
14.0 (2.09-
108.0) 
Association b/w SNP 
in TS gene and LD  
(Marzocchetti, Schwarz 
et al. 2011) *,c,d 
Caucasians 
(Spanish) 
 
Cross-
sectional 
/case control 
AZT, ddl, 
d4T,3TC 
 
 
174 151 23 MDR1, TNF-
a, APM1, 
APOE, 
Adipo, LPL 
 
DEXA 
MDR1 3435; C/T: 0.02 1 Association b/w 
SNPs in MDR1 and 
TNF-a and LD 
TNF-α -308 : 0.04 4  (1.02-4.47) 
(Nazih, Raffi et al. 2012) 
*,c,d 
Caucasians 
(French) 
Cross-
sectional 
/case control 
cART 363 NA NA PPARa, 
PPARγ  
 
Clinical 
observation 
 
n/a 
 
n/a 
No association b/w 
SNPs in PPARa, 
PPARγ 
and LD 
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Table 5.3 (continued) 
References Ethnicity of 
the 
population 
Type of study  Drugs 
used in 
cART 
Total 
number 
of 
patients 
HIVLD 
+ive 
cases 
HIVLD 
-ive 
control 
 
Gene (s) 
studied 
Diagnosis 
method 
p-values OR Final outcome 
(Domingo, Mateo et 
al. 2013) *,c,b,d 
Caucasians 
 
Cross-sectional 
/case control 
d4T  
along with 
PIs,NNRTIs
, NRTIs 
336 187 149 TS, MTHFR, 
HLA-B*4001 
DEXA  TS;     p=0.0001 2.4 (1.5-3.8) SNP in TS is 
associated with LD MTHFR,  
rs1801133, p = 0.0940 
rs1801131, p = 0.1080 
NA 
HLA-B*4001 p= 0.7315 NA 
 
(Suwalak, Srisawasdi 
et al. 2015) *,d 
Thai Cross-sectional 
/case control 
d4T 85 67 15 APOE Clinical 
observation 
rs429358 ; p = 0.804 
rs7412; p = 0.962 
NA No association with 
LD 
 
 
 
 
(Castilhos, Sprinz et 
al. 2015) *,b,d 
Caucasians 
and African 
 
Cross-sectional 
/case control 
HAART 407 217 190 ADIPOR1  
ADIPOR2 
Clinical 
Observation 
No p value available 
with LD but only with 
various LD phenotypic 
parameters 
NA No association with 
LD  
(Trinca, Sprinz et al. 
2010) *,b,d 
Caucasians 
and  
African 
Cross-sectional 
/case control 
??? 410 217 193 LEP, LEPR, 
APM1 
 
Clinical 
observation 
LEP; rs7799039, 
p =0.091 
NA No association with 
LD but  APM1 SNP is 
associated with 
AdipoQ serum levels 
LEPR;  
rs1137101 p = 0.308 
APM1;  
rs17300539 p= 0.979 
rs26672        p=0.652 
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Table 5.3 (Continued) 
References Ethnicity of 
the 
population 
Type of study  Drugs 
used in 
cART 
Total 
number 
of 
patients 
HIVLD 
+ive 
cases 
HIVLD 
-ive 
control 
 
Gene (s) 
studied 
Diagnosis 
method 
p-values OR Final outcome 
(Vilades, Escote et al. 
2014)a 
White/ 
Spanish 
Cross-sectional 
/case control 
AZT based 
HAART 
558 240 318 LBP, CD14, 
MD2, TLR4 
Clinical 
observation 
LBP; 
rs2232582, p= 0.01 
rs2232596 p = 0.51 
rs2232618 p = 0.94 
NA SNP rs2232582 in LBP 
gene is associated with 
HALS/LD 
 
CD14; 
rs2569190 p= 0.64 
MD2 
rs11465996, p=0.85 
TLR4; 
rs4986791      p= 0.43, 
rs11536889   p= 0.52 
rs1927911     p=0.46 
rs4986790     p= 0.73 
(Pushpakom, Owen et 
al. 2013) * a,c,d 
Caucasians 
(English)  
Cross-sectional 
/case control 
3TC, APV, 
AZT, d4T, 
IDV, LPV, 
NFV, SQV 
180 124 56 LXRa,LXRb, 
PPARa, RXRa, 
RXRg, PXR, 
CAR, FXR, 
HNF4a 
Clinical 
Observation 
RXRϒ ;  
rs2134095, p = 0.03 
rs113471, p = 0.01 
rs2194899, p = 0.02 
1.7 (1.0–2.8) 
2.0 (1.1 – 3.6) 
1.7 (1.0 – 2.7) 
SNPs in RXRϒ associated 
with LD 
(Likanonsakul, 
Rattanatham et al. 
2013)a,b,d 
Japanese 
 
Cross-sectional 
/case control 
d4T, 3TC 829 270 559 FAS, APOC3, 
ARβ3 
Clinical 
observation 
FAS, rs1800682  
p= 0.015 
1.41 
 (1.06–1.86) 
SNP in FAS gene is 
associated with 
LA/LD APOC3, rs2854116  
p = 0.474 
1.11  
(0.82–1.47) 
ARβ3, rs4994,  
p = 0.621 
0.93  
(0.69–1.27) 
(Gasparotto, Sprinz 
et al. 2012) * a, ,d 
Caucasians  
( Brazilian) 
Cross-sectional 
/case control 
d4T, ZDV,  614 304 310 ESR1, 
ESR2 
Clinical 
observation 
ESR1, rs2813544,  
p = 0.004  
NA 
 
rs2813544 
associated with LA in 
female patients  ESR2 , rs3020450 AA  
P= 0.007 
1.3 (1.09–1.73) 
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Table 5.3 (Continued) 
References Ethnicity 
of the 
population 
Type of study  Drugs 
used in 
cART 
Total 
number 
of 
patients 
HIVLD 
+ive 
cases 
HIVLD 
-ive 
control 
 
Gene (s) 
studied 
Diagnosis 
method 
p-values OR Final outcome 
(Pushpakom, Owen 
et al. 2011) * a,c,d 
Caucasians 
(English) 
 
Cross-sectional 
/case control 
3TC, APV, 
AZT, d4T, 
IDV, LPV, 
NFV, SQV 
180 124 56 LPIN1,PPARg
C/EBPa , 
C/EBPb, 
LMNA, BSCL2, 
AGPAT2, 
ZMPSTE24 
Clinical 
observation 
LIPIN1, rs11524 p=0.02 
C/EBPa 
rs12691, p=0.03 
ZMPSTE24, 
rs7516571 p =0.05 
2.5 (1.1–6.8) 
2.4 (1.1–6.1) 
1.7 (0.99–3.2) 
SNPs in LPIN1 and 
C/EBPa are 
associated with LD 
(Montes, Valle-Garay 
et al. 2010) *,d 
16 White/ 
Spanish 
Cross-sectional 
/case control 
d4T, AZT 216 82 134 MMP1 DEXA -16071G/2G, p =0.002 2.73 (1.41-5.29)  SNP -16071G/2G in 
MMP1 associated to 
LD 
 (Castelar, Silva et al. 
2010) *,b,d 
White/ 
Mulatto 
/Black 
Cross-sectional 
/case control 
PIs, NRTIs, 
NnRTIs 
167 88 79 IL 18 , INFY Clinical 
observation 
IL18 -137 p = 0.38 
IL18 -607 p = 0.01 
INFY ; p = 0.47 
2.8 (0.7–11.07) 
0.6 (0.30–1.47) 
IL18 -607 SNP 
associated with LD 
(Cordery, Martin et 
al. 2012) ,d 
Caucasians
, African, 
Asian 
Cross-sectional 
 
TDF, FTC, 
ABC-3TC 
305 NA Na HLA DEXA HLA A01 p = 0.006 
HLA B08 p = 0.089 
HLA DQ2 p = 0.012 
4.1 (1.2 - 7) 
3.5 (0.5 - 7.6) 
3.7(0.8- 6.7) 
HLA A01, HLA DQ2 
are associated 
with LD 
(Silva, Simoes et al. 
2010) *,c,b,d 
White, 
black 
Cross-sectional 
/case control 
NNRTI, 
NRTI, PIs  
117 67 50 TNF-α 
 
Clinical 
observation 
-238 ,    p = 0.0328 
- 308 ,   p = 0.0311 
2.2 (1.09-4.43) 
2.6 (1 – 6.2) 
Both the SNPs 
associated with LD 
(Zanone Poma, Riva 
et al. 2008) b,c,d 
Caucasians 
(Italian) 
Cross-sectional 
/case control 
AZT, 3TC,  
d4T, ddI, 
PIs, NNRTIs 
255 193 62 APOC3, 
ARβ2, ARβ3, 
FAS, PPARY, 
Clinical 
observation 
ApoC3 - 455   p = 0.037 
ARβ3 cod64,  p = 0.066 
ARβ2 cod27 p = 0.0006 
FAS -670,        p = 0.053 
PPARY -161    p = 0.681 
0.2 (0.046-0.91) 
0.39 (0.14-1.06) 
0.21 0.08-0.51 
0.51 (0.26-1.01) 
0.83 (0.35-1.98) 
 
SNPs in FAS, 
APOC3, ARβ2 are 
associated with LD 
(Ranade, Geese et al. 
2008) d 
Caucasians 
, Black , 
Hispanic , 
Asians 
Cross-sectional 
/Longitudinal 
EFV, ddl, 
d4T, ZDV, 
3TC, ZDV, 
NFV,  
189 47 147 299 SNPs in 
135 gens 
DEXA RETN, rs3219177 
p = 0.02  
NA RETN, rs3219177 
associated with LD 
in Caucasian 
populations only 
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Table 5.3 (Continued) 
References Ethnicity 
of the 
population 
Type of study  Drugs 
used in 
cART 
Total 
number 
of 
patients 
HIVLD 
+ive 
cases 
HIVLD 
-ive 
control 
 
Gene (s) 
studied 
Diagnosis 
method 
p-values OR Final outcome 
(Saumoy, Lopez-
Dupla et al. 2008) *,d 
African Cross-sectional 
/case control 
IND, NFV, 
LPV/r, SQV 
299 143 156 IL6 Clinical 
observation  
IL6 -174 , p= 0.82 NA No association 
between Il6 -174 
(Bonnet, Bernard et 
al. 2008) d 
Caucasians Cross-sectional 
 
d4T,IND, 
3Tc 
40 NA NA APOC3 DEXA NA NA No association 
with LD 
(Nolan, Moore et al. 
2003) d 
White Cross-sectional 
 
d4T, ZDV, 
NVP 
230 NA NA TNF-α 
TNF-β 
Clinical 
Observation 
TNF-α ; 
-238, p= 0.01 
-308, p= 0.12 
TNF-β; 
-250, p= 0.22 
NA SNP -238 in TNF-a 
associated with 
LD 
(Maher, Alfirevic et 
al. 2002) d 
Caucasians 
 
Cross-sectional 
/case control 
PIs, AZT, 
d4T, 3TC, 
ddl, EFV, 
NVP 
92 61 35 TNF-α 
 
Clinical 
observation 
 
 
-238, p= 0.02 
-308, P= 0.2 
1.6 (0.6–3.5) 
0.7 (0.3–1.6) 
Association b/w 
LD and TNF-a -238 
SNP 
(Wangsomboonsiri, 
Mahasirimongkol et 
al. 2010) b,d 
 
Thai 
Cross-sectional 
/case control 
d4T 
 
103 55 48 HLA-A,HLA-
B, 
HLA-C, HLA-
D 
DEXA 
 
 
HLA-B 4001; p=0.002 
 
14.05 
(2.57-76.59) 
HLA-B 4001 
associated with 
d4T related LD 
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Table 5.3 (Continued) 
 
References Ethnicity 
of the 
population 
Type of study  Drugs 
used in 
cART 
Total 
number 
of 
patients 
HIVLD 
+ive 
cases 
HIVLD 
-ive 
control 
 
Gene (s) 
studied 
Diagnosis 
method 
p-values OR Final outcome 
 
(Irvin, Shrestha et al. 
2011) *, c,d 
 
White 
 
Cross-sectional 
/case control 
/GWAS 
 
d4T, AZT, 
ddl 
 
192 
 
119 
 
73 
SLC26A7, 
KATNALI, 
GPSM2, 
MIAT, 
LGALSI, 
PDXP, 
LGALSI, 
CLCCI 
MRI scan 
 
 
 
 
 
 
rs921231;   p=9.8 x 10-7 
rs73335631;p=2.6 x 10-6 
rs7523050;p=4.8  x 10-6 
rs4417; p= 5.0 x 10-6 
rs4820294;p=5.2  x 10-6 
rs713835; p=6.2  x 10-6 
rs929039; p=7.3 x 10-6 
rs193139;p=9.5 x x 10-6 
 
 
NA 
Multiples SNPs 
(rs921231, 
rs73335631, 
rs7523050, rs4417, 
rs4820294, rs713835 
rs929039, rs193139 
found associated 
with LD 
(Tarr, Taffé et al. 
2005)b,d 
White, 
Black, 
Hispanic, 
Asian, 
Others 
Longitudinal/  
 
RTV, ddl, 
d4T,  
329 NA NA APOC3, 
APOE,  
TNF-α 
Clinical 
observation 
 
TNF-α; -238 p=0.625 
APOE;  
All allels, p= 0.653 
APOC3;  
all alleles p=0.46 
1.2(0.5-3.2) 
 
1.1(0.6-2.1) 
 
1.8(1-3.5) 
No association with 
LD, Alleles in APOC3 
show higher risk of 
developing LD 
(Bonnet, Bernard et 
al. 2008) * 
White Cross-sectional 
 
IDV , d4T, 
3TC 
40 NA NA APOC3, 
APOE, 
TNF-α, 
SREBP1, 
APOA5 
DEXA APOC3; -455, 
P= 0.014 
NA Allele -455C  in 
APOC3 is associated 
with Lipoatrophy  
 
3TC, lamivudine; APV, amprenavir; AZT, zidovudine; D4T, stavudine; HIVLD – , highly active antiretroviral therapy-treated HIV + patients without 
lipodystrophy; HIVLD +, highly active antiretroviral therapy-treated HIV + patients with lipodystrophy; IDV, indinavir; LPV, lopinavir; NFV, 
nelfinavir; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; RTV, ritonavir; SQV, saquinavir. * = study tested Hardy-
Weinberg equilibrium, a = multiple testingperformed, b = primer sequence /reference mentioned, c = studies with quality control checks  
d=studies with description of genotyping technique. 
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AIDS trial group 384 and A5005 study teams assessed any potential association 
between lipoatrophy and mtDNA haplogroup along with the hemochromatosis gene 
(HFE) in a sub set of 96 patients but, surprisingly, they found that the mitochondrial 
haplogroup “J” can protect against HIV lipodystrophy (Hulgan, Tebas et al. 2008).  A 
later study employing samples from the MACS cohort reported that haplogroup H 
was associated with lipoatrophy (p = 0.007) whereas haplogroup T was found to be 
protective against loss of fat in the limbs (p = 0.04) (Hendrickson, Kingsley et al. 2009). 
In another recent study, 231 HIV patients were randomised for different treatments 
of cART for 96 weeks to study the mtDNA related haplogroups and their association 
with HIVLD. To assess the fat status in the body, dual energy X-ray absorptiometry 
(DEXA) was used with fat loss greater than 20% defined as lipoatrophy. Patients with 
haplogroup W (n=5) developed lipohypertrophy while individuals with haplogroup I 
(n=10) developed severe lipoatrophy (Hulgan, Haubrich et al. 2011).  
While using a different strategy, French investigators focussed on genetic variants in 
mtDNA involved in coding for polymerase gamma (POLϒ) polymorphisms in HIVLD 
patients’ blood samples. They studied 3 amino acid residues called R1142, E1143 and 
R1146 along with repeats of CAG in POLϒ gene. Their assessment included samples 
from 69 HIV infected patients with LD in comparison with 138 patients without LD 
and they found E1143 to be significantly associated with lipodystrophy (p = 0.048). 
They also reported an association between E1143 and d4T treatment which 
elaborates the relationship between the importance of this polymorphism and a 
decrease in mtDNA via this particular polymorphism in cART treated patients 
(Chiappini, Teicher et al. 2009). Besides the  positive or negative associations found 
in the above mentioned studies of mtDNA and lipodystrophy, there is lack of 
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consensus on the diagnostic criteria that define HIVLD and also the small sample sizes 
present another issue which needs to be addressed, suggesting the need  for further 
replication of the results described in table 5.2. 
5.3.6 Polymorphisms in cytokine genes  
Several cytokines have been reported to be dysregulated in HIV associated 
lipodystrophy such as TNF-α. Many pathogenic and metabolic events associated with 
HIV infection are considered to be involved with TNF-α (Johnson, Albu et al. 2004). 
The alteration in the homeostasis of TNF-α by antiretrovirals has been observed in 
many studies (Ledru, Christeff et al. 2000, Domingo, Vidal et al. 2005, Cawthorn and 
Sethi 2008). Various studies have reported associations of gene polymorphisms in 
the promoter region of TNF-α with lipodystrophy. A study conducted in the UK using 
a cohort of 61 HIV patients with lipodystrophy, 35 without and 239 healthy controls 
found association between TNF-α  - 238G> polymorphism and HIVLD (Maher, 
Alfirevic et al. 2002). However subsequent studies focussing on the same 
polymorphism could not  find any association with HIVLD (Tarr, Taffe et al. 2005, 
Asensi, Rego et al. 2008). A later study, conducted in an Australian cohort, did  find 
association between the gene variant 238A of TNF-α gene and the early onset of 
lipodystrophy (Nolan, Moore et al. 2003). In 2011, a Spanish study reported no 
association between TNF-α polymorphisms and lipodystrophy in HIV patients 
receiving cART (Veloso, Olona et al. 2011). At present, the role of polymorphisms in 
TNF-α gene in the onset of lipodystrophy is controversial 
Since the discovery of cytokines secreted by adipocytes (adipokines), it has been 
established that adipocytes can exert an effect on their surrounding environment via 
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these adipokines (Lago, Gomez et al. 2009). The most studied adipokines such as 
leptin, adiponectin and resistin, along with many others have a key role in lipid 
metabolism, development of obesity and insulin resistance (Nishida, Funahashi et al. 
2007, Sweeney, Brennan et al. 2007, Kelesidis, Kelesidis et al. 2010). Given that 
adipokine-encoding genes are polymorphic, various studies have looked into the 
relationship between polymorphisms in these genes and development of 
lipodystrophy along with the mechanism of pathogenesis of HIV associated 
lipodystrophy. Therefore, the importance of pro-inflammatory cytokines cannot be 
neglected because many of them are secreted by adipocytes, and many studies have 
focused on the polymorphism in the genes that encode for these cytokines (Ledru, 
Christeff et al. 2000, Kannisto, Sutinen et al. 2003, Lindegaard, Hansen et al. 2004, 
He, Andersen et al. 2005).  
An allelic variant +3954 C/T in the cytokine IL-1β, has been found to be associated 
with HIVLD in study involving 232 Caucasian HIV patients who were on cART for at 
least 3 years  (Asensi, Rego et al. 2008). Genetic variants in the IL6 gene were also 
the focus of a study conducted in a Spanish cohort of HIV patients but no genetic 
association was found with lipodystrophy (Asensi, Rego et al. 2008, Saumoy, Lopez-
Dupla et al. 2008). Meanwhile a Brazilian study found SNPs in the IL18 gene, a novel 
adipokine with potential role in the pathogenesis of HIVLD to be associated with 
HIVLD (Castelar, Silva et al. 2010). These SNPs were also investigated in a UK based 
cohort of HIV patients as part of this PhD project (as described in chapter 2); however 
this was not replicated.  Genetic variants in IFNϒ were also tested in a population of 
88 patients with HIVLD and  were compared to 79 HIV patients without LD and 133 
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healthy controls but no significant association was discovered (Castelar, Silva et al. 
2010). Resistin is a pleiotropic adipokine with a dual role, acting both as immune and 
inflammatory mediator;  its role in obesity has been suggested (Steppan, Bailey et al. 
2001). Studies have assessed potential relationships between genetic variants in the 
RETN gene and LD in HIV-infected patients. In one study, 299 SNPs in 135 candidate 
genes including RETN were evaluated and analysis revealed that polymorphism 
within the RETN gene was significantly associated with higher levels of lipids and 
insulin resistance (p = 0.0003); these patients also experienced lipoatrophy in their 
limbs (Ranade, Geese et al. 2008). Similarly another study conducted in Spain 
suggested that genetic variants in RETN may modulate the appearance of 
lipodystrophy in HIV-infected patients receiving cART (Escote, Miranda et al. 2011); 
however the association was with another RETN SNP rather than a replication of 
Ranade et al’s result.  Data published about genetic variants in the leptin gene in 
relation to HIVLD are scarce with only one report published to date. In a Brazilian 
cohort of HIV patients receiving cART, the association between polymorphism in the 
LEP and leptin receptor genes were assessed but no significance was observed 
(Trinca, Sprinz et al. 2010). In the same study, polymorphisms in adiponectin gene  
(APM1; gene; -11391G > A and -11377C > G) were investigated and were found to be 
associated with adiponectin levels rather than lipodystrophy in HIV-infected patients 
receiving cART (Trinca, Sprinz et al. 2010) as mentioned in Table 5.3.  
5.3.7 Genes important in adipocyte differentiation  
It has been suggested that some transcription factors such as PPARγ which play a role 
in adipogenesis, obesity and metabolic syndrome (Ahmed, Ziouzenkova et al. 2007) 
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could be important in the development of HIVLD. In a Spanish study performed using 
samples collected from Caucasian HIV patients on cART, PPARγ Pro12Ala 
polymorphism was not found to be associated with HIVLD (Saumoy, Veloso et al. 
2009). The negative association was further replicated in various other studies 
confirming the lack of association between PPARγ polymorphisms and LD (Zanone 
Poma, Riva et al. 2008). An Italian cohort study and a UK study observed no significant 
association between LD and SNPs in the PPARγ gene (Zanone Poma, Riva et al. 2008, 
Pushpakom, Owen et al. 2011, Pushpakom, Owen et al. 2013). In the ANRS CO8 
Aproco-copilote study in France, 363 HIV-1 positive patients receiving cART were 
recruited and tested for polymorphisms in PPARϒ and PPARα genes; no association 
was reported with LD but Pro12Ala was found to be associated with diabetes (Nazih, 
Raffi et al. 2012), ref table 5.3.  
A mutation in laminin gene (LMNA) is responsible for the inherited partial LD called 
Dunnigan type partial lipodystrophy (Shackleton, Lloyd et al. 2000). In 2002 it was 
reported that interaction between LMNA and SREBP-1 is crucial for adipocyte 
differentiation (Lloyd, Trembath et al. 2002). It has also been reported that 
antiretrovirals can modulate the expression of LMNA in HIV patients and it may have 
a role in the development of LD (Caron, Auclair et al. 2003). Animal models have 
indicated that protease inhibitors such as IND and NFV may be associated with 
genetic variants in LMNA maturation and SREBP-1 localization into the nucleus, 
leading to interference with adipocyte differentiation (Behrens, Lloyd et al. 2000). In 
a recent study conducted in a cohort of UK HIV patients (124 patients with 
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lipodystrophy; 56 without lipodystrophy), polymorphisms in the LMNA gene were 
assessed but no association was demostrated (Pushpakom, Owen et al. 2011).  
A zinc-dependent endoprotease called MMP has a role in the modulation of 
adipokines such as TNF-α which are upregulated in the context of the HIV/cART-
related lipodystrophy syndrome. Also, it can degrade extracellular matrix proteins. 
MMPs are also involved in extracellular matrix remodelling and may modulate 
adipocyte differentiation (Chavey, Mari et al. 2003).   As the polymorphisms in MMP 
genes are of functional significance, a Spanish study tested whether polymorphism 
within the MMP1 gene might be responsible for HIV/cART-related lipodystrophy 
syndrome (Montes, Valle-Garay et al. 2010).  216 HIV-infected patients receiving 
cART with lipodystrophy (n = 82), and without lipodystrophy (n = 134), were assessed 
for body fat while using clinical scales and DEXA. The 2G/2G MMP1 SNP genotype 
was reported to be associated with lipodystrophy [OR (95%CI): 2.73 (1.41 – 5.29); p 
= 0.002]. It was also observed that carriers of this genotype had higher serum levels 
of MMP1. The MMP1 2G carriage was also associated with cART containing stavudine 
(p < 0.0001) and zidovudine (p = 0.006) (Montes, Valle-Garay et al. 2010). 
Another important regulator of adipocyte differentiation is Apolipoprotein C3 
(APOC3), which also has a role in lipid metabolism in adipocytes as it is a very strong 
inhibitor of lipoprotein lipase (LPL). Absence of APOC3 can result in diet induced 
obesity and higher uptake of plasma triglycerides in adipose tissue followed by 
severe insulin resistance (Duivenvoorden, Teusink et al. 2005). In a Swiss cohort of 
HIV patients, consisting of 329 individuals receiving cART, polymorphisms in APOC3 
were assessed. The carrier of all the alleles showed no significant association with 
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the development of LD but there was ahigher risk of developing LD (Tarr, Taffe et al. 
2005). Soon after, a French study (n=40) also investigated the association between 
APOC3 and LD assessed using DEXA. They provided further evidence showing an 
association between polymorphism in APOC3 (-455C) and lipodystrophy and related 
this to d4T and PI based cART (Tarr, Taffe et al. 2005) see Table 5.3 for details.   
In obesity and lipodystrophy, the dysregulation of lipid metabolism in adipose tissue, 
skeletal muscle and liver results in insulin resistance and diabetes and Lipin 1 
influences lipid homeostasis (Reue 2007). Various studies in mouse models and in 
humans have shown that lipin 1 levels and triglyceride storage in adipose tissue are 
directly related to insulin sensitivity and also  lipin 1 deficiency in the mouse results 
in the development of lipodystrophy and insulin resistance (Reue 2007). C/EBPalpha 
is a critical transcription factor in adipogenesis; but its precise mechanism of action 
is not yet fully understood.  It has been shown that C/EBPα and PPARϒ both have a 
feedback regulatory mechanism between them and C/EBPα can only promote 
adipogenesis in the presence of PPARϒ (Rosen, Hsu et al. 2002). A study conducted 
in HIV infected patients (124 with LD and 56 without LD) tested 62 SNPs in eight genes 
related to adipogenesis including SNPs in LPIN1 and C/EBPalpha. The study reported 
a SNP C>T located in the 3’UTR region in LPIN1 gene and SNP T>C, also in 3’UTR region 
of C/EBPalpha were associated with HIVLD (Pushpakom, Owen et al. 2011).  
5.3.8 Studies focusing on SNPs in other genes  
Various studies have reported that lipoatrophy is associated with cART based on 
NRTIs such as d4T. d4T acts through its metabolite (called stavudine triphosphate) 
which interacts directly with thymidylate synthase (TS) and methylene 
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tetrahydrofolate reductase (MTHFR). In a study involving 33 HIV patients, a SNP in 
the TS gene was found associated with HIVLD (Domingo, Cabeza et al. 2011) which 
was replicated in a larger cohort of patients thereby further confirminga role for SNPs 
in TS in d4T induced lipodystrophy in HIV patients (Domingo, Mateo et al. 2013). The 
larger cohort study also observed the association between HIVLD and the TS 
genotype to be influenced by the MTHFR genotype (Domingo, Mateo 2013). Both 
these studies were conducted in a Spanish population of HIV patients and it would 
be interesting to test and replicate the results in other cohorts of different ethnicity.  
Another study was designed on the basis of the close proximity of the major 
histocompatibility complex (MHC) and TNF-a considering that there might be a 
possibility of a role for polymorphisms in the MHC in the development of HIVLD. 
Therefore, a study was performed in 103 HIV patients, 55 of whom developed 
lipodystrophy and 48 of whom did not show any sign of LD. Polymorphisms for 
genotyping were selected amongst HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DBQ1 and 
HLA-DPB1 . All  103 patients received d4T based cART and it was established that 
HLA-B*4001 polymorphism is associated with d4T related lipodystrophy in these 
patients (Wangsomboonsiri, Mahasirimongkol et al. 2010) 
Treatment using NRTIs are associated with both peripheral neuropathy and 
lipodystrophy;  mitochondrial dysfunction resulting from ddl and d4T treatment has 
been suggested to play a role in both these conditions. Mitochondrial dysfunction 
affects iron metabolism and this provides the rationale for studying the potential 
involvement of the hemochromatosis (HFE) gene in ARV related LD. To assess this 
potential role of SNPs in the HFE gene, a study was designed to investigate the 
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genotype of 384 HIV patients receiving d4T and ddl. Diagnosis of LD in these patients 
was done using DEXA. Two polymorphisms, 845 G>A and 187 C>G in the HFE gene 
were assessed; only the 187 C> G was found to be associated with LD (Hulgan, Tebas 
et al. 2008).  
5.3.9 Concluding remarks 
This systematic review has aimed to comprehensively describe the most recent and 
convincing studies on the pharmacogenetics of the lipodystrophy syndrome to 
provide an evidence base for future strategies in this area . The genes were 
characterised in two general groups, i.e. one group for mitochondrial DNA genes and 
the rest into another group.. The results of mtDNA were not found to be consistent 
in terms of positive associations. This could be due to several reasons such as 
difference in the ethnicity of populations studied, difference in cART treatment, 
difference in the selection of methods of diagnosis of LD and the possibility of any 
analytical errors that may have occurred. Similarly TNF-α studies have shown some 
inconsistency and some gene polymorphisms have not yet been replicated in any 
other cohort. There are several reasons for the lack of replication of association 
observed with some of the major candidate genes described here. 
Sample size used in many of these studies were small; and therefore raises a question 
about their ability to ascertain the contribution of genetic variants which confer a 
modest or smaller effect towards the development of HIVLD (modest effect sizes). 
These associations can only be validated once  samples in larger numbers are 
obtained. The difference in treatment between various groups of HIV patients is a 
possible major source of variability amongst the studies. Clinical heterogeneity 
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between studies and how the HIVLD phenotype is defined is another major limitation 
and this is further compounded by the lack of unified guidelines on diagnostic criteria 
for HIVLD. Methods for measuring body fat for assignment of appropriate phenotype 
were not consistent across the studies.  While some study groups used modern and 
more accurate methods such as DEXA or CT, the majority relied on patients’ self-
reports and clinicians' decisions based on observation.  
Addressing these confounding factors to establish a uniform assessment presents a 
significant problem. If possible, studies should be conducted in a longitudinal manner 
but there is a limitation for every study as the life span of HIV patients undergoing 
cART is not expansive  although it has improved recently.  Multi-gene studies are 
becoming increasingly common but still pharmacogenetics related to HIVLD is 
confined to the laboratory. Hopefully with the advancement of technology, it will 
soon be in the clinic where  HIV patients need it.  
Finally, another issue of importance is that different studies have used different 
diagnostic criteria, which makes it difficult to evaluate whether any associations are 
truly important (as the association may only be with a sub-phenotype).  For all the 
reasons outlined above, it was therefore felt that a systematic review was feasible, 
but that a meta-analysis of the different gene variants would provide an inaccurate 
picture of any association.  The only way to overcome this would be to obtain 
individual patient data from all the studies published and undertake an individual 
patient data meta-analysis.  This is obviously a major undertaking which would need 
an assessment of the phenotypes first of all, followed by a meta-analysis of the 
genotypes.  It also relies on all authors providing individual patient data, which of 
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course, cannot be guaranteed.  An alternative approach for future studies would be 
to combine both genetic and functional analyses, and when both are positive, it may 
provide some confidence in the results. 
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6.1 An Overview of the entire thesis 
The initial reports relating to adverse effects of HIV treatment started emerging in 
the 1990s when lipodystrophy was first noticed in HIV patients receiving a 
combination of antiretroviral drugs (Guaraldi, Stentarelli et al. 2013). Clinicians 
started reporting concerns about fat redistribution, considering it to be a direct result 
of antiretroviral drugs.  They also noticed the emergence of related complications 
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such as insulin resistance leading to diabetes (Engelson, Kotler et al. 1999). It was at 
about this time that clinicians began considering new ideas and devising new 
strategies to measure the fat distribution across the body of HIV patients under ARV 
treatment using dual-energy X-ray absorptiometry (DEXA) (Carr, Samaras et al. 1998).  
A number of studies showed variability in the prevalence of LD amongst the HIV 
patients receiving combination antiretroviral therapy, ranging from 11% to 83% 
(Lana, Junqueira et al. 2014). These can be accompanied by various complications 
and metabolic abnormalities associated such as type 2 diabetes and cardiovascular 
disease (Wierzbicki, Purdon et al. 2008). Although related to the drug combinations 
used, individual susceptibility is evident from the clinical features, which has been 
related to genetic variants (Tarr and Telenti 2007, Vidal, Domingo et al. 2011). 
The main aim of this thesis was to understand the molecular mechanisms involved in 
ARV-mediated adipocyte toxicity by focusing on the role of PIs and NNRTIs in vitro 
along with the role of any potential genetic variants in the development of HIVLD. 
Chapter 2 focused on the effects of lopinavir, atazanavir, efavirenz and ritonavir on 
expression levels of a proinflammatory cytokine, IL18, in adipocytes. Investigation of 
single nucleotide polymorphisms in the IL18 gene, in relation to their association with 
lipodystrophy in patient samples, both from HIVLD positive and negative individuals, 
along with healthy controls, was also part of the initial study. As a pleiotropic and 
multifunctional proinflammatory cytokine, IL18 is normally produced in response to 
a viral infection (Iannello, Samarani et al. 2010). Higher levels of IL18 in the adipose 
tissue obtained from HIV patients with lipoatrophy in the Danish cohort of study, has 
been reported (Lindegaard, Hansen et al. 2004). In this report, it has been shown that 
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all the antiretroviral drugs used in the study significantly upregulated the IL18 levels, 
both at gene and protein level, which suggests that ARVs play a role in the 
upregulation of IL18 in adipocytes. However the exact mechanism involved in the 
upregulation is still unclear. Previously published literature suggests that caspase-1, 
which acts as an activator of IL18 from its inactive form (Sansonetti, Phalipon et al. 
2000), is upregulated in HIV patients (Song, Jiao et al. 2015), suggesting that caspase 
1 may be responsible for the over activation of IL18 resulting in an immune response 
triggered by IL18 (Iannello, Samarani et al. 2009).   
None of the SNPs studied in the IL18 gene revealed any association with HIVLD in the 
cohort of patients used in this study.  By contrast, a SNP in the IL18 gene, rs1946518, 
was found to be significantly associated with HIVLD in a Brazilian population 
(Castelar, Silva et al. 2010).  The difference in the  genetic results between this study 
and the findings of the Brazilian group may be due  mainly to the different 
populations under study in both cases in terms of differences in their phenotypes 
and genetic structure.  Thus, the work presented in this study, taken together with 
the literature relating to IL18, suggests the need for further studies to explore the 
role of IL-18 in ARV induced toxicity over a longer period of time both in vivo and in 
vitro.  This may potentially prove this cytokine is a useful target for therapeutic 
intervention in patients suffering from lipodystrophy and metabolic syndrome, but 
of course, the use of any IL-18 therapy would have to carefully balance the benefits 
and risks.  
It has been reported that IL18 can suppress adiponectin expression in adipocytes via 
ERK1/2-dependent NFATc4 phosphorylation, which suggests a role for NFATc4 in the 
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modulation of adiponectin (Chandrasekar, Patel et al. 2008). Initially, this study 
investigated the effect of all four ARV treatments on NFATc4 which showed 
significant upregulation in NFATc4 expression, both at gene and protein levels.  It was 
also noticed that co-incubation of Tel, along with ARVs, significantly reversed the 
ARV-mediated upregulation of NFATc4 expression both at gene and protein levels. 
Considering the results here, and the published literature by Chandrasekar et al. 
2008, the effect of ARVs and IL18 via NFATc4 in downregulation of adiponectin in this 
in vitro model (Schematic view in figure 3.2) was assessed.  This study also aimed to 
investigate the expression levels of another important proinflammatory marker, IL6, 
which is transcribed by NFATc4 (Nilsson, Sun et al. 2007) and the expression of the 
master adipogenic gene, PPARϒ, which is also regulated by NFATc4 (Yang, Xiong et al. 
2002), both before and after NFATc4 knockdown using siRNAs, in adipocytes 
receiving ARV treatment. The data in chapter 3 of this thesis suggests that NFATc4 
knockdown can block the effect of ARVs and IL18 on adiponectin while resulting in 
significant improvement in adiponectin expression levels in adipocytes.  
In a clinical study, IL6 was found to be upregulated in HIV lipodystrophy patients who 
received cART (Lihn, Richelsen et al. 2003) and an in vitro study reported that higher 
IL6 levels were observed in 3T3-F442A adipocytes after being treated with ARVs. 
However, rosiglitazone reduced the levels of IL6 in the presence of ARVs (Tungsiripat, 
El-Bejjani et al. 2012).  It was also observed that after blockade of NFATc4, the 
expression levels of IL6 were significantly reduced in adipocytes even after ARV 
treatment.  
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PPARϒ is a master adipogenic gene and has a central role in adipocyte maturation (Ali, 
Hochfeld et al. 2013), but it is also regulated by NFATc4 (Yang, Xiong et al. 2002).  
Although ARVs cause significant reduction in the expression of PPARϒ in human 
adipocytes, showing its involvement in the pathogenesis of HIV lipodystrophy, the 
mechanism involved is, as yet, unclear (Gallego-Escuredo, Del Mar Gutierrez et al. 
2010). The results of this investigation show significant improvement in the protein 
levels of PPARϒ after NFATc4 Knockdown in adipocytes receiving ARVs (see figures 
3.11, 3.12 and 3.13).  
Besides the knockdown study results,  the effects of Tel , on its own, on adiponectin, 
IL6 and PPARgamma expression levels were investigated.  Tel partially reversed these 
effects suggesting that it may also be useful as an alternative pharmacological 
strategy in these cells to improve adiponectin and PPARϒ expression in the presence 
of ARVs simultaneously. Tel also reduced the levels of IL6 in the presence of ARVs in 
adipocytes.  The data in this thesis is also consistent with the notion that NFATc4 is 
the key player between IL-18 and adiponectin and also that the inverse relationship 
between IL-18 and adiponectin is maintained through NFATc4 (Chandrasekar, Patel 
et al. 2008). The findings of this study show that NFATc4 can be used potentially as a 
therapeutic target to reverse the deleterious effects of ARVs such as its effect on 
proinflammatroy markers such as IL6, and may improve the expression of 
proadipogenic markers i.e. adiponectin and PPARgamma. 
MicroRNAs are a newly discovered class of regulatory molecules that also play a role 
in adipocyte maturation (Zhang, Wang et al. 2013). It has been reported that cellular 
microRNAs influence HIV infectivity by directly targeting the viral genome or by 
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targeting host cellular proteins required for viral replication.  Hence HIV-1 infection 
and replication may be directly affected by miRNAs inside the cell (Swaminathan, 
Navas-Martín et al. 2014). There is very little published about the effect of 
antiretroviral drugs on the microRNA profile of adipocytes.  It was therefore decided, 
in this investigation, to perform a screening study to uncover the effects of ARVs on 
the microRNA profile in in the adipocyte in vitro model (3T3-F442A). The study used 
medium throughput RT-PCR arrays to conduct, a screening to investigate changes in 
expression levels of various microRNAs in preadipocytes and adipocytes, with or 
without ARVs.  . Another aim of the study was to observe the effects of Tel on the 
microRNA expression profile in the presence of ARVs.   
In an earlier microarray study, miR-34a was shown to be upregulated in mature 
adipocytes in obese and T2DM women (Ortega, Moreno-Navarrete et al. 2010), 
whereas, in this study, miR-34a was upregulated in differentiating adipocytes further 
suggesting its role in adipocyte maturation. miR-26b is another important miRNA;  
higher levels of miR-26bhave been shown to be related to adipokine secretion in both 
mature mice and human adipocytes (Xu, Shi et al. 2014) whereas  miR-26b inhibition 
results in  stopping of  adipogenesis (Song, Xu et al. 2014)therebymaking it a potential 
therapeutic target (Xu, Ji et al. 2015).  The results from the current study also show a 
significant (5 fold) upregulation of miR-26b in differentiating adipocytes when 
compared with its expression in preadipocytes.  
Blockade of miR-210 results in inhibition of adipogenesis and it has been previously 
reported as a positive regulator of adipogenesis in 3T3L1 adipocytes. It was similarly 
found to be upregulated almost 6-fold in the in vitro model used in this study . 
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Similarly, the importance of let-7 was mentioned in a study where  it was reported 
that its blockade can result in the inhibition of maturation of adipocytes (Sun, Fu et 
al. 2009). This was confirmed in this study. It is however important to note that this 
study investigated changes in  microRNA expression during the process of 
differentiation rather than in a  mature adipocyte.                             
Expression of miR-200b has been reported to be low in both obese and diabetic 
human and mouse models (Oger, Gheeraert et al. 2014); this  study observed that 
miR-200b is upregulated in differentiating adipocytes (Seale, Bjork et al. 2008). These 
findings suggest the potential therapeutic importance of miR-200b but it needs 
further investigation. There were also much microRNA detected only in 
prepadipocytes and a large number of microRNAs were only expressed in adipocytes 
which relates to their differing functions, which would need further investigation.  
The effects of antiretroviral drugs on the microRNA profile of differentiating 
adipocytes was also investigated.  It was found that miR-145 was upregulated 19-fold 
after treatment with LPV.  Similarly miR-182 was also upregulated in samples treated 
with LPV. These finding relates to earlier published work where it was shown that 
miR-145 inhibits adipocyte differentiation (Guo, Chen et al. 2012) and miR-182 was 
found to be involved in the induction of a proinflammatory cytokine, IL-2 (Stittrich, 
Haftmann et al. 2010). On the basis of these findings, microRNAs 143 and 182 can be 
classed as microRNAs with a role in inflammation and  protease inhibitors such as 
Lopinavir may be involved in dysregulation of inflammatory markers by upregulating 
miRNAs in adipocytes resulting in metabolic disturbances. 
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There were only two microRNAs which were significantly modulated in all three drug 
treatments i.e. miR-106b and miR-140. Interestingly, both miRs have completely 
opposite properties, as mentioned in previously published literature, where miR-
106b has been referred to as a negative regulator of adipogenesis via suppressing 
Ucp1 in differentiating brown adipocytes (Wu, Zuo et al. 2013),  miR-140 acts as a 
promoter of adipogenesis by guiding stem cells to commit towards white or brown 
adipose tissue (Liu, Zhang et al. 2013).  The fact that miR-140 was differentially 
regulated with all 3 ARVs may suggest a tilt towards  the commitment of the stem 
cells towards white adipose tissue rather than toward brown adipose tissue, resulting 
in deregulated expansion of white adipose tissue mass.  It is however important to 
note that these microRNAs have only been upregulated in drug treated 
differentiating adipocytes.  It is quite possible that the imbalance seen with these 
microRNAs, resulting from ARV treatment may play a role in over production of white 
adipose tissue in specific anatomical regions (e.g. abdomen or areas surrounding 
visceral organs) in HIV infected individuals receiving HAART.  To confirm this 
hypothesis, it would be necessary to investigate the profile of microRNAs in the 
adipose tissues of HIV  patients’ fat samples from different parts of the body including 
the limbs and abdominal area.               
A Swiss group, reported that miR-103 and miR-107 were involved in the regulation 
of insulin resistance and silencing miR-103 and miR-107 results in better insulin 
tolerance in ob/ob mouse primary adipocytes in vitro (Trajkovski, Hausser et al. 
2011). We observed that miR-103 was up regulated significantly in differentiating 
adipocytes. Because miR-103 and miR-107 were closely related, we studied them 
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together along with their common target gene Cav-1. Our results showed that there 
was no relationship between ARVs treatment and miR-103/107 induced insulin 
resistance as miR-103 and miR-107 both were down regulated significantly at all time 
points over the span of 16 days contradicting the  Swiss study. Also Cav-1 protein 
expression was down regulated by the ARV treatment at all time points. We agree 
that ARV (LPV) is known to cause insulin resistance in adipocytes (Hruz 2008); hence 
the downregulation of two miRNAs which are supposed to mediate insulin resistance 
was an unexpected result. But at the same time these results makes sense from an 
adipogenesis angle; these 2 miRNAs are upregulated during adipogenesis and LPV 
caused a downregulation of these. One possible explanation could be the difference 
of cell type between our study and Swiss study as we used normal adipocyte cell line 
but they used leptin deficient (ob/ob) primary mouse adipocytes which are known to 
become insulin resistant when mature. Also, insulin resistance is not developed in 
the HIV patients receiving HAART in 16 days of the treatment which was the 
maximum length of our in vitro experiment; therefore the time span could be 
another reason. We suggests the replication of the Swiss study because no other 
group has reported the replication of their results in any other in vitro or in vivo 
model yet.  
                In the systematic review on the pharmacogenetics of HIVLD, efforts have 
been made to collect data from all those studies which passed the inclusion criteria 
set for this study. The execution of searches was performed by two authors 
independently and then matched toensure that all data was credible and no 
important study had been missed from the search results before the extraction of 
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data.   Although similar genes were studied by different authors, there is a problem 
with replication, mostly because the patient groups differed.  It is important to note 
that most of the mtDNA studies have NNRTIs based treatment regimens.  Some 
studies have suggested mTDNA content as a marker of cellular wellbeing but there is 
no consensus amongst the scientists concerned  (Walker, Bickel et al. 2002, de 
Mendoza, Sanchez-Conde et al. 2004). The difference between the treatments given 
to HIV patients across the studies is also an important reason behind the variability 
in the results. Also the methods used to measure body fat were not universal as a 
few studies used DEXA but others relied upon the observations of clinicians. It is 
almost impossible to remove all the above confounding factors from the 
pharmacogenetic studies. Studies focussing on HIVLD and associated SNPs should be 
conducted in a longitudinal fashion where possible. An additional approach might be 
to conduct an individual patient data meta-analysis. 
 
 
6.2 Future work  
There has been a substantial advance in the understanding of HIVLD in the last two 
decades but still the basic mechanisms resulting in HIVLD  remain unclear.  It is 
suggested that more complex and robust in vitro studies, such as co-culture of 
adipocytes with macrophages, may uncover the mechanisms involved in the 
inflammatory meshwork of HIVLD. There is very little known about the effect of ARVs 
upon the microRNA profile of mature adipocytes over long term treatment and this 
needs to be investigated using microarray and other technologies such as RNA 
sequencing. This would provide large sets of data to help draw more comprehensive 
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conclusions in terms of finding possible drug targets and better treatment options. 
Few animal studies have been done to understand HIV associated lipodystrophy.  
Knockout models of adipogenic genes, such as PPARgamma and CEBP-α, may be 
helpful to understand the actual mechanism involved in metabolic dysregulation in 
LD in the presence and absence of ARVs, but of course, the ultimate model to study 
HIV LD is a patient who has been infected with HIV to capture the complex 
interactions occurring between the virus, the resulting inflammation and the multiple 
drugs being used in the patients.  
However, it is also important to note that all the LD studies performed in clinical 
settings have lot of variable factors such as treatments used and methods used to 
measure the fat content of the body. It has of course been difficult to keep the 
standards of the studies the same across the world because of the lack of a uniform 
approach in diagnosing and characterising LD, and how it progresses. Further, more 
genetic studies would be required with larger sample numbers perhaps using whole 
genome approaches.  But it is important to note that HIVLD per se is becoming less 
common since the introduction of newer more lipid-friendly ARVs, and thus this may 
never be possible.  An alternative approach would be to use changes in metabolic 
parameters which predispose to cardiovascular disease as end-points, which would 
also be in keeping with the current needs where cardiovascular mortality is now 
being recognised as a major problem in HIV-infected individuals.  
6.3 Conclusions  
Single nucleotide polymorphisms in humans are largely responsible for the inter-
individual variance in responses to antiretroviral drugs. However,  even in the 21st 
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century, the application of pharmacogenetics into clinical practice is  not yet easy 
(Rodriguez-Novoa, Barreiro et al. 2006). All ARVs interact with various targets such 
as carrier proteins, transporters, metabolising enzymes and nuclear receptors which 
present an array of investigative pathways in order to identify the main source of 
variation (Eiselt, Domanski et al. 2001). Different drugs can have different effects on 
regulatory molecules such as microRNAs (microRNA data), which may result in 
altered responses to the drugs. In summary, in this thesis, novel data has been 
presented which explains that the pathogenesis of LD is multi-factorial and complex. 
To develop new drugs for HIV with the least adverse effects, a greater understanding 
of the mutual interaction between drugs and essential tissues such as skeletal muscle 
and adipose tissue that modulate insulin resistance is needed. This may help in the 
identification of potential drug targets and new compounds to find a therapy for HIV- 
and drug-related metabolic adverse effects.  
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Appendix 1. Genotype data for SNPs studied in IL-18 gene  
SAMPLE_ID Status rs2115763 rs360719 rs1946518 rs1834481 rs549908 rs5744280 rs5744290 rs5744292 rs543810 
E045 CONTROL - - - - - - - - -   
E047 CONTROL TT AA GG CC TT CC CC GA AA 
E049 CONTROL TT GG TT GG GG CC CC AA AA 
E050 CONTROL AA AG GT GG GT CT CC AA AA 
E0 51 CONTROL TT AG TT GG GT CT CC AA AA 
E051 CONTROL TT AG TT GG GT CT CC AA AA 
E052 CONTROL TT AA GT CG TT CC CC - GA 
E053 CONTROL TT GG TT GG GG CC CC AA AA 
E054 CONTROL TT AG GT CG GT CC CT - AA 
E055 CONTROL AT AA GG CG TT CT CC GA AA 
E057 CONTROL AT AG GT GG GT CT CC AA AA 
E058 CONTROL AT AA GG CG TT CT CC - AA 
E059 CONTROL AT AG GT GG GT CT CC AA AA 
E060 CONTROL TT AG TT GG GT CC CC AA GA 
E061 CONTROL AT AA GG CG TT CT CC GA AA 
E062 CONTROL AT AG GT GG GT CT CC AA AA 
E063 CONTROL AT AA GG CG TT CT CC GA AA 
E064 CONTROL AT AG GT GG GT CT CC AA AA 
E065 CONTROL TT AA GG CC TT CC CC GA AA 
E067 CONTROL TT AA GT CG TT CC CC GA GA 
E068 CONTROL AT AG GT GG GT CT CC AA AA 
E069 CONTROL AT AG GT GG GT CT CC AA AA 
E070 CONTROL TT AG GT CG GT CC CC GA AA 
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E071 CONTROL TT AG GT GG GT CT CC AA AA 
E072 CONTROL TT AA GT CG TT CT CC - AA 
E073 CONTROL TT AG GT CG GT CC CC GA AA 
E074 CONTROL TT AA GG CC TT CC CC GA AA 
E074 CONTROL TT AA GG CC TT CC CC GA AA 
E074 CONTROL TT AA GG CC TT CC CC GA AA 
E075 CONTROL TT AG GT CG GT CC CC GA AA 
E077 CONTROL TT AA GG CC TT CC CC GA AA 
E078 CONTROL TT AA GG CG GT CC CC GA AA 
E079 CONTROL TT AG GT CG GT CC CC GA AA 
E080 CONTROL TT AG GT CG GT CC CC GA AA 
E081 CONTROL TT AG TT GG GT CC CC AA GA 
E082 CONTROL TT AG TT GG GT CC CC AA GA 
E083 CONTROL AT AA GG CG GT CC CC - AA 
E084 CONTROL TT AG GT CG GT CC CC GA AA 
E085 CONTROL AT AA GG CG TT CT CC - AA 
E086 CONTROL AT AG GT GG GT CT CC AA AA 
E087 CONTROL TT GG TT GG GG CC CC AA AA 
E088 CONTROL AT AA GG CG TT CT CC GA AA 
E089 CONTROL TT AA TT GG TT CT CC AA GA 
E090 CONTROL TT AG GT CG GT CC CT GA AA 
E091 CONTROL TT AG GT CG GT CC CC - AA 
E092 CONTROL AA AA GG GG TT TT CC AA AA 
E093 CONTROL AT AG GT GG GT CT CC AA AA 
E094 CONTROL TT AG TT GG GT CT CC AA AA 
E095 CONTROL AT AA GT GG TT TT CC AA AA 
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E096 CONTROL AT AG GT GG GT CT CC AA AA 
E097 CONTROL AT AG GT GG GT CT CC AA AA 
E098 CONTROL TT AG GT CG GT CC CC - AA 
E099 CONTROL AT AG GT GG GT CT CC AA AA 
E100 CONTROL TT AA GG CC TT CC CT GA AA 
E101 CONTROL TT GG TT GG GG CC CC AA AA 
E102 CONTROL TT AG GT CG GT CC CC - AA 
E103 CONTROL AT AA GG CG TT CT CC - AA 
E104 CONTROL TT AG GT CG GT CC CC - AA 
E105 CONTROL TT AA GG CC TT CC CC GA AA 
E106 CONTROL AT AA GG CG TT CT CC - AA 
E107 CONTROL TT AG GT CG GT CC CC GA AA 
E108 CONTROL AT AA GG CG TT CT CC - AA 
E109 CONTROL TT AA GG CG TT CT CC - AA 
J001 CONTROL TT AG GT CG GT CC CC - AA 
J002 CONTROL TT AG GT CG GT CC CC - AA 
J003 CONTROL TT AG GT CG GT CC CC GA AA 
J003 CONTROL TT AG GT CG GT CC CC - AA 
J004 CONTROL TT AA GT CG TT CC CT - GA 
J005 CONTROL AT AA GT GG TT CT CC AA GA 
J005 CONTROL AT AA GT GG TT CT CC AA GA 
J007 CONTROL TT AG GT CG GT CC CC GA AA 
J009 CONTROL TT AG TT GG GT CC CC AA GA 
J011 CONTROL TT AG GT CG GT CC CC - AA 
J012 CONTROL AT AG GT GG GT CT CC AA AA 
J013 CONTROL AA AA GG GG GT CT CC AA AA 
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J013 CONTROL AA AA GG GG GT CT CC AA AA 
J014 CONTROL TT AG GT CG GT CC CT - AA 
J015 CONTROL AT AA GT GG TT TT CC AA AA 
J016 CONTROL AT AA GG CG TT CT CC - AA 
J017 CONTROL AT AG GT GG GT CT CC AA AA 
J018 CONTROL AT AA GG CG TT CT CT - AA 
J020 CONTROL AT AA GG CG TT CT CC - AA 
J020 CONTROL AT AA GG CG TT CT CC - AA 
J023 CONTROL AT AA GG CG TT CT CC - AA 
J025 CONTROL AA AA GG GG TT TT CC AA AA 
J026 CONTROL AT AG GT GG GT CT CC AA AA 
J027 CONTROL AA AA GG GG TT TT CC AA AA 
J028 CONTROL TT AG GT CG GT CC CT - AA 
J029 CONTROL AT AA GT GG TT CT CC AA GA 
J030 CONTROL TT AA GT CG TT CT CC - AA 
J031 CONTROL TT AA TT GG TT CC CC AA GG 
J032 CONTROL AT AA GG CG GT CC CC - AA 
J032 CONTROL AT AA GG CG GT CC CC - AA 
MAN_100 HIVLD CASE TT AG TT GG GT CC CC AA GA 
MAN_113 HIVLD CONTROL AT AA GG GG TT CT CC AA GA 
MAN_115 HIVLD CONTROL TT AG GT GG GT CT CC AA AA 
MAN_118 HIVLD CONTROL AT AA GT GG TT CT CC AA GA 
MAN_119 HIVLD CONTROL TT AA GG CC TT CC CC GA AA 
MAN_120 HIVLD CASE TT GG TT GG GG CC CC AA AA 
MAN_125 HIVLD CONTROL TT AA GG CC TT CC CC - AA 
MAN_128 HIVLD CASE AT AG GT GG GT CT CC AA AA 
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MAN_135 HIVLD CASE TT AG - CG - - CC GA AA 
MAN_140 HIVLD CASE AT AA GG CG TT CT CC - AA 
MAN_150 HIVLD CONTROL AT AA GG CG TT CT CC - AA 
MAN_151 HIVLD CASE AA AA GG GG TT TT CC AA AA 
MAN_153 HIVLD CASE TT AG GT CG GT CC CT - AA 
MAN_157 HIVLD CASE AT AA GG CG GT CC CC - AA 
MAN_201 HIVLD CASE TT AA GT CG TT CC CC - GA 
MAN_204 HIVLD CASE AT AG GT GG GT CT CC AA AA 
MAN_205 HIVLD CASE TT AG GT CG GT CC CC GA AA 
MAN_206 HIVLD CASE AT AA GT GG TT CT CC AA GA 
MAN_208 HIVLD CASE TT GG TT GG GG CC CC AA AA 
MAN_21 HIVLD CONTROL TT AG GT GG GT CT CC AA AA 
MAN_210 HIVLD CASE TT AA GT CG TT CC CT - GA 
MAN_211 HIVLD CASE AA AA GG GG GT CT CC AA AA 
MAN_212 HIVLD CASE AT AA GT GG TT CT CC AA GA 
MAN_213 HIVLD CASE AT AA GG GG GT CT CC AA AA 
MAN_214 HIVLD CASE TT AG GT CG GT CC CC - AA 
MAN_215 HIVLD CASE AA AA GG GG TT TT CC AA AA 
MAN_216 HIVLD CASE AT AG GT GG GT CT CC AA AA 
MAN_217 HIVLD CASE AT AG GT GG GT CT CC AA AA 
MAN_218 HIVLD CASE AT AA GT GG TT CT CC AA GA 
MAN_219 HIVLD CASE AT AG GT CG GT CC CC - AA 
MAN_220 HIVLD CASE AT AA GG CG TT CT CC GA AA 
MAN_221 HIVLD CASE AT AG GT GG GT CT CC AA AA 
MAN_222 HIVLD CASE AA AA GG GG GT CT CC AA AA 
MAN_223 HIVLD CASE AT AA GG CG TT CT CC - AA 
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MAN_224 HIVLD CASE TT AG GT CG GT CC CC - AA 
MAN_225 HIVLD CASE TT AA GT CG TT CC CT GA GA 
MAN_226 HIVLD CASE TT AA GT GG TT CT CC AA GA 
MAN_227 HIVLD CASE AA AA GG GG TT TT CC AA AA 
MAN_228 HIVLD CASE AT AG GT GG GT CT CC AA AA 
MAN_229 HIVLD CASE AT AA GT GG TT CT CC AA GA 
MAN_230 HIVLD CASE AA AA GG GG TT TT CC AA AA 
MAN_231 HIVLD CASE AT AA GG CG TT CT CC - AA 
MAN_232 HIVLD CASE AA AA GG GG TT TT CC AA AA 
MAN_233 HIVLD CASE AA AA GG GG TT TT CC AA AA 
MAN_234 HIVLD CASE AT AG GT GG GT CT CC AA AA 
MAN_235 HIVLD CASE AT AG GT GG GG CC CC AA AA 
MAN_236 HIVLD CASE AT AA GG CG TT CT CC  AA 
MAN_237 HIVLD CASE TT AG GT CG GT CC CC  AA 
MAN_238 HIVLD CONTROL TT GG TT GG GG CC CC AA AA 
MAN_239 HIVLD CONTROL TT AG GT CG GT CC CC GA AA 
MAN_240 HIVLD CONTROL AT AG GT GG GT CT CC AA AA 
MAN_241 HIVLD CONTROL TT AG GT CG GT CC CC  AA 
MAN_242 HIVLD CONTROL TT AG TT GG GT CC CC AA GA 
MAN_243 HIVLD CONTROL - - - - - - - - - 
MAN_243b HIVLD CONTROL AT AG GT GG GT CT CC AA AA 
MAN_30 HIVLD CASE AA AA GG GG TT TT CC AA AA 
MAN_40 HIVLD CONTROL AA AA GG GG TT TT CC AA AA 
MAN_46 HIVLD CONTROL AT AG GT GG GT CT CC AA AA 
MAN_5 HIVLD CASE TT AG TT GG GT CT CC AA AA 
MAN_51 HIVLD CASE AT AG GT GG GT CT CC AA AA 
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MAN_52 HIVLD CASE AT AG GT GG GT CT CC AA AA 
MAN_54 HIVLD CONTROL TT AG TT GG GT CC CC AA GA 
MAN_55 HIVLD CASE AT AG GT GG GT CT CC AA AA 
MAN_56 HIVLD CONTROL TT GG TT GG GG CC CC AA AA 
MAN_62 HIVLD CONTROL AT AA GT GG TT CT CC AA GA 
MAN_64 HIVLD CONTROL AT AA GT GG TT CT CC AA GA 
MAN_68 HIVLD CASE TT AG GT GG GT CC CC AA AA 
MAN_73 HIVLD CASE TT AG GT GG GT CT CC AA AA 
MAN_78 HIVLD CONTROL AA AA GG GG GT CT CC AA AA 
MAN_79 HIVLD CASE AT AA GG GG GT CT CC AA AA 
MAN_8 HIVLD CONTROL AT AA GG CG TT CT CC  AA 
MAN_83 HIVLD CONTROL AA AA GG GG TT TT CC AA AA 
MAN_85 HIVLD CASE AT AA GT GG TT CT CC AA GA 
MAN_86 HIVLD CONTROL TT AA GT CG TT CC CC - GA 
MAN_89 HIVLD CONTROL AT AG GT GG GT CT CC AA AA 
MAN_9 HIVLD CONTROL TT AA GG CC TT CC CC GA AA 
MRCX245 HIVLD CASE TT AA GT CG TT CC CC - GA 
MRCX246 HIVLD CASE TT AG GT CG GT CC CC - AA 
MRCX247 HIVLD CASE TT AA TT GG TT CT CC AA GA 
MRCX248 HIVLD CASE TT GG TT GG GG CC CC AA AA 
MRCX249 HIVLD CASE AT AA GG CG TT CT CT - AA 
MRCX250 HIVLD CASE AT AA GG CG TT CT CC - AA 
MRCX251 HIVLD CASE TT AG TT GG GT CC CC AA GA 
MRCX252 HIVLD CASE TT AG GT CG GT CC CT - AA 
MRCX253 HIVLD CASE AT AA GT GG TT TT CC AA AA 
MRCX254 HIVLD CONTROL TT AA GG CC TT CC CC GA AA 
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MRCX256 HIVLD CASE AT AA GG GG TT CT CC AA AA 
MRCX257 HIVLD CASE AT AA GG GG TT CT CC AA AA 
MRCX258 HIVLD CONTROL AT AG GT GG GT CT CC AA AA 
MRCX259 HIVLD CASE AT AA GG CG GT CC CC - AA 
MRCX260 HIVLD CASE AT AA GT GG TT CT CC AA GA 
MRCX261 HIVLD CASE AT AA GG CG TT CT CC - AA 
MRCX262 HIVLD CASE AT AA GT GG GT CT CC AA GA 
MRCX264 HIVLD CASE AA AA GG GG TT TT CC AA AA 
MRCX265 HIVLD CASE AT AG GT GG GT CT CC AA AA 
MRCX266 HIVLD CASE AT AG GT GG GT CT CC AA AA 
MRCX267 HIVLD CASE AT AG GT GG GT CT CC AA AA 
MRCX269 HIVLD CASE TT AG GT CG GT CC CC - AA 
MRCX271 HIVLD CASE AT AA GG CG TT CT CC - AA 
MRCX272 HIVLD CASE TT AG GT GG GG CC CC AA AA 
MRCX273 HIVLD CASE AT AG TT GG GT CC CC AA GA 
MRCX274 HIVLD CONTROL - - GT - - - CC AA AA 
MRCX275 HIVLD CASE - - GT - TT CC CC AA GA 
MRCX276 HIVLD CASE - GG TT - GG CC CC AA AA 
MRCX278 HIVLD CASE - - GG CC TT CC CC - AA 
MRCX279 HIVLD CASE  - GT -  CC CC - - 
MRCX280 HIVLD CASE TT AA GT CG TT CC CC  GA 
MRCX282 HIVLD CASE TT AG TT GG GT CC CC AA GA 
MRCX283 HIVLD CASE AT AA GG CG TT CT CC - AA 
MRCX284 HIVLD CASE TT AA GT CG TT CC CC - GA 
MRCX285 HIVLD CASE TT AA GT CG TT CC CC - GA 
MRCX287 HIVLD CASE AT AG GT GG GT CT CC AA AA 
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MRCX290 HIVLD CASE TT AG TT GG GT CC CC AA GA 
MRCX291 HIVLD CASE AT - GG CG TT CT CC - AA 
MRCX292 HIVLD CASE AT AG GT GG GT CT CC AA AA 
MRCX293 HIVLD CASE AT AG GT GG GT CT CC AA AA 
MRCX294 HIVLD CASE AT AG GT GG GT CT CC AA AA 
MRCX295 HIVLD CASE AA AA GG GG TT TT CC AA AA 
MRCX297 HIVLD CASE AT AA GG CG TT CT CC - AA 
MRCX300 HIVLD CASE AT AA GT GG TT CT CC AA GA 
MRCX301 HIVLD CASE AT AG GT GG GT CT CC AA AA 
MRCX303 HIVLD CASE AT AA GT GG TT CT CC AA GA 
MRCX304 HIVLD CASE AT AG GT GG GT CT CC AA AA 
MRCX305 HIVLD CASE AT AA GT GG TT CT CC AA GA 
MRCX307 HIVLD CASE TT AG TT GG GT CC CC AA GA 
MRCX308 HIVLD CONTROL AT AA GG CG TT CT CC - AA 
MRCX315 HIVLD CASE TT GG TT GG GG CC CC AA AA 
MRCX316 HIVLD CONTROL TT AA GT CG TT CT CC - AA 
MRCX318 HIVLD CONTROL AT AA GG CG TT CT CC GA AA 
MRCX319 HIVLD CASE TT AA GT CG TT CC CC GA GA 
MRCX320 HIVLD CASE TT AG TT GG GT CC CC AA GA 
MRCX322 HIVLD CASE TT AG TT GG GT CC CC AA GA 
MRCX323 HIVLD CASE AT AG GT CG GT CC CC GA AA 
MRCX324 HIVLD CASE AA AA GG GG TT TT CC AA AA 
MRCX325 HIVLD CONTROL AT AG GT GG GT CT CC AA AA 
MRCX326 HIVLD CASE TT AA GG CC TT CC CC GA AA 
MRCX327 HIVLD CASE TT AG GT CG GT CC CC - AA 
MRCX328 HIVLD CASE TT AA GG CC TT CC CC - AA 
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MRCX331 HIVLD CASE TT AG GT CG GT CC CC GA AA 
MRCX337 HIVLD CASE AA AA GG GG TT TT CC AA AA 
MRCX339 HIVLD CASE TT AA GG CC TT CC CC GA AA 
MRCX340 HIVLD CASE TT AG GT CG GT CC CC - AA 
MRCX342 HIVLD CASE AT AA GT GG TT CT CC AA GA 
MRCX343 HIVLD CASE TT AA GG GG TT CC CC AA GA 
MRCX344 HIVLD CONTROL AT AA GG GG TT TT CC AA AA 
MRCX345 HIVLD CONTROL TT AA GG CG TT CC CC - AA 
MRCX346 HIVLD CASE AA AA GG GG TT TT CC AA AA 
MRCX347 HIVLD CONTROL AA AA GG GG TT TT CC AA AA 
MRCX348 HIVLD CONTROL AT AG GT GG GT CT CC AA AA 
MRCX349 HIVLD CONTROL AA AA GG GG TT TT CC AA AA 
MRCX350 HIVLD CONTROL TT AA GG CC TT CC CC GG AA 
MRCX352 HIVLD CONTROL TT AA GT GG TT CC CC AA GG 
MRCX353 HIVLD CONTROL TT AA GT GG TT CT CC AA GA 
MRCX354 HIVLD CONTROL TT AG GT GG GT CT CC AA AA 
MRCX355 HIVLD CONTROL AT AG GT GG GT CT CC AA AA 
MRCX356 HIVLD CONTROL TT AA GG GG TT CC CC AA AA 
MRCX357 HIVLD CONTROL AA AG GT GG GT CT CC AA AA 
MRCX358 HIVLD CASE AT AG GT GG GT CT CC AA AA 
MRCX359 HIVLD CASE AT AA GG CG TT CT CC GA AA 
MRCX361 HIVLD CASE AT AG GT GG GT CT CC AA AA 
MRCX362 HIVLD CASE AA AA GG GG TT TT CC AA AA 
MRCX363 HIVLD CASE TT AG GT CG GT CC CC  AA 
MRCX366 HIVLD CASE TT AA TT GG TT CT CC AA GA 
MRCX367 HIVLD CASE TT AG TT GG GT CC CC AA GA 
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MRCX368 HIVLD CASE AT AG GT GG GT CT CC AA AA 
MRCX370 HIVLD CASE TT AA GG GG TT CT CC AA GA 
MRCX371 HIVLD CASE TT AG TT GG TT CC CC AA GA 
MRCX372 HIVLD CASE TT AG TT GG GT CC CC AA GA 
MRCX391 HIVLD CASE TT AA GG CG TT CT CC - AA 
V002 CONTROL AT AA GG CG TT CT CC - AA 
V003 CONTROL AT AG GT GG GT CT CC AA AA 
V005 CONTROL TT AG GT CG GT CC CC GA AA 
V006 CONTROL AA AA GG GG GT CT CC AA AA 
V007 CONTROL AT AG GT - GT CC CC AA AA 
V008 CONTROL TT AG TT GG GT CC CC AA GA 
V009 CONTROL TT AG TT GG GT CC CC AA GA 
V010 CONTROL AT AG GT GG GT CT CC AA AA 
V011 CONTROL TT AG GT CG GT CC CC - AA 
V012 CONTROL TT AA TT GG TT CC CC AA GG 
V013 CONTROL AT AG GT GG GT CT CC AA AA 
V014 CONTROL TT GG TT GG GG CC CC AA AA 
V016 CONTROL TT AG GT CG GT CC CC GA AA 
V017 CONTROL AA AA GG GG TT TT CC AA AA 
V018 CONTROL AT - - CG - CT CC - AA 
V019 CONTROL AA AA GG GG GT CT CC AA AA 
V020 CONTROL AT AG GT GG GT - CC AA AA 
V021 CONTROL TT AA GG CG TT CT CC - AA 
V022 CONTROL TT AA GG CG TT CT CC - AA 
V023 CONTROL AT AA GT GG GT CT CC AA GA 
V024 CONTROL AT AG GT GG GT CT CC AA AA 
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V025 CONTROL TT AG GT CG GT CC CC GA AA 
V026 CONTROL AA AA GG GG TT TT CC AA AA 
V026 CONTROL AT  GT GG - -- CC AA AA 
V027 CONTROL AT AA GT GG TT CT CC AA GA 
V028 CONTROL TT AG GT GG GG CC CC AA AA 
V029 CONTROL AT AG GT GG GT CT CC AA AA 
V030 CONTROL AT AA GG CG TT CT CC - AA 
V031 CONTROL TT AG - CG - - CC - AA 
V032 CONTROL AA - GG GG TT TT CC AA AA 
V033 CONTROL AA AA GG GG TT TT CC AA AA 
V034 CONTROL TT AG TT GG GT CC CC AA GA 
V035 CONTROL TT AG TT GG GT CC CC AA GA 
V036 CONTROL AA AA GG GG TT TT CC AA AA 
V037 CONTROL TT AG GT CG GT CC CC GA AA 
V038 CONTROL AT AG GT GG GT CT CC AA AA 
V039 CONTROL TT AA GG CC TT CC CT GA AA 
V040 CONTROL TT AA GT CG TT CC CC GA GA 
V041 CONTROL TT AG TT GG GT CC CC AA GA 
V042 CONTROL TT AA GG CC TT CC CC GA AA 
V043 CONTROL TT - - - - CT CC AA GA 
V044 CONTROL AT AA GG CG GT CC CC - AA 
V045 CONTROL AT AA GG CG GT CC CC - AA 
V046 CONTROL AT AA GT GG TT CT CC AA GA 
V047 CONTROL AT AA GG CG TT CT CC - AA 
V048 CONTROL AT AG GT GG GT CT CC AA AA 
V049 CONTROL TT AG TT GG GT CT CC AA AA 
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V049 CONTROL AT AG GT GG GT CT CC AA AA 
V050 CONTROL TT AG GT CG GT CC CC GA AA 
V051 CONTROL AA AA GG GG TT TT CC AA AA 
V052 CONTROL AT AA GG CG TT CT CC GA AA 
V053 CONTROL TT GG TT GG GG CC CC AA AA 
V054 CONTROL TT AG GT CG GT CC CC - AA 
V055 CONTROL AT AA - CG TT - CC - - 
V056 CONTROL AT AA GG CG TT CT CC GA AA 
V057 CONTROL AT AA GG CG TT CT CC GA AA 
V058 CONTROL TT AG GT CG GT CC CC  AA 
V059 CONTROL AT AG GT GG GT CT CC AA AA 
V059 CONTROL AT AG GT GG GT CT CC AA AA 
V060 CONTROL TT AG GT CG GT CC CC - AA 
V061 CONTROL AT AG GT GG GT CT CC AA AA 
V062 CONTROL AT AG GT GG GT CT CC AA AA 
V063 CONTROL TT AG GT CG GT CC CC - AA 
V064 CONTROL AT AA GG CC TT CC CC GA AA 
V065 CONTROL AT AA GG CG TT CT CC GA AA 
V066 CONTROL TT AG GT CG GT CC CC - AA 
V066 CONTROL TT AG GT CG GT CC CC - AA 
V067 CONTROL AT AA GT CG TT  CC AA GA 
V068 CONTROL TT AG TT GG GT CC CC AA GA 
V069 CONTROL TT AG TT GG GT CC CC AA GA 
V070 CONTROL AA AA GG GG - - CC AA AA 
V071 CONTROL TT AG TT GG GT CC CC AA GA 
V072 CONTROL TT AA GT CG TT CC CC GA GA 
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V073 CONTROL AT AA GG CG TT CT CC GA AA 
V074 CONTROL AA AA GG GG GT CT CC AA AA 
V075 CONTROL TT AG GT CG GT CC CC GA AA 
V076 CONTROL TT AA TT GG TT TT CC AA AA 
V077 CONTROL TT AG TT GG GT CC CC AA GA 
V078 CONTROL TT AG TT GG GT CC CC AA GA 
V079 CONTROL AT - - - TT CT CC AA AA 
V080 CONTROL AT AA GG CG TT CT CC - AA 
V080 CONTROL TT AG GT CG GT CC CC GA AA 
V081 CONTROL AT AA GG CG TT CT CC - AA 
V085 CONTROL AT AA GG CG TT CT CT GA AA 
V085 CONTROL AT AA GG CG TT CT CT GA AA 
V086 CONTROL AT AG GT GG GT CT CC AA AA 
V087 CONTROL AA AA GG GG GG CC CC AA AA 
V088 CONTROL AA AA GG GG TT TT CC AA AA 
V089 CONTROL AT AG GT GG GT CT CC AA - 
V091 CONTROL - - - - - - - - - 
V092 CONTROL AT AG GT GG GT CT CC AA AA 
 
HIVLD case:  HIV-positive patients with LD; HIVLD Control:  HIV-positive patients without LD 
 
 
 
 
